Index of Molecular Images

To facilitate comparison of similar structures, the images are listed by clan and family.

Clan MEROPS ID Peptidase Comment PDB Entry
AA A01.001 pepsin A Uropepsin 1FLH
AA A01.001 pepsin A pepsin 3A 1PSN
AA A01.001 pepsin A pepsin 3A; complex with pepstatin 1PSO
AA A01.001 pepsin A complex with phosphonate inhibitor Iva-Val-Val-Leu(P)-(O)Phe-Ala-Ala-Ome 1QRP
AA A01.001 pepsin A complex with Ascaris suum pepsin inhibitor-3 1F34_A
AA A01.001 pepsin A complex with A-62905 1PSA
AA A01.001 pepsin A effect of dimethyl sulphoxide 1YX9
AA A01.001 pepsin A precursor 2PSG
AA A01.001 pepsin A 3PEP
AA A01.001 pepsin A precursor 3PSG
AA A01.001 pepsin A 4PEP
AA A01.001 pepsin A 5PEP
AA A01.003 gastricsin activation intermediate 2 1AVF
AA A01.003 gastricsin precursor 1HTR
AA A01.004 BACE1 g.p. (Homo sapiens) protease domain; complex with Glu-Val-Asn-leucinol-2-methyl-propionyl-Ala-Glu-Phe inhibitor 1FKN_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor OM00-3 1M4H
AA A01.004 BACE1 g.p. (Homo sapiens) unbound catalytic domain 1SGZ
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 1TQF_A
AA A01.004 BACE1 g.p. (Homo sapiens) 1W50
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 3-[((1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propylamino)(hydroxy)methyl]-N,N-dipropylbenzamide 1W51
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-aur200 1YM2_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-amk640 1YM4_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2B8L_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with l- l000430,469 2B8V_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with axq093, a macrocyclic inhibitor 2F3E_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with bdf488, a macrocyclic inhibitor 2F3F_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2HIZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2IRZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2IS0_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2NTR_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2OAH_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with isophthalamide s2 hydroxyethylamine inhibitor 2P83_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2P8H_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2PH6_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 2PH8_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 1 2Q11_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 3a 2Q15_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 1 2QU2_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 2 2QU3_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with i21 2QZK_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with ixs 2QZL_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with n-((1s,2r)-1-benzyl-2-hydroxy-3-((1,1,5- trimethylhexyl)amino)propyl)-3-(ethylamino)-5-(2-oxopyrrolidin-1-yl) benzamide 2VIE_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 3-(1,1-dioxidotetrahydro-2h-1,2-thiazin- 2-yl)-5-(ethylamino)-n-((1s,2r)-2-hydroxy-1-(phenylmethyl)-3-(1,2,3, 4- tetrahydro-1-naphthalenylamino)propyl)benzamide 2VIJ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (pentylsulfonyl)benzamide 2VIY_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(2- oxo- 1-pyrrolidinyl)-5-(propyloxy)benzamide 2VIZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide 2VJ6_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 3-(ethylamino)-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-5-(2-oxo-1-pyrrolidinyl)benzamide 2VJ7_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with n-((1s,2r)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(ethylamino)-5-(2-oxo-1-pyrrolidinyl) benzamide 2VJ9_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 3-(1,1-dioxidotetrahydro-2h-1,2-thiazin- 2-yl)-5-(ethylamino)-n-((1s,2r)-2-hydroxy-1-(phenylmethyl)-3-(((3- (trifluoromethyl)phenyl)methyl)amino)propyl)benzamide 2VNM_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 7-ethyl-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-1-methyl-3,4-dihydro-1h-(1,2,5)thiadiazepino(3,4,5-hi)indole-9- carboxamide 2,2-dioxide 2VNN_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 1-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-4-(2-oxo-1- pyrrolidinyl)-1h-indole-6-carboxamide 2WEZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 4-ethyl-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-8-(2-oxo-1-pyrrolidinyl)-6-quinolinecarboxamide 2WF0_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 7-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl(methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4-dihydro-1h-(1,2,5)thiadiazepino(3,4,5-hi)indole-9-carboxamide 2,2- dioxide 2WF1_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 8-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4,7, 8-tetrahydro-1h,6h-(1,2,5)thiadiazepino(5,4,3-de)quinoxaline-10- carboxamide 2,2-dioxide 2WF2_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 6-(ethylamino)-n-((1s,2r)-2-hydroxy-3- (((3-(methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1- methyl-1, 3,4,5-tetrahydro-2,1-benzothiazepine-8-carboxamide 2,2- dioxide 2WF3_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with 6-ethyl-1-methyl-n-((1s)-2-oxo-1- (phenylmethyl)-3-(tetrahydro-2h-pyran-4-ylamino)propyl)-1,3,4,6- tetrahydro(1,2)thiazepino(5,4,3-cd)indole-8-carboxamide 2,2-dioxide 2WF4_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- ((methylsulfonyl)(phenyl)amino)benzamide 2XFI_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide 2XFJ_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-((methylsulfonyl)(phenyl)amino)benzamide 2XFK_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 3.b.10 2ZDZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 6g 2ZE1_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor OM99-2 at pH 5.0 2ZHR
AA A01.004 BACE1 g.p. (Homo sapiens) at pH 4.0 2ZHS
AA A01.004 BACE1 g.p. (Homo sapiens) at pH 4.5 2ZHT
AA A01.004 BACE1 g.p. (Homo sapiens) at pH 5.0 2ZHU
AA A01.004 BACE1 g.p. (Homo sapiens) at pH 7.0 2ZHV
AA A01.004 BACE1 g.p. (Homo sapiens) catalytic domain; complex with 4-(4-fluoro-benzyl)-piperazine-2-carboxylic acid(3-mercapto-propyl)-amide 2ZJK_A
AA A01.004 BACE1 g.p. (Homo sapiens) catalytic domain; complex with n-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)- piperidin-4-yl]-2-(4-sulfamoyl-phenoxy)-acetamide 2ZJM_A
AA A01.004 BACE1 g.p. (Homo sapiens) catalytic domain; complex with n-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)- piperidin-4-yl]-2-(2-methyl-4-sulfamoyl-phenoxy)-acetamide 2ZJN_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 1 3BRA_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 2 3BUF_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 3 3BUG_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 4 3BUH_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with statine-based inhibitor 3DM6_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-afj144 3DUY_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-arv999 3DV1_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bav544 3DV5_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 3EXO_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with spiropiperdine iminohydantoin inhibitor 3FKT_A
AA A01.004 BACE1 g.p. (Homo sapiens) discovery of aminoheterocycles as a novel beta-secretase inhibitor class 3H0B_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with ev0 3HVG_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with ligand ev2 3HW1_A
AA A01.004 BACE1 g.p. (Homo sapiens) potent beta-secretase 1 hydroxyethylene inhibitor 3I25_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 3 3IGB_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 30 3IN3_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 38 3IN4_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminohydantoin compound 29 3IND_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminohydantoin compound s-34 3INE_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminohydantoin compound 37 3INF_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminohydantoin compound r-58 3INH_A
AA A01.004 BACE1 g.p. (Homo sapiens) potent beta-secretase 1 inhibitor 3IXK_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 complex with nb-216 3K5C_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with ahm178 3K5D_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 complex with ayh011 3K5F_A
AA A01.004 BACE1 g.p. (Homo sapiens) human bace-1 complex with bjc060 3K5G_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a norstatine type inhibitor 3KYR_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminopyridine compound 44 3L38_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminopyridine compound 32 3L3A_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch589432 3L58_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch710413 3L59_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch713601 3L5B_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch723871 3L5C_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch723873 3L5D_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch736062 3L5E_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch736201 3L5F_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminohydantoin compound 4g 3LHG_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch745132 3LPI_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch743641 3LPJ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with sch747123 3LPK_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 3MSJ_A
AA A01.004 BACE1 g.p. (Homo sapiens) fragment based discovery and optimisation of bace-1 inhibitors 3MSK_A
AA A01.004 BACE1 g.p. (Homo sapiens) fragment based discovery and optimisation of bace-1 inhibitors 3MSL_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with bms-655295 aka n~3~-((1s,2r)-1- benzyl-2-hydroxy-3-((3- methoxybenzyl)amino)propyl)-n~1~, n~1~-dibutyl-1h-indole-1,3- dicarboxamide 3OHF_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with bms-681889 aka n~1~-butyl-5-cyano- n~3~-((1s,2r)-1-(3,5- difluorobenzyl)-2-hydroxy-3-((3- methoxybenzyl)amino)propyl)-n~1~- methyl-1h-indole-1,3- dicarboxamide 3OHH_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with the aminohydantoin compound 102 3OOZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with bfg356 3PI5_A
AA A01.004 BACE1 g.p. (Homo sapiens) structure based design, synthesis and sar of cyclic hydroxyethylamine (hea) bace-1 inhibitors 3QBH_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of hydroxyethylamine (hea) bace-1 inhibitors: prime side chromane-containing inhibitors 3QI1_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with bms-693391 aka (2s)-2-((3r)-3-acetamido-3-isobutyl-2-oxo-1- pyrrolidinyl)-n-((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-2-((2r,4r)-4-propoxy-2-pyrrolidinyl)ethyl)-4-phenylbutanamide 3R2F_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 3-(2- aminoquinolin-3-yl)-n-(cyclohexylmethyl)propanamide 3RU1_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-((2-amino-6-o- tolylquinolin-3-yl)methyl)-n-(cyclohexylmethyl)pentanamide 3RVI_A
AA A01.004 BACE1 g.p. (Homo sapiens) fragment based discovery and optimisation of bace-1 inhibitors 3S2O_A
AA A01.004 BACE1 g.p. (Homo sapiens) pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors 3S7L_A
AA A01.004 BACE1 g.p. (Homo sapiens) pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors 3S7M_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (2s)-2-((3s)-3-(acetylamino)-3-(butan-2-yl)-2-oxopyrrolidin-1- yl)-n-((2s,3r)-3-hydroxy-4-((3-methoxybenzyl)amino)-1-phenylbutan-2- yl)-4-phenylbutanamide 3SKF_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (2s)-2-((3r)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-n- ((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3- isoquinolinyl)ethyl)-4-phenylbutanamide 3SKG_A
AA A01.004 BACE1 g.p. (Homo sapiens) apo form 3TPJ_A
AA A01.004 BACE1 g.p. (Homo sapiens) apo form 3TPL_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 3TPP_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 3TPR_A
AA A01.004 BACE1 g.p. (Homo sapiens) rational design and synthesis of aminopiperazinones as beta secretase (bace) inhibitors 3U6A_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 3UQP_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 3UQR_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 3UQU_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 3UQW_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 3UQX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-avi326 3VEU_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bqq711 3VF3_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bur436, derived from a soaking experiment 3VG1_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-amino-3-methyl-6-((1s, 2r)-2-phenylcyclopropyl)pyrimidin-4(3h)-one 3VV6_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-amino-3,6- dimethyl-6-(2-phenylethyl)-3,4,5,6-tetrahydropyrimidin-4-one 3WB4_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (6s)-2-amino-3,6- dimethyl-6-[(1r,2r)-2-phenylcyclopropyl]-3,4,5,6-tetrahydropyrimidin-4-one 3WB5_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with chemical ligand 3ZMG_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with chemical ligand 3ZOV_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 14 4ACU_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 23 4ACX_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound 10) 4AZY_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound (r)-41) 4B00_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with azd3839 4B05_A
AA A01.004 BACE1 g.p. (Homo sapiens) new aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain 4B1C_A
AA A01.004 BACE1 g.p. (Homo sapiens) aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain 4B70_A
AA A01.004 BACE1 g.p. (Homo sapiens) aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain 4B72_A
AA A01.004 BACE1 g.p. (Homo sapiens) aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain 4B77_A
AA A01.004 BACE1 g.p. (Homo sapiens) aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain 4B78_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with chemical ligand 4BEK_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with chemical ligand 4BFD_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bur436, derived from a co-crystallization experiment 4D83_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bvi151 4D85_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bxq490 4D88_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bxd552, derived from a soaking experiment 4D89_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with nvp-bxd552, derived from a co-crystallization experiment 4D8C_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hydroxyethylamine inhibitor37 4DI2_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-imino-3-methyl-5,5-diphenylimidazolidin- 4-one 4DJU_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3- yl)phenyl)imidazolidin-4-one 4DJW_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-(3-(5-chloropyridin-3-yl)phenyl)-5- cyclopropyl-2-imino-3-methylimidazolidin-4-one 4DJX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (r)-5-cyclopropyl-2-imino-3-methyl-5-(3-(5-(prop-1-yn-1-yl)pyridin-3-yl)phenyl)imidazolidin-4-one 4DJY_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a hea-macrocyclic type inhibitor 4DPF_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hea-macrocyclic inhibitor, mv078512 4DPI_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 4DV9_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 4DVF_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors 4EWO_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors 4EXG_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 4FCO_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 4FGX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 14g 4FM7_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 12a 4FM8_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with biarylspiro aminooxazoline 6 4FRI_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with aminooxazoline xanthene 9l 4FRJ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with aminooxazoline xanthene 11a 4FRK_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (s)-4-(3-chloro-5-(5-(prop-1-yn-1- yl)pyridin-3-yl)thiophen-2-yl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1h)-iminium 4FRS_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with n-(n-(4-amino-3,5- dichlorobenzyl)carbamimidoyl)-3-(4- methoxyphenyl)-5- methyl-4-isothiazolecarboxamide 4FSE_A
AA A01.004 BACE1 g.p. (Homo sapiens) bace-db-mutant; complex with n-(n-(4- acetamido-3-chloro-5-methylbenzyl) carbamimidoyl)-3-(4- methoxyphenyl)-5-methyl-4-isothiazolecarboxamide 4FSL_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 4GID_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hea-type macrocyclic inhibitor, mv078571 4GMI_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (7ar)-6-benzoyl-7a-(4-(3-cyanophenyl) thiophen-2-yl)-3-methyl-4-oxohexahydro-1h-pyrrolo[3,4-d]pyrimidin- 2(3h)-iminium 4H1E_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 3-(5-((7ar)-2-imino-6-(6-methoxypyridin-2- yl)-3-methyl-4-oxooctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl) thiophen-3-yl)benzonitrile 4H3F_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-((7ar)-7a-(4-(3-cyanophenyl)thiophen-2- yl)-2-imino-3-methyl-4-oxohexahydro-1h-pyrrolo[3,4-d]pyrimidin-6(2h)-yl)nicotinonitrile 4H3G_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 3-(5-((7ar)-2-imino-6-(3-methoxypyridin-2- yl)-3-methyl-4-oxooctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl) thiophen-3-yl)benzonitrile 4H3I_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-fluoro-5-(5-(2-imino-3-methyl-4-oxo-6- phenyloctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-2-yl) benzonitrile 4H3J_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (s)-3-(5-(2-imino-1,4-dimethyl-6- oxohexahydropyrimidin-4-yl)thiophen-3-yl)benzonitrile 4HA5_A
AA A01.004 BACE1 g.p. (Homo sapiens) structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates 4HZT_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors ***caveat 4i0d a his 423 ca has chirality not corresponding to the amino ***caveat 2 4i0d acid definition. some close contacts 4I0D_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors ***caveat 4i0e several close contacts 4I0E_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors 4I0F_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors ***caveat 4i0g few water molecules are involved in close contacts 4I0G_A
AA A01.004 BACE1 g.p. (Homo sapiens) spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors. 4I0H_A
AA A01.004 BACE1 g.p. (Homo sapiens) spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors 4I0I_A
AA A01.004 BACE1 g.p. (Homo sapiens) spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors 4I0J_A
AA A01.004 BACE1 g.p. (Homo sapiens) structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates 4I0Z_A
AA A01.004 BACE1 g.p. (Homo sapiens) structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates 4I10_A
AA A01.004 BACE1 g.p. (Homo sapiens) structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates. 4I11_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors 4I12_A
AA A01.004 BACE1 g.p. (Homo sapiens) design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors 4I1C_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 4IVS_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with an inhibitor 4IVT_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-4-methyl-5,6-dihydro-4h-[1,3]oxazin- 4-yl)-4-fluoro-phenyl]-amide 4J0P_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-ethoxy-pyridine-2- carboxylic acid [3-((r)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J0T_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J0V_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5s)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J0Y_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,5r)-2-amino-5-fluoro-4-fluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J0Z_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-4-difluoromethyl-5,6-dihydro-4h-[1, 3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J17_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-5,5-difluoro-4-fluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J1C_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6s)-2-amino-4-fluoromethyl-6-trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J1E_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6s)-2-amino-4-methyl-6-trifluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J1F_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6r)-2-amino-4-methyl-6-trifluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 4J1H_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r,6r)-2-amino-5-fluoro-4-methyl-6- trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]- amide 4J1I_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r,6s)-2-amino-5-fluoro-4-methyl-6- trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]- amide 4J1K_A
AA A01.004 BACE1 g.p. (Homo sapiens) spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4JOO_A
AA A01.004 BACE1 g.p. (Homo sapiens) spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4JP9_A
AA A01.004 BACE1 g.p. (Homo sapiens) spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4JPC_A
AA A01.004 BACE1 g.p. (Homo sapiens) spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4JPE_A
AA A01.004 BACE1 g.p. (Homo sapiens) hydroxyethylamine-based inhibitors of bace1: p1-p3 macrocyclization can improve potency, selectivity, and cell activity 4K8S_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 4K9H_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hydroxyethylamine- macrocyclic inhibitor 13 4KE0_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hydroxyethylamine- macrocyclic inhibitor 19 4KE1_A
AA A01.004 BACE1 g.p. (Homo sapiens) diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace1) 4L7G_A
AA A01.004 BACE1 g.p. (Homo sapiens) diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1) 4L7H_A
AA A01.004 BACE1 g.p. (Homo sapiens) diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1) 4L7J_A
AA A01.004 BACE1 g.p. (Homo sapiens) aminooxazoline inhibitor of bace-1 4LC7_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 11a 4LXA_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 11d 4LXK_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 12a 4LXM_A
AA A01.004 BACE1 g.p. (Homo sapiens) discovery of 7-thp chromans: bace1 inhibitors that reduce a-beta in the cns 4N00_A
AA A01.004 BACE1 g.p. (Homo sapiens) synthesis, characterization and pk/pd studies of a series of spirocyclic pyranochromene bace1 inhibitors 4PZW_A
AA A01.004 BACE1 g.p. (Homo sapiens) synthesis, characterization and pk/pd studies of a series of spirocyclic pyranochromene bace1 inhibitors 4PZX_A
AA A01.004 BACE1 g.p. (Homo sapiens) 8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4R5N_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (r)-4-(2-cyclohexylethyl)-4-(((r)-1-(2- cyclopentylacetyl)pyrrolidin-3-yl)methyl)-1-methyl-5-oxoimidazolidin-2-iminium 4R8Y_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (r)-4-(2-cyclohexylethyl)-4-(((1s,3r)-3- (cyclopentylamino)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2- iminium 4R91_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (r)-4-(2-cyclohexylethyl)-4-(((1s,3r)-3- (isonicotinamido)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2- iminium 4R92_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (r)-4-(2-cyclohexylethyl)-1-methyl-5-oxo-4- (((1s,3r)-3-(3-phenylureido)cyclohexyl)methyl)imidazolidin-2-iminium 4R93_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-(((1r,3s)-3-(((r)-4-(2-cyclohexylethyl)-2- iminio-1-methyl-5-oxoimidazolidin-4-yl)methyl)cyclohexyl)amino) quinolin-1-ium 4R95_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a 2-aminooxazoline 4- azaxanthene inhibitor 4RCD_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with aminooxazoline xanthene inhibitor 2 4RCE_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-aminooxazoline 4- fluoroxanthene inhibitor 49 4RCF_A
AA A01.004 BACE1 g.p. (Homo sapiens) 8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4RRN_A
AA A01.004 BACE1 g.p. (Homo sapiens) 8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4RRO_A
AA A01.004 BACE1 g.p. (Homo sapiens) 8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors 4RRS_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a syn-hea-type inhibitor 4TRW_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a hea-type inhibitor 4TRY_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-thiophenyl hea-type inhibitor 4TRZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-aminooxazoline 3-aza-4- fluoro-xanthene inhibitor 22 4WTU_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 24b 4WY1_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 36 4WY6_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 6 4X2L_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with amino thiazine inhibitor ly2886721 4X7I_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-aminooxazoline 3- azaxanthene inhibitor 28 4XKX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a pyrazole-substituted tetrahydropyranthioamidine 4XXS_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with amino thiazine inhibitor ly2811376 4YBI_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3- isopropoxybenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one 4ZPE_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 8-(3-((1-aminopropan-2-yl)oxy)benzyl)-4- (cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en- 2-one 4ZPF_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one 4ZPG_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with bicyclic aminothiazine fragment 4ZSM_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with bicyclic aminothiazine inhibitor 4ZSP_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with tricyclic aminothiazine inhibitor 4ZSQ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with tricyclic aminothiazine inhibitor 4ZSR_A
AA A01.004 BACE1 g.p. (Homo sapiens) 1,4-oxazine bace1 inhibitors 5CLM_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 0211 5DQC_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 18 5ENK_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 10 5ENM_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (1r,2r)-2-[(r)-2-amino-4-(4-difluoromethoxy-phenyl)-4,5-dihydro-oxazol-4-yl]-cyclopropyl-(5- chloro-pyridin-3-yl)-methanone 5EZX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (4s)-4-[3-(5-chloro-3- pyridyl)phenyl]-4-[4-(difluoromethoxy)-3-methyl-phenyl]-5h-oxazol-2- amine 5EZZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 5-[3-[(3-chloro-8- quinolyl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine 5F00_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (1sr,2sr)-2-((r)-2-amino- 5,5-difluoro-4-methyl-5,6-dihydro-4h-1,3-oxazin-4-yl)-n-(3- chloroquinolin-8-yl)cyclopropanecarboxamide 5F01_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (7ar)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3,4- d]pyrimidin-2-iminium 5HD0_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (7ar)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5- fluoro-4-methoxypyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3,4-d]pyrimidin-2-iminium 5HDU_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4- methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3,4-d]pyrimidin-2-iminium 5HDV_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(4-ethoxy-5- fluoro-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3, 4-d]pyrimidin-2-iminium 5HDX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4- methyl-6-(methylthio)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h- pyrrolo[3,4-d]pyrimidin-2-iminium 5HDZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (4ar,7as)-7a-(2,6-difluorophenyl)-6-(5-fluoro- 4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h- pyrrolo[3,4-d]pyrimidin-2-iminium 5HE4_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4- methyl-6-(methylamino)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h- pyrrolo[3,4-d]pyrimidin-2-iminium 5HE5_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (4ar,7as)-7a-(2,4-difluorophenyl)-6-(5-fluoro- 4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methyloctahydro-4h- pyrrolo[3,4-d]pyrimidin-4-one 5HE7_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (s)-5-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3- yl)thiophen-2-yl)-2,5-dimethyl-1,2,4-thiadiazinan-3-iminium 1,1- dioxide 5HTZ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 4-(3-(furan-2-carboxamido)phenyl)-1-methyl-5- oxo-4-phenylimidazolidin-2-iminium 5HU0_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (r)-n-(3-(3-amino-2,5-dimethyl-1,1-dioxido-5,6- dihydro-2h-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5- fluoropicolinamide 5HU1_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with aminoquinoline compound 1 5I3V_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-aminooxazoline-3- azaxanthene inhibitor 2 5I3W_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with aminoquinoline inhibitor 6 5I3X_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with aminoquinoline inhibitor 9 5I3Y_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 3-(2-amino-6-(o-tolyl) quinolin-3-yl)-n-(3,3-dimethylbutyl)propanamide 5IE1_A
AA A01.004 BACE1 g.p. (Homo sapiens) (4~s,6~s)-4-[2,4-bis(fluoranyl)phenyl]-4-methyl-6-pyrimidin-5-yl- 5,6-dihydro-1,3-thiazin-2-amine (compound 12) bound to bace1 5KQF_A
AA A01.004 BACE1 g.p. (Homo sapiens) (4~s,6~s)-4-[2,4-bis(fluoranyl)phenyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine (compound 5) bound to bace1 5KR8_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with active site inhibitor GRL-8234 and exosite peptide 5MCO_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with active site and exosite binding peptide inhibitor 5MCQ_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with ligand 32397778 5MXD_A
AA A01.004 BACE1 g.p. (Homo sapiens) aminomethyl-derived beta secretase (bace1) inhibitors: engaging gly230without an anilide functionality 5T1U_A
AA A01.004 BACE1 g.p. (Homo sapiens) aminomethyl-derived beta secretase (bace1) inhibitors: engaging gly230without an anilide functionality 5T1W_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with n-(3-((4as,7as)-2-amino-4,4a,5,6-tetrahydro-7ah-furo[2,3-d][1, 3]thiazin-7a-yl)-4-fluorophenyl)-5-bromo-2-pyridinecarboxamide 5TOL_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with 2-aminooxazoline-3- azaxanthene compound 12 5UYU_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with inhibitor 5g 5V0N_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with n-(3-((4r,5r,6s)-2-amino-6-(1,1- difluoroethyl)-5-fluoro-4-methyl-5,6-dihydro-4h-1,3-oxazin-4-yl)-4- fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide 5YGX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with (s)-n-(3-(2-amino-6- (fluoromethyl)-4 -methyl-4h-1,3-oxazin-4-yl)-4-fluorophenyl)-5- cyanopicolinamide 5YGY_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hydroxy pyrrolidine inhibitor 6BFD_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hydroxy pyrrolidine inhibitor 6BFE_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hydroxy morpholine inhibitor 6BFW_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with hydroxy pyrrolidine inhibitor 6BFX_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with : n-(3-((1r,5s, 6r)-3-amino-5-methyl-2-oxa-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4- fluorophenyl)-5-methoxypyrazine-2-carboxamide 6C2I_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a bicyclic isoxazoline carboxamide as the p3 ligand 6DHC_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with a multiconformer ligand 5t5 6DMI_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with compound 28 6EJ2_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with B7T ((1r,4r)-4-methoxy-6'-(5-methyl-3-pyridinyl)-3'H-dispiro[cyclohexane-1,2'-indene-1',4''-[1,3]oxazol]-2''-amine) 6EJ3_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with cnp520 6EQM_A
AA A01.004 BACE1 g.p. (Homo sapiens) complex with amino-1,4-oxazine compound 4 6FGY_A
AA A01.006 chymosin recombinant 1CMS
AA A01.006 chymosin complex with inhibitor CP-113972 1CZI
AA A01.006 chymosin Val111Phe mutant 3CMS
AA A01.006 chymosin 4AA8
AA A01.006 chymosin complex with pepstatin 4AUC
AA A01.006 chymosin 4CMS
AA A01.006 chymosin camel chymosin at 1.6a resolution 4AA9_A
AA A01.007 renin recombinant glycosylated form 1BBS
AA A01.007 renin complex with butanediamide inhibitor BILA 1908 1BIL
AA A01.007 renin complex with butanediamide inhibitor BILA 2151 1BIM
AA A01.007 renin complex with polyhydroxymonoamide inhibitor BILA 980 1HRN
AA A01.007 renin complex with CGP 38,560 1RNE
AA A01.007 renin complex with PF00074777 2BKS_A
AA A01.007 renin complex with PF00257567 2BKT_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the c ring 2FS4_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G1N_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G1O_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the c ring 2G1R_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the c ring 2G1S_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G1Y_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the c ring 2G20_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G21_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G22_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G24_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G26_A
AA A01.007 renin ketopiperazine-based renin inhibitors: optimization of the "c" ring 2G27_A
AA A01.007 renin complex with PF02342674 2I4Q_A
AA A01.007 renin complex with 5-4-[(3,5-difluorobenzyl)amino]phenyl-6-ethylpyrimidine-2,4-diamine 2IKO_A
AA A01.007 renin complex with 6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine 2IKU_A
AA A01.007 renin complex with N-[2-(2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-ylamino)ethyl]naphthalene-2-sulfonamide 2IL2_A
AA A01.007 renin recombinant 2REN
AA A01.007 renin complex with inhibitor 10 (aliskiren) 2V0Z_C
AA A01.007 renin complex with inhibitor 9 ((2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide) 2V10_C
AA A01.007 renin complex with inhibitor 6 ((2S,4S,5R,7R)-4-amino-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctyl 1-benzyl-1H-indole-3-carboxylate) 2V11_C
AA A01.007 renin complex with inhibitor 8 (N-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(3-methoxypropoxy)benzamide) 2V12_C
AA A01.007 renin complex with inhibitor 7 (N-[(2R,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctyl]-2-(3-methoxypropoxy)benzamide) 2V13_A
AA A01.007 renin complex with inhibitor 3 2V16_A
AA A01.007 renin complex with inhibitor 3 2V16_C
AA A01.007 renin complex with human angiotensinogen 2X0B_A
AA A01.007 renin complex with remikiren 3D91
AA A01.007 renin 3G6Z
AA A01.007 renin 3G70
AA A01.007 renin 3G72
AA A01.007 renin 3GW5
AA A01.007 renin 3K1W
AA A01.007 renin 3KM4
AA A01.007 renin 3O9L
AA A01.007 renin 3OAD
AA A01.007 renin complex with piperidine inhibitor 3OAG
AA A01.007 renin 3OOT
AA A01.007 renin 3OQF
AA A01.007 renin 3OQK
AA A01.007 renin 3OWN
AA A01.007 renin 3Q3T
AA A01.007 renin 3Q4B
AA A01.007 renin 3Q5H
AA A01.007 renin 3SFC
AA A01.007 renin 3VCM
AA A01.007 renin 3VSW
AA A01.007 renin 3VSX
AA A01.007 renin 3VUC
AA A01.007 renin 3VYD
AA A01.007 renin 3VYE
AA A01.007 renin 3VYF
AA A01.007 renin 4AMT
AA A01.007 renin 4GJ5
AA A01.007 renin 4GJ6
AA A01.007 renin 4GJ7
AA A01.007 renin 4GJ8
AA A01.007 renin 4GJ9
AA A01.007 renin 4GJA
AA A01.007 renin 4GJB
AA A01.007 renin 4GJC
AA A01.007 renin 4GJD
AA A01.007 renin 4PYV
AA A01.007 renin 4Q1N
AA A01.007 renin 4RYC
AA A01.007 renin 4RYG
AA A01.007 renin 4RZ1
AA A01.007 renin 4S1G
AA A01.007 renin 4XX3
AA A01.007 renin 4XX4
AA A01.007 renin discovery of tak-272: a novel, potent and orally active renin in- hibitor ***caveat 5koq nag b 401 has wrong chirality at atom c1 5KOQ_A
AA A01.007 renin discovery of tak-272: a novel, potent and orally active renin in- hibitor 5KOS_A
AA A01.007 renin discovery of tak-272: a novel, potent and orally active renin in- hibitor 5KOT_A
AA A01.007 renin structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors 5SXN_A
AA A01.007 renin structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors 5SY2_A
AA A01.007 renin structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors 5SY3_A
AA A01.007 renin structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors 5SZ9_A
AA A01.007 renin novel approach of fragment-based lead discovery applied to renin inhibitors 5T4S_A
AA A01.007 renin optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor 5TMG_A
AA A01.007 renin optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor 5TMK_A
AA A01.007 renin complex with a biphenylpipderidinylcarbinol 5V8V_A
AA A01.007 renin complex with a biphenylpipderidinylcarbinol 5VPM_A
AA A01.007 renin complex with a biphenylpipderidinylcarbinol 5VRP_A
AA A01.007 renin complex with human angiotensinogen 6I3F_B
AA A01.008 renin-2 complex with inhibitor CH-66 1SMR_A
AA A01.008 renin-2 precursor 5MLG_A
AA A01.009 cathepsin D 1LYA
AA A01.009 cathepsin D complex with pepstatin 1LYB
AA A01.009 cathepsin D pH 7.5 1LYW_A
AA A01.009 cathepsin D 4OBZ
AA A01.009 cathepsin D 4OC6
AA A01.009 cathepsin D 4OD9
AA A01.010 cathepsin E theoretical model 1LCG
AA A01.010 cathepsin E activation intermediate 1TZS
AA A01.011 penicillopepsin complex with isoval-Val-Val-Lysta-O-Et 1APT
AA A01.011 penicillopepsin complex with isoval-Val-Val-Sta-O-Et 1APU
AA A01.011 penicillopepsin complex with isoval-Val-Val-hydrated difluorostatone-N-methylamide 1APV
AA A01.011 penicillopepsin complex with isoval-Val-Val-difluorostatone-N-methylamide 1APW
AA A01.011 penicillopepsin complex with ethyl cyclo[(2S)-2-[[(1R)-1-(N-(l-N-(3-methylbutanoyl)valyl-L-aspartyl)amino)-3-methylbutyl]hydroxyphosphinyloxy]-3-(3-aminomethyl)phenylpropanoate 1BXO
AA A01.011 penicillopepsin complex with phosphonate inhibitor 1BXQ
AA A01.011 penicillopepsin complex with isoval-Val-Val-Sta(P)-O-Et 1PPK
AA A01.011 penicillopepsin complex with isoval-Val-Val-Leu(P)-O(Phe)-OME 1PPL
AA A01.011 penicillopepsin complex with CBZ-Ala-Ala-Leu(P)-(O)Phe-OME 1PPM
AA A01.011 penicillopepsin complex with phosphonate inhibitor methyl[cyclo-7[(2R)-((N-valyl)amino)-2-(hydroxyl-(1S)-1-methyloxycarbonyl-2-phenylethoxy)phosphinyloxy-ethyl]-1-naphthaleneacetamide] 2WEA
AA A01.011 penicillopepsin complex with phosphonate inhibitor methyl (2S)-[1-((N-formyl)-l-valyl)amino-2-(2-naphthyl)ethyl)hydroxyphosphinyloxy]-3-phenyl propanoate 2WEB
AA A01.011 penicillopepsin complex with phosphonate inhibitor methyl (2S)-[1-((N-(naphthaleneacetyl))-L-valyl)aminomethyl)hydroxyphosphinyloxy]-3-phenyl propanoate 2WEC
AA A01.011 penicillopepsin complex with phosphonate macrocyclic inhibitor 2WED
AA A01.011 penicillopepsin 3APP
AA A01.012 rhizopuspepsin pH 4.6 1UH7
AA A01.012 rhizopuspepsin pH 8.0 1UH8
AA A01.012 rhizopuspepsin pH 7.0 1UH9
AA A01.012 rhizopuspepsin 2APR
AA A01.012 rhizopuspepsin complex with psi-(CH2-NH)-D-His-Pro-Phe-His-Phe-Phe-Val-Tyr 3APR
AA A01.012 rhizopuspepsin complex with a pepstatin-like renin inhibitor 4APR
AA A01.012 rhizopuspepsin complex with a pepstatin-like renin inhibitor 5APR
AA A01.012 rhizopuspepsin complex with pepstatin 6APR
AA A01.013 mucorpepsin 2ASI
AA A01.013 mucorpepsin complex with pepstatin A 2RMP_A
AA A01.013 mucorpepsin 1MPP
AA A01.014 candidapepsin SAP1 2QZW
AA A01.016 aspergillopepsin I 1IZD
AA A01.016 aspergillopepsin I 1IZE
AA A01.016 aspergillopepsin I 1IBQ_A
AA A01.017 endothiapepsin complex with inhibitor DB2 1E5O
AA A01.017 endothiapepsin complex with renin inhibitor Merck-KGAA-EMD56133 1E80
AA A01.017 endothiapepsin complex with renin inhibitor Merck-KGAA-EMD61395 1E81
AA A01.017 endothiapepsin complex with renin inhibitor Merck-KGAA-EMD59601 1E82
AA A01.017 endothiapepsin complex with cyclohexyl renin inhibitor PD125754 1EED
AA A01.017 endothiapepsin complex with inhibitor PD130328 1ENT
AA A01.017 endothiapepsin complex with PS1 (Pro-Leu-Glu-PSA-Arg-Leu) 1EPL
AA A01.017 endothiapepsin complex with PS2 (Thr-Phe-Gln-Ala-PSA-Leu-Arg-Glu) 1EPM
AA A01.017 endothiapepsin complex with CP-80,794 (MOR-Phe-Cys-CH3-NOR) 1EPN
AA A01.017 endothiapepsin complex with CP-81,282 (MOR-Phe-Nle-CHF-NME) 1EPO
AA A01.017 endothiapepsin complex with PD-130,693 (MAS-Phe-Lys-MTF-Sta-MBA) 1EPP
AA A01.017 endothiapepsin complex with PD-133,450 (SOT-Phe-Gly-SCC-GCL) 1EPQ
AA A01.017 endothiapepsin complex with PD-135,040 (TSM-DPH-His-CHF-EMR) 1EPR
AA A01.017 endothiapepsin complex with H-77 (D-His-Pro-Phe-His-Leu-Leu-Val-Tyr) 1ER8_E
AA A01.017 endothiapepsin complex with transition state analogue inhibitor H261 1GKT
AA A01.017 endothiapepsin complex with CP-80,794 (N-carbonylmorphine-Phe-S-methyl-Cys-cyclohexyl-norstatine) inhibitor 1GVT
AA A01.017 endothiapepsin complex with inhibitor H189 1GVU
AA A01.017 endothiapepsin complex with Glu-statine-Leu-meta-di(aminomethyl)benzene inhibitor 1GVV
AA A01.017 endothiapepsin complex with PD-130,328 inhibitor 1GVW
AA A01.017 endothiapepsin complex with inhibitor H256 1GVX
AA A01.017 endothiapepsin complex with PD135,040 1OD1
AA A01.017 endothiapepsin 1OEW
AA A01.017 endothiapepsin complex with transition state analogue inhibitor H261 1OEX
AA A01.017 endothiapepsin complex with L364,099 (IVA-His-Pro-Phe-His-CHS-Leu-Phe-NH2) 2ER0
AA A01.017 endothiapepsin complex with H-256 (Pro-Thr-Glu-Phe-Phe-Arg-Glu) 2ER6
AA A01.017 endothiapepsin complex with H-261 2ER7_E
AA A01.017 endothiapepsin complex with L636,564 2ER9
AA A01.017 endothiapepsin complex with gem-diol inhibitor PD-135.040 2JJI_A
AA A01.017 endothiapepsin 2JJJ
AA A01.017 endothiapepsin complex with compound 1 2V00
AA A01.017 endothiapepsin neutron diffraction structure; complex with gem-diol inhibitor PD-135.040 . 2VS2_A
AA A01.017 endothiapepsin complex with CP-71,362 3ER3
AA A01.017 endothiapepsin complex with H-189 3ER5_E
AA A01.017 endothiapepsin 3LZY
AA A01.017 endothiapepsin 3PB5
AA A01.017 endothiapepsin 3PBD
AA A01.017 endothiapepsin 3PBZ
AA A01.017 endothiapepsin 3PCW
AA A01.017 endothiapepsin 3PCZ
AA A01.017 endothiapepsin 3PGI
AA A01.017 endothiapepsin 3PI0
AA A01.017 endothiapepsin 3PLD
AA A01.017 endothiapepsin 3PLL
AA A01.017 endothiapepsin 3PM4
AA A01.017 endothiapepsin 3PMU
AA A01.017 endothiapepsin 3PMY
AA A01.017 endothiapepsin 3PRS
AA A01.017 endothiapepsin 3PSY
AA A01.017 endothiapepsin 3PWW
AA A01.017 endothiapepsin 3Q6Y
AA A01.017 endothiapepsin 3T6I
AA A01.017 endothiapepsin 3T7P
AA A01.017 endothiapepsin 3T7Q
AA A01.017 endothiapepsin 3T7X
AA A01.017 endothiapepsin 3URI
AA A01.017 endothiapepsin 3URJ
AA A01.017 endothiapepsin 3URL
AA A01.017 endothiapepsin 3WZ6
AA A01.017 endothiapepsin 3WZ7
AA A01.017 endothiapepsin 3WZ8
AA A01.017 endothiapepsin 4APE
AA A01.017 endothiapepsin complex with PD125967 (BNA-His-CAL-DCI) 4ER1
AA A01.017 endothiapepsin complex with pepstatin 4ER2
AA A01.017 endothiapepsin complex with Pro-His-Pro-Phe-His-Leu-Val-Ile-His-Lys 4ER4
AA A01.017 endothiapepsin 4KUP
AA A01.017 endothiapepsin 4L6B
AA A01.017 endothiapepsin 4LAP
AA A01.017 endothiapepsin 4LBT
AA A01.017 endothiapepsin 4LHH
AA A01.017 endothiapepsin 4LP9
AA A01.017 endothiapepsin complex with BW624 (LOL-CH2-Val-Ile-Phe-OMe) 5ER1
AA A01.017 endothiapepsin complex with CP-69,799 (BOC-Phe-His-AHS-Lys-Phe) 5ER2
AA A01.017 endothiapepsin endothiapepsin in complex with biacylhydrazone 5HCT_A
AA A01.017 endothiapepsin treated with fragment 115 5P1W_A
AA A01.017 endothiapepsin treated with fragment 116 5P1X_A
AA A01.017 endothiapepsin treated with fragment 117 5P1Y_A
AA A01.017 endothiapepsin treated with fragment 118 5P1Z_A
AA A01.017 endothiapepsin treated with fragment 119 5P20_A
AA A01.017 endothiapepsin treated with fragment 120 5P22_A
AA A01.017 endothiapepsin treated with fragment 121 5P23_A
AA A01.017 endothiapepsin treated with fragment 122 5P24_A
AA A01.017 endothiapepsin treated with fragment 123 5P25_A
AA A01.017 endothiapepsin treated with fragment 124 5P26_A
AA A01.017 endothiapepsin treated with fragment 125 5P27_A
AA A01.017 endothiapepsin treated with fragment 126 5P28_A
AA A01.017 endothiapepsin treated with fragment 127 5P29_A
AA A01.017 endothiapepsin treated with fragment 128 5P2A_A
AA A01.017 endothiapepsin treated with fragment 129 5P2B_A
AA A01.017 endothiapepsin treated with fragment 130 5P2C_A
AA A01.017 endothiapepsin treated with fragment 131 5P2D_A
AA A01.017 endothiapepsin treated with fragment 132 5P2E_A
AA A01.017 endothiapepsin treated with fragment 133 5P2F_A
AA A01.017 endothiapepsin treated with fragment 134 5P2G_A
AA A01.017 endothiapepsin treated with fragment 135 5P2H_A
AA A01.017 endothiapepsin treated with fragment 136 5P2I_A
AA A01.017 endothiapepsin treated with fragment 137 5P2J_A
AA A01.017 endothiapepsin treated with fragment 138 5P2K_A
AA A01.017 endothiapepsin treated with fragment 139 5P2L_A
AA A01.017 endothiapepsin treated with fragment 140 5P2M_A
AA A01.017 endothiapepsin treated with fragment 141 5P2N_A
AA A01.017 endothiapepsin treated with fragment 142 5P2O_A
AA A01.017 endothiapepsin treated with fragment 143 5P2Q_A
AA A01.017 endothiapepsin treated with fragment 144 5P2R_A
AA A01.017 endothiapepsin treated with fragment 145 5P2S_A
AA A01.017 endothiapepsin treated with fragment 146 5P2T_A
AA A01.017 endothiapepsin treated with fragment 147 5P2U_A
AA A01.017 endothiapepsin treated with fragment 148 5P2V_A
AA A01.017 endothiapepsin treated with fragment 149 5P2W_A
AA A01.017 endothiapepsin treated with fragment 150 5P2X_A
AA A01.017 endothiapepsin treated with fragment 151 5P2Y_A
AA A01.017 endothiapepsin treated with fragment 152 5P2Z_A
AA A01.017 endothiapepsin treated with fragment 153 5P30_A
AA A01.017 endothiapepsin treated with fragment 154 5P31_A
AA A01.017 endothiapepsin treated with fragment 155 5P32_A
AA A01.017 endothiapepsin treated with fragment 156 5P33_A
AA A01.017 endothiapepsin treated with fragment 157 5P34_A
AA A01.017 endothiapepsin treated with fragment 158 5P35_A
AA A01.017 endothiapepsin treated with fragment 159 5P36_A
AA A01.017 endothiapepsin treated with fragment 160 5P37_A
AA A01.017 endothiapepsin treated with fragment 161 5P38_A
AA A01.017 endothiapepsin treated with fragment 162 5P39_A
AA A01.017 endothiapepsin treated with fragment 163 5P3A_A
AA A01.017 endothiapepsin treated with fragment 164 5P3B_A
AA A01.017 endothiapepsin treated with fragment 165 5P3C_A
AA A01.017 endothiapepsin treated with fragment 166 5P3D_A
AA A01.017 endothiapepsin treated with fragment 167 5P3E_A
AA A01.017 endothiapepsin treated with fragment 168 5P3F_A
AA A01.017 endothiapepsin treated with fragment 169 5P3G_A
AA A01.017 endothiapepsin treated with fragment 170 5P3H_A
AA A01.017 endothiapepsin treated with fragment 171 5P3I_A
AA A01.017 endothiapepsin treated with fragment 172 5P3J_A
AA A01.017 endothiapepsin treated with fragment 173 5P3K_A
AA A01.017 endothiapepsin treated with fragment 174 5P3L_A
AA A01.017 endothiapepsin treated with fragment 175 5P3M_A
AA A01.017 endothiapepsin treated with fragment 176 5P3N_A
AA A01.017 endothiapepsin treated with fragment 177 5P3O_A
AA A01.017 endothiapepsin treated with fragment 178 5P3P_A
AA A01.017 endothiapepsin treated with fragment 179 5P3Q_A
AA A01.017 endothiapepsin treated with fragment 180 5P3R_A
AA A01.017 endothiapepsin treated with fragment 181 5P3S_A
AA A01.017 endothiapepsin treated with fragment 182 5P3T_A
AA A01.017 endothiapepsin treated with fragment 183 5P3U_A
AA A01.017 endothiapepsin treated with fragment 184 5P3V_A
AA A01.017 endothiapepsin treated with fragment 185 5P3W_A
AA A01.017 endothiapepsin treated with fragment 186 5P3X_A
AA A01.017 endothiapepsin treated with fragment 187 5P3Y_A
AA A01.017 endothiapepsin treated with fragment 188 5P3Z_A
AA A01.017 endothiapepsin treated with fragment 189 5P40_A
AA A01.017 endothiapepsin treated with fragment 190 5P41_A
AA A01.017 endothiapepsin treated with fragment 191 5P42_A
AA A01.017 endothiapepsin treated with fragment 192 5P43_A
AA A01.017 endothiapepsin treated with fragment 193 5P44_A
AA A01.017 endothiapepsin treated with fragment 194 5P45_A
AA A01.017 endothiapepsin treated with fragment 195 5P46_A
AA A01.017 endothiapepsin treated with fragment 196 5P47_A
AA A01.017 endothiapepsin treated with fragment 197 5P48_A
AA A01.017 endothiapepsin treated with fragment 198 5P49_A
AA A01.017 endothiapepsin treated with fragment 199 5P4A_A
AA A01.017 endothiapepsin treated with fragment 200 5P4B_A
AA A01.017 endothiapepsin treated with fragment 201 5P4C_A
AA A01.017 endothiapepsin treated with fragment 202 5P4D_A
AA A01.017 endothiapepsin treated with fragment 203 5P4E_A
AA A01.017 endothiapepsin treated with fragment 204 5P4F_A
AA A01.017 endothiapepsin treated with fragment 205 5P4G_A
AA A01.017 endothiapepsin treated with fragment 206 5P4H_A
AA A01.017 endothiapepsin treated with fragment 207 5P4I_A
AA A01.017 endothiapepsin treated with fragment 208 5P4J_A
AA A01.017 endothiapepsin treated with fragment 209 5P4K_A
AA A01.017 endothiapepsin treated with fragment 210 5P4L_A
AA A01.017 endothiapepsin treated with fragment 211 5P4M_A
AA A01.017 endothiapepsin treated with fragment 212 5P4N_A
AA A01.017 endothiapepsin treated with fragment 213 5P4O_A
AA A01.017 endothiapepsin treated with fragment 214 5P4P_A
AA A01.017 endothiapepsin treated with fragment 215 5P4Q_A
AA A01.017 endothiapepsin treated with fragment 216 5P4R_A
AA A01.017 endothiapepsin treated with fragment 217 5P4S_A
AA A01.017 endothiapepsin treated with fragment 218 5P4T_A
AA A01.017 endothiapepsin treated with fragment 219 5P4U_A
AA A01.017 endothiapepsin treated with fragment 220 5P4V_A
AA A01.017 endothiapepsin treated with fragment 221 5P4W_A
AA A01.017 endothiapepsin treated with fragment 222 5P4X_A
AA A01.017 endothiapepsin treated with fragment 223 5P4Y_A
AA A01.017 endothiapepsin treated with fragment 224 5P4Z_A
AA A01.017 endothiapepsin treated with fragment 225 5P50_A
AA A01.017 endothiapepsin treated with fragment 226 5P51_A
AA A01.017 endothiapepsin treated with fragment 227 5P52_A
AA A01.017 endothiapepsin treated with fragment 228 5P53_A
AA A01.017 endothiapepsin treated with fragment 229 5P54_A
AA A01.017 endothiapepsin treated with fragment 230 5P55_A
AA A01.017 endothiapepsin treated with fragment 231 5P56_A
AA A01.017 endothiapepsin treated with fragment 232 5P57_A
AA A01.017 endothiapepsin treated with fragment 233 5P58_A
AA A01.017 endothiapepsin treated with fragment 234 5P59_A
AA A01.017 endothiapepsin treated with fragment 235 5P5A_A
AA A01.017 endothiapepsin treated with fragment 236 5P5B_A
AA A01.017 endothiapepsin treated with fragment 237 5P5C_A
AA A01.017 endothiapepsin treated with fragment 238 5P5D_A
AA A01.017 endothiapepsin treated with fragment 239 5P5E_A
AA A01.017 endothiapepsin treated with fragment 240 5P5F_A
AA A01.017 endothiapepsin treated with fragment 241 5P5G_A
AA A01.017 endothiapepsin treated with fragment 242 5P5H_A
AA A01.017 endothiapepsin treated with fragment 243 5P5I_A
AA A01.017 endothiapepsin treated with fragment 244 5P5J_A
AA A01.017 endothiapepsin treated with fragment 245 5P5K_A
AA A01.017 endothiapepsin treated with fragment 246 5P5L_A
AA A01.017 endothiapepsin treated with fragment 247 5P5M_A
AA A01.017 endothiapepsin treated with fragment 248 5P5N_A
AA A01.017 endothiapepsin treated with fragment 249 5P5O_A
AA A01.017 endothiapepsin treated with fragment 250 5P5P_A
AA A01.017 endothiapepsin treated with fragment 251 5P5Q_A
AA A01.017 endothiapepsin treated with fragment 252 5P5R_A
AA A01.017 endothiapepsin treated with fragment 253 5P5S_A
AA A01.017 endothiapepsin treated with fragment 254 5P5T_A
AA A01.017 endothiapepsin treated with fragment 255 5P5U_A
AA A01.017 endothiapepsin treated with fragment 256 5P5V_A
AA A01.017 endothiapepsin treated with fragment 257 5P5W_A
AA A01.017 endothiapepsin treated with fragment 258 5P5X_A
AA A01.017 endothiapepsin treated with fragment 259 5P5Y_A
AA A01.017 endothiapepsin treated with fragment 260 5P5Z_A
AA A01.017 endothiapepsin treated with fragment 261 5P60_A
AA A01.017 endothiapepsin treated with fragment 262 5P61_A
AA A01.017 endothiapepsin treated with fragment 263 5P62_A
AA A01.017 endothiapepsin treated with fragment 264 5P63_A
AA A01.017 endothiapepsin treated with fragment 265 5P64_A
AA A01.017 endothiapepsin treated with fragment 266 5P65_A
AA A01.017 endothiapepsin treated with fragment 267 5P66_A
AA A01.017 endothiapepsin treated with fragment 268 5P67_A
AA A01.017 endothiapepsin treated with fragment 269 5P68_A
AA A01.017 endothiapepsin treated with fragment 270 5P69_A
AA A01.017 endothiapepsin treated with fragment 271 5P6A_A
AA A01.017 endothiapepsin treated with fragment 272 5P6B_A
AA A01.017 endothiapepsin treated with fragment 273 5P6C_A
AA A01.017 endothiapepsin treated with fragment 274 5P6D_A
AA A01.017 endothiapepsin treated with fragment 275 5P6E_A
AA A01.017 endothiapepsin treated with fragment 276 5P6F_A
AA A01.017 endothiapepsin treated with fragment 277 5P6G_A
AA A01.017 endothiapepsin treated with fragment 278 5P6H_A
AA A01.017 endothiapepsin treated with fragment 279 5P6I_A
AA A01.017 endothiapepsin treated with fragment 280 5P6J_A
AA A01.017 endothiapepsin treated with fragment 281 5P6K_A
AA A01.017 endothiapepsin treated with fragment 282 5P6L_A
AA A01.017 endothiapepsin treated with fragment 283 5P6M_A
AA A01.017 endothiapepsin treated with fragment 284 5P6N_A
AA A01.017 endothiapepsin treated with fragment 285 5P6O_A
AA A01.017 endothiapepsin treated with fragment 286 5P6P_A
AA A01.017 endothiapepsin treated with fragment 287 5P6Q_A
AA A01.017 endothiapepsin treated with fragment 288 5P6R_A
AA A01.017 endothiapepsin treated with fragment 289 5P6S_A
AA A01.017 endothiapepsin treated with fragment 290 5P6T_A
AA A01.017 endothiapepsin treated with fragment 291 5P6U_A
AA A01.017 endothiapepsin treated with fragment 292 5P6V_A
AA A01.017 endothiapepsin treated with fragment 293 5P6W_A
AA A01.017 endothiapepsin treated with fragment 294 5P6X_A
AA A01.017 endothiapepsin treated with fragment 295 5P6Y_A
AA A01.017 endothiapepsin treated with fragment 296 5P6Z_A
AA A01.017 endothiapepsin treated with fragment 297 5P70_A
AA A01.017 endothiapepsin treated with fragment 298 5P71_A
AA A01.017 endothiapepsin treated with fragment 299 5P72_A
AA A01.017 endothiapepsin treated with fragment 300 5P73_A
AA A01.017 endothiapepsin treated with fragment 301 5P74_A
AA A01.017 endothiapepsin treated with fragment 302 5P75_A
AA A01.017 endothiapepsin treated with fragment 303 5P76_A
AA A01.017 endothiapepsin treated with fragment 304 5P77_A
AA A01.017 endothiapepsin treated with fragment 305 5P78_A
AA A01.017 endothiapepsin treated with fragment 306 5P79_A
AA A01.017 endothiapepsin treated with fragment 307 5P7A_A
AA A01.017 endothiapepsin treated with fragment 308 5P7B_A
AA A01.017 endothiapepsin treated with fragment 309 5P7C_A
AA A01.017 endothiapepsin treated with fragment 310 5P7D_A
AA A01.017 endothiapepsin treated with fragment 311 5P7E_A
AA A01.017 endothiapepsin treated with fragment 312 5P7F_A
AA A01.017 endothiapepsin treated with fragment 313 5P7G_A
AA A01.017 endothiapepsin treated with fragment 314 5P7H_A
AA A01.017 endothiapepsin treated with fragment 315 5P7I_A
AA A01.017 endothiapepsin treated with fragment 316 5P7J_A
AA A01.017 endothiapepsin treated with fragment 317 5P7K_A
AA A01.017 endothiapepsin treated with fragment 318 5P7L_A
AA A01.017 endothiapepsin treated with fragment 319 5P7M_A
AA A01.017 endothiapepsin treated with fragment 320 5P7N_A
AA A01.017 endothiapepsin treated with fragment 321 5P7O_A
AA A01.017 endothiapepsin treated with fragment 322 5P7P_A
AA A01.017 endothiapepsin treated with fragment 323 5P7Q_A
AA A01.017 endothiapepsin treated with fragment 324 5P7R_A
AA A01.017 endothiapepsin treated with fragment 325 5P7S_A
AA A01.017 endothiapepsin treated with fragment 326 5P7T_A
AA A01.017 endothiapepsin treated with fragment 327 5P7U_A
AA A01.017 endothiapepsin treated with fragment 328 5P7V_A
AA A01.017 endothiapepsin treated with fragment 329 5P7W_A
AA A01.017 endothiapepsin treated with fragment 330 5P7X_A
AA A01.017 endothiapepsin treated with fragment 331 5P7Y_A
AA A01.017 endothiapepsin treated with fragment 332 5P7Z_A
AA A01.017 endothiapepsin treated with fragment 333 5P80_A
AA A01.017 endothiapepsin treated with fragment 334 5P81_A
AA A01.017 endothiapepsin treated with fragment 335 5P82_A
AA A01.017 endothiapepsin treated with fragment 336 5P83_A
AA A01.017 endothiapepsin treated with fragment 337 5P84_A
AA A01.017 endothiapepsin treated with fragment 338 5P85_A
AA A01.017 endothiapepsin treated with fragment 339 5P86_A
AA A01.017 endothiapepsin treated with fragment 340 5P87_A
AA A01.017 endothiapepsin treated with fragment 341 5P88_A
AA A01.017 endothiapepsin treated with fragment 342 5P89_A
AA A01.017 endothiapepsin treated with fragment 343 5P8A_A
AA A01.017 endothiapepsin treated with fragment 344 5P8B_A
AA A01.017 endothiapepsin treated with fragment 345 5P8C_A
AA A01.017 endothiapepsin treated with fragment 346 5P8D_A
AA A01.017 endothiapepsin treated with fragment 347 5P8E_A
AA A01.017 endothiapepsin treated with fragment 348 5P8F_A
AA A01.017 endothiapepsin treated with fragment 349 5P8G_A
AA A01.017 endothiapepsin treated with fragment 350 5P8H_A
AA A01.017 endothiapepsin treated with fragment 351 5P8I_A
AA A01.017 endothiapepsin treated with fragment 352 5P8J_A
AA A01.017 endothiapepsin treated with fragment 353 5P8K_A
AA A01.017 endothiapepsin treated with fragment 354 5P8L_A
AA A01.017 endothiapepsin treated with fragment 355 5P8M_A
AA A01.017 endothiapepsin treated with fragment 356 5P8N_A
AA A01.017 endothiapepsin treated with fragment 357 5P8O_A
AA A01.017 endothiapepsin treated with fragment 358 5P8P_A
AA A01.017 endothiapepsin treated with fragment 359 5P8Q_A
AA A01.017 endothiapepsin treated with fragment 360 5P8R_A
AA A01.017 endothiapepsin treated with fragment 361 5P8S_A
AA A01.017 endothiapepsin treated with fragment 362 5P8T_A
AA A01.017 endothiapepsin treated with fragment 363 5P8U_A
AA A01.017 endothiapepsin treated with fragment 364 5P8V_A
AA A01.018 saccharopepsin complex with IA3 mutant inhibitor 1DP5_A
AA A01.018 saccharopepsin complex with IA3 inhibitor 1DPJ_A
AA A01.018 saccharopepsin 1FMU
AA A01.018 saccharopepsin 1FMX
AA A01.018 saccharopepsin complex with hydroxythylene inhibitor CP-108,420 1FQ4
AA A01.018 saccharopepsin complex with cyclic statine inhibitor PD-129,541 1FQ5
AA A01.018 saccharopepsin complex with glycol inhibitor PD-133,450 1FQ6
AA A01.018 saccharopepsin complex with inhibitor CP-72,647 1FQ7
AA A01.018 saccharopepsin complex with difluorostatine inhibitor CP81,198 1FQ8
AA A01.018 saccharopepsin complex with proteinase A inhibitor 3 mutant 1G0V_A
AA A01.018 saccharopepsin complex with N-carbonylmorpholine-Phe-norLeu-cyclohexylfluorostatone-methylamine 2JXR
AA A01.019 polyporopepsin 1WKR
AA A01.020 phytepsin zymogen 1QDM
AA A01.020 phytepsin 1B5F_A
AA A01.020 phytepsin 5NFG_A
AA A01.021 plasmepsin (Plasmodium sp.) 1MIQ
AA A01.021 plasmepsin (Plasmodium sp.) complex with pepstatin A inhibitor 1QS8
AA A01.021 plasmepsin (Plasmodium sp.) complex with allophenylnorstatine inhibitor KNI-764 2ANL
AA A01.021 plasmepsin (Plasmodium sp.) theoretical model 1KBX
AA A01.022 plasmepsin-1 theoretical model 1LCR
AA A01.022 plasmepsin-1 1LDU
AA A01.022 plasmepsin-1 3QRV
AA A01.022 plasmepsin-1 complex with KNI-10006 inhibitor 3QS1
AA A01.023 plasmepsin-2 theoretical model 1J8J
AA A01.023 plasmepsin-2 complex with inhibitor RS367 1LEE
AA A01.023 plasmepsin-2 complex with inhibitor RS370 1LF2
AA A01.023 plasmepsin-2 complex with EH58 inhibitor 1LF3
AA A01.023 plasmepsin-2 1LF4
AA A01.023 plasmepsin-2 complex with pepstatin A 1M43
AA A01.023 plasmepsin-2 complex with a statine based inhibitor 1ME6
AA A01.023 plasmepsin-2 precursor 1PFZ
AA A01.023 plasmepsin-2 complex with pepstatin A 1SME
AA A01.023 plasmepsin-2 complex with TIT inhibitor 1W6H
AA A01.023 plasmepsin-2 complex with pepstatin A 1W6I
AA A01.023 plasmepsin-2 complex with pepstatin A 1XDH
AA A01.023 plasmepsin-2 complex with a pepstatin analogue 1XE5
AA A01.023 plasmepsin-2 complex with a pepstatin analogue 1XE6
AA A01.023 plasmepsin-2 complex with N-(R-carboxy-ethyl)-alpha-(S)-(2-phenylethyl) 2BJU
AA A01.023 plasmepsin-2 2BL3
AA A01.023 plasmepsin-2 achiral, cheap and potent inhibitors of plasmepsins ii 2IGX_A
AA A01.023 plasmepsin-2 achiral, cheap and potent inhibitors of plasmepsins ii 2IGY_A
AA A01.023 plasmepsin-2 complex with KPFS-(CH2-NH)-LQF 2R9B_A
AA A01.023 plasmepsin-2 re-refinement of uncomplexed plasmepsin ii from plasmodium falciparum. 3F9Q_A
AA A01.023 plasmepsin-2 4CKU
AA A01.023 plasmepsin-2 4Y6M
AA A01.023 plasmepsin-2 4YA8
AA A01.027 trichodermapepsin 3C9X
AA A01.027 trichodermapepsin complex with pepstatin A 3C9Y
AA A01.027 trichodermapepsin complex with pepstatin A 3EMY
AA A01.030 yapsin-1 theoretical model 1YPS
AA A01.037 canditropsin Complex with Thr-Ile-Thr-Ser 1J71
AA A01.038 candiparapsin complex with pepstatin 3FV3
AA A01.038 candiparapsin 3TNE
AA A01.041 BACE2 g.p. (Homo sapiens) complex with hydroxyethylenamine transition-state inhibitor N-(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methylbenzyl)amino]propyldibenzo[B,F]oxepine-10-carboxamide 2EWY_A
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZKG
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZKI
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZKM
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZKN
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZKQ
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZKS
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZKX
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZL7
AA A01.041 BACE2 g.p. (Homo sapiens) 3ZLQ
AA A01.041 BACE2 g.p. (Homo sapiens) 4BEL
AA A01.041 BACE2 g.p. (Homo sapiens) 4BFB
AA A01.043 histoaspartic peptidase (Plasmodium falciparum) ON HOLD; apoenzyme 3FNS
AA A01.043 histoaspartic peptidase (Plasmodium falciparum) complex with pepstatin A 3FNT
AA A01.043 histoaspartic peptidase (Plasmodium falciparum) complex with inhibitor KNI-10006 3FNU
AA A01.043 histoaspartic peptidase (Plasmodium falciparum) 3QVC_A
AA A01.043 histoaspartic peptidase (Plasmodium falciparum) complex with kni-10395 3QVI_A
AA A01.055 Mername-AA047 peptidase 1AM5
AA A01.059 plasmepsin-4 complex with pepstatin A 1LS5_A
AA A01.060 candidapepsin SAP2 complex with A70450 1EAG_A
AA A01.060 candidapepsin SAP2 complex with N-ethyl-N-[(4-methylpiperazin-1-yl)carbonyl]- D-phenylalanyl-N-[(1S,2S,4R)-4-(butylcarbamoyl)- 1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]- L-norleucinamide 1ZAP
AA A01.061 candidapepsin SAP3 secreted aspartic proteinase (sap) 3 from candida albicans 2H6S_A
AA A01.061 candidapepsin SAP3 complex with pepstatin A 2H6T_A
AA A01.063 candidapepsin SAP5 complex with pepstatin A 2QZX
AA A01.070 pepsin A4 Uropepsin 1FLH
AA A01.070 pepsin A4 pepsin 3A 1PSN
AA A01.070 pepsin A4 pepsin 3A; complex with pepstatin 1PSO
AA A01.070 pepsin A4 complex with phosphonate inhibitor Iva-Val-Val-Leu(P)-(O)Phe-Ala-Ala-Ome 1QRP
AA A01.070 pepsin A4 3UTL
AA A01.075 plasmepsin-5 (Plasmodium sp.) plasmepsin v from plasmodium vivax bound to a transition state mimetic(wehi-842) 4ZL4_A
AA A01.075 plasmepsin-5 (Plasmodium sp.) plasmepsin v from plasmodium vivax bound to a transition state mimetic(wehi-601) 6C4G_A
AA A01.076 Sapp2p peptidase (Candida parapsilosis) aspartic proteinase sapp2 secreted from candida parapsilosis at 0.82 aresolution. 4Y9W_A
AA A01.076 Sapp2p peptidase (Candida parapsilosis) aspartic proteinase sapp2 secreted from candida parapsilosis at 1.25 aresolution 4YBF_A
AA A01.950 cockroach allergen Asn93Gln mutant 1YG9
AA A01.950 cockroach allergen Asn93Gln mutant; complex with monoclonal antibody 2NR6_A
AA A01.950 cockroach allergen 3LIZ
AA A01.950 cockroach allergen 4RLD
AA A01.974 xylanase inhibitor precursor 1T6E_X
AA A01.974 xylanase inhibitor precursor complex with Aspergillus niger xylanase-I 1T6G_A
AA A01.974 xylanase inhibitor precursor complex with Bacillus subtilis xylanase 2B42_A
AA A01.974 xylanase inhibitor precursor complex with bacillus subtilis xylanase 3HD8_A
AA A01.UNB subfamily A1B non-peptidase homologues 3VLA_A
AA A01.UNB subfamily A1B non-peptidase homologues 3VLB_A
AA A01.UNB subfamily A1B non-peptidase homologues 4PPH_A
AA A01.UNB subfamily A1B non-peptidase homologues 3AUP
AA A01.UPA subfamily A1A unassigned peptidases 1IZD
AA A01.UPA subfamily A1A unassigned peptidases 1IZE
AA A01.UPA subfamily A1A unassigned peptidases complex with the n-terminal octapeptide of the propeptid 5N70_A
AA A01.UPA subfamily A1A unassigned peptidases 5N71_A
AA A01.UPA subfamily A1A unassigned peptidases zymogen 5N7N_A
AA A01.UPA subfamily A1A unassigned peptidases complex with the inhibitor pepstatin a 5N7Q_A
AA A01.UPA subfamily A1A unassigned peptidases complex with kni-10343 5YIA_A
AA A01.UPA subfamily A1A unassigned peptidases complex with kni-10743 5YIB_A
AA A01.UPA subfamily A1A unassigned peptidases complex with kni-10333 5YIC_A
AA A01.UPA subfamily A1A unassigned peptidases complex with kni-10395 5YID_A
AA A01.UPA subfamily A1A unassigned peptidases complex with kni-10742 5YIE_A
AA A01.UPA subfamily A1A unassigned peptidases precursor 5MKT_A
AA A02.001 HIV-1 retropepsin complex with Glu-Asp-Leu inhibitor 1A30
AA A02.001 HIV-1 retropepsin complex with SDZ283-910 inhibitor 1A8G
AA A02.001 HIV-1 retropepsin complex with CA-P2 peptide substrate analogue 1A8K
AA A02.001 HIV-1 retropepsin complex with Arg-Val-Leu-Phe-Glu-Ala-norLeu-NH2 1A94
AA A02.001 HIV-1 retropepsin complex with U-89360E inhibitor 1A9M
AA A02.001 HIV-1 retropepsin complex with methyl N-(4S,5S)-5-[(L-alanyl-L-alanyl)amino]- 4-hydroxy-6-phenylhexanoyl-L-valyl-L-valinate 1AAQ
AA A02.001 HIV-1 retropepsin complex with UCSF8 inhibitor 1AID
AA A02.001 HIV-1 retropepsin complex with AHA006 inhibitor 1AJV
AA A02.001 HIV-1 retropepsin complex with AHA001 inhibitor 1AJX
AA A02.001 HIV-1 retropepsin Ala28Ser mutant 1AXA
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 1 1B6J
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 5 1B6K
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 4 1B6L
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 6 1B6M
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 3 1B6N
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 2 1B6O
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 7 1B6P
AA A02.001 HIV-1 retropepsin mutant; complex with SB203386 inhibitor 1BDL
AA A02.001 HIV-1 retropepsin complex with SB203386 inhibitor 1BDQ
AA A02.001 HIV-1 retropepsin mutant; complex with SB203386 inhibitor 1BDR
AA A02.001 HIV-1 retropepsin Val3Ile, Ile64Val, Val77Ile mutant; complex with cyclic urea amide XV638 1BV7
AA A02.001 HIV-1 retropepsin mutant; complex with XV638 (Dupont Pharmaceuticals) 1BV9
AA A02.001 HIV-1 retropepsin NMR structure; complex with DMP323 1BVE
AA A02.001 HIV-1 retropepsin NMR structure; complex with DMP323 1BVG
AA A02.001 HIV-1 retropepsin Val82Phe and Ile84Val double mutant; complex with XV638 (Dupont Pharmaceuticals) 1BWA
AA A02.001 HIV-1 retropepsin Val82Phe and Ile84Val double mutant; complex with SD146 (Dupont Pharmaceuticals) 1BWB
AA A02.001 HIV-1 retropepsin complex with L-739,622 inhibitor 1C6X
AA A02.001 HIV-1 retropepsin complex with L-735,524 inhibitor 1C6Y
AA A02.001 HIV-1 retropepsin complex with ROC 505 inhibitor 1C6Z
AA A02.001 HIV-1 retropepsin complex with L-756,423 inhibitor 1C70
AA A02.001 HIV-1 retropepsin complex with a cyclic peptide inhibitor 1CPI
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA435 1D4H
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA425 1D4I
AA A02.001 HIV-1 retropepsin complex with inhibitor MSL370 1D4J
AA A02.001 HIV-1 retropepsin complex with N-13-[(10S,13S)-9,12-dioxo-10-(2-butyl)-2-oxa-8,11-diazabicyclo [13.2.2] nonadeca-15,17,18-triene] (2R)-benzyl-(4S)-hydroxy-5-aminopentanoic (1R)- hydroxy-(2S)-indaneamide 1D4K
AA A02.001 HIV-1 retropepsin complex with (10S,13S,1'R)-13-[1'-hydroxy-2'-(N-P-aminobenzenesulfonyl-1''-amino-3''-methylbutyl)ethyl]-8,11-dioxo-10-isopropyl-2-oxa-9,12-diazabicyclo [13.2.2]nonadeca-15,17,18-triene 1D4L
AA A02.001 HIV-1 retropepsin Val82Phe, Ile84Val double mutant; complex with tipranavir inhibitor 1D4S
AA A02.001 HIV-1 retropepsin Gln7Lys, Leu33Ile, Leu63Ile mutant: complex with tipranavir 1D4Y
AA A02.001 HIV-1 retropepsin drug resistant mutant; complex with peptide inhibitor 1DAZ
AA A02.001 HIV-1 retropepsin complex with a difluoroketone containing inhibitor A79285 1DIF
AA A02.001 HIV-1 retropepsin complex with DMP450 (Dupont-Merck) 1DMP
AA A02.001 HIV-1 retropepsin complex with inhibitor analogue of CA-P2 processing site 1DW6
AA A02.001 HIV-1 retropepsin drug-resistant mutant 1EBK
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA322 1EBW
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA369 1EBY
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA388 1EBZ
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA403 1EC0
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA409 1EC1
AA A02.001 HIV-1 retropepsin complex with inhibitor BEA428 1EC2
AA A02.001 HIV-1 retropepsin complex with inhibitor MSA367 1EC3
AA A02.001 HIV-1 retropepsin complex with Lys-Ala-Arg-Val-Leu-Ala-Glu-Ala-Met-Ser substrate 1F7A
AA A02.001 HIV-1 retropepsin Val48Gly, Met90Leu mutant; complex with saquinavir 1FB7
AA A02.001 HIV-1 retropepsin complex with substrate acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg 1FEJ
AA A02.001 HIV-1 retropepsin engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor 1FF0
AA A02.001 HIV-1 retropepsin engineered; complex with Arg-Val-2-amino-4-methyl-pentan-1-ol-Phe-Glu-Ala-norLeu-NH2 inhibitor 1FFF
AA A02.001 HIV-1 retropepsin engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor 1FFI
AA A02.001 HIV-1 retropepsin engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor 1FG6
AA A02.001 HIV-1 retropepsin engineered; complex with Arg-Val-2-amino-4-methyl-pentan-1-ol-Phe-Glu-Ala-norLeu-NH2 inhibitor 1FG8
AA A02.001 HIV-1 retropepsin engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor 1FGC
AA A02.001 HIV-1 retropepsin complex with Boc-3(S)-amino-4-phenyl-butan-2(S)-yl-Phe-Glu-Phe-NH2 inhibitor 1FQX
AA A02.001 HIV-1 retropepsin complex with cyclic sulfamide inhibitor AHA047 1G2K
AA A02.001 HIV-1 retropepsin complex with AHA024 inhibitor 1G35
AA A02.001 HIV-1 retropepsin homodimer covalently linked through engineered pentapeptide linker 1G6L
AA A02.001 HIV-1 retropepsin Val82Asp mutant; complex with U89360E inhibitor 1GNM
AA A02.001 HIV-1 retropepsin Val82Asn mutant; complex with U89360E inhibitor 1GNN
AA A02.001 HIV-1 retropepsin complex with U89360E inhibitor 1GNO
AA A02.001 HIV-1 retropepsin complex with SB203238 1HBV
AA A02.001 HIV-1 retropepsin recombinant 1HEF
AA A02.001 HIV-1 retropepsin recombinant 1HEG
AA A02.001 HIV-1 retropepsin recombinant 1HHP
AA A02.001 HIV-1 retropepsin complex with CGP 53820 1HIH
AA A02.001 HIV-1 retropepsin 1HIV
AA A02.001 HIV-1 retropepsin complex with SB204144 1HOS
AA A02.001 HIV-1 retropepsin mutant form; complex with benzenesulfonamide inhibitor U103265 1HPO
AA A02.001 HIV-1 retropepsin 1HPS
AA A02.001 HIV-1 retropepsin complex with VX-478 1HPV
AA A02.001 HIV-1 retropepsin complex with inhibitor KNI-272 1HPX
AA A02.001 HIV-1 retropepsin complex with L-735,524 1HSG
AA A02.001 HIV-1 retropepsin complex with GR123976 1HTE
AA A02.001 HIV-1 retropepsin complex with GR126045 1HTF
AA A02.001 HIV-1 retropepsin complex with GR137615 1HTG
AA A02.001 HIV-1 retropepsin complex with A-76928 1HVC
AA A02.001 HIV-1 retropepsin complex with Q8261 inhibitor 1HVH
AA A02.001 HIV-1 retropepsin complex with A77003 1HVI
AA A02.001 HIV-1 retropepsin complex with A78791 1HVJ
AA A02.001 HIV-1 retropepsin complex with A-76928 1HVK
AA A02.001 HIV-1 retropepsin complex with A76889 1HVL
AA A02.001 HIV-1 retropepsin theoretical model 1HVP
AA A02.001 HIV-1 retropepsin complex with XK263 1HVR
AA A02.001 HIV-1 retropepsin Val82Ala mutant; complex with A77003 1HVS
AA A02.001 HIV-1 retropepsin complex with synthetic cyclic urea inhibitor XK216 1HWR
AA A02.001 HIV-1 retropepsin complex with RO 31-8959 1HXB
AA A02.001 HIV-1 retropepsin complex with A-84538 1HXW
AA A02.001 HIV-1 retropepsin 1IHV
AA A02.001 HIV-1 retropepsin 1IHW
AA A02.001 HIV-1 retropepsin complex with hydroxyethylamine peptidomimetic inhibitor Boc-Pso-Phe-Gln-Phe-NH2 1IIQ
AA A02.001 HIV-1 retropepsin complex with inhibitor Q50 1IZH
AA A02.001 HIV-1 retropepsin complex with inhibitor Q50 1IZI
AA A02.001 HIV-1 retropepsin engineered multiple mutant form 1K1T
AA A02.001 HIV-1 retropepsin engineered multiple mutant form 1K1U
AA A02.001 HIV-1 retropepsin engineered multiple mutant form 1K2B
AA A02.001 HIV-1 retropepsin engineered multiple mutant form 1K2C
AA A02.001 HIV-1 retropepsin complex with inhibitor MK1 1K6C
AA A02.001 HIV-1 retropepsin complex with inhibitor XN3 1K6P
AA A02.001 HIV-1 retropepsin complex with inhibitor XN1 1K6T
AA A02.001 HIV-1 retropepsin complex with inhibitor XN2 1K6V
AA A02.001 HIV-1 retropepsin complex with GAG protein fragment 1KJ4
AA A02.001 HIV-1 retropepsin complex with GAG protein fragment 1KJ7
AA A02.001 HIV-1 retropepsin complex with GAG protein fragment 1KJF
AA A02.001 HIV-1 retropepsin complex with decapeptide substrate 1KJG
AA A02.001 HIV-1 retropepsin complex with POL protein fragment 1KJH
AA A02.001 HIV-1 retropepsin complex with inhibitor JE-2147 1KZK
AA A02.001 HIV-1 retropepsin engineered tethered dimer 1LV1
AA A02.001 HIV-1 retropepsin Ala71Val, Val82Thr, Ile84Val mutant; complex with Boc-Phe-Psi[CH2CH2NH]-Phe-Glu-Phe-NH2 1LZQ
AA A02.001 HIV-1 retropepsin complex with Boc-Phe-Psi[CH2CH2NH]-Phe-Glu-Phe-NH2 1M0B_A
AA A02.001 HIV-1 retropepsin complex with DMP450 1MER
AA A02.001 HIV-1 retropepsin Ile84Val mutant; complex with DMP323 1MES
AA A02.001 HIV-1 retropepsin Val82Phe mutant; complex with DMP323 1MET
AA A02.001 HIV-1 retropepsin Val82Phe, Ile84Val mutant; complex with DMP323 1MEU
AA A02.001 HIV-1 retropepsin Gln7lys/Leu33Ile/Leu63Ile mutant; complex with kni-577 1MRW_A
AA A02.001 HIV-1 retropepsin mutant q7k l33i l63i v82f i84v; complex with kni-577 1MRX_A
AA A02.001 HIV-1 retropepsin Gln7Lys, Leu33Ile, Leu63Ile mutant; complex with KNI-764 inhibitor 1MSM_A
AA A02.001 HIV-1 retropepsin Gln7Lys, Leu33Ile, Leu63Ile, Val82Phe, Ile84Valmutant; complex with KNI-764 inhibitor 1MSN_A
AA A02.001 HIV-1 retropepsin complex with GAG protein fragment 1MT7
AA A02.001 HIV-1 retropepsin complex with GAG protein fragment 1MT8
AA A02.001 HIV-1 retropepsin complex with GAG protein fragment 1MT9
AA A02.001 HIV-1 retropepsin complex with Saquinavir 1MTB
AA A02.001 HIV-1 retropepsin complex with a cyclic Phe-Ile-Val peptidomimetic inhibitor 1MTR
AA A02.001 HIV-1 retropepsin complex with lopinavir 1MUI
AA A02.001 HIV-1 retropepsin complex with Ritonavir 1N49
AA A02.001 HIV-1 retropepsin 1.03 a structure of hiv-1 protease: inhibitor binding inside and outside the active site 1NH0_A
AA A02.001 HIV-1 retropepsin complex with LDC271 1NPV
AA A02.001 HIV-1 retropepsin complex with inhibitor LGZ479 1NPW
AA A02.001 HIV-1 retropepsin 1ODW
AA A02.001 HIV-1 retropepsin Ala71Thr, Val82Ala mutant 1ODX
AA A02.001 HIV-1 retropepsin complex with inhibitor LP-130 1ODY
AA A02.001 HIV-1 retropepsin complex with nelfinavir mesylate AG1343 inhibitor 1OHR
AA A02.001 HIV-1 retropepsin dimer; complex with A-98881 1PRO
AA A02.001 HIV-1 retropepsin complex with inhibitor XV638 1QBR
AA A02.001 HIV-1 retropepsin complex with inhibitor DMP323 1QBS
AA A02.001 HIV-1 retropepsin complex with inhibitor SD146 1QBT
AA A02.001 HIV-1 retropepsin complex with inhibitor Q8467 (Dupont-Merck) 1QBU
AA A02.001 HIV-1 retropepsin resistant strain (Val82Ala mutant); complex with ritonavir 1RL8_A
AA A02.001 HIV-1 retropepsin multidrug-resistant hiv-1 protease 1RV7_A
AA A02.001 HIV-1 retropepsin complex with SB203386 1SBG
AA A02.001 HIV-1 retropepsin Val82Ala and Ile90Met mutant; complex with indinavir 1SDT_A
AA A02.001 HIV-1 retropepsin Val82Ala and Ile90Met mutant 1SDU_A
AA A02.001 HIV-1 retropepsin Val82Ala and Ile90Met mutant 1SDV_A
AA A02.001 HIV-1 retropepsin comparing the accumulation of active site and non-active site mutations in the hiv-1 protease 1SGU_A
AA A02.001 HIV-1 retropepsin comparing the accumulation of active site and non-active site mutations in the hiv-1 protease 1SH9_A
AA A02.001 HIV-1 retropepsin complex with a product of autoproteolysis 1SP5_A
AA A02.001 HIV-1 retropepsin complex with TMC114 inhibitor 1T3R_A
AA A02.001 HIV-1 retropepsin triple mutant; complex with SB203386 1TCX
AA A02.001 HIV-1 retropepsin Val82Ala/Asp25Asn mutant; complex with AP2V substrate variant of NC-P1 decamer peptide 1TSQ_A
AA A02.001 HIV-1 retropepsin Val82Ala/Asp25Asn mutant; complex with AP2V substrate variant of NC-P1 decamer peptide 1TSQ_P
AA A02.001 HIV-1 retropepsin wild-type Asp25Asn variant; complex with decamer NCP1 substrate peptide 1TSU_A
AA A02.001 HIV-1 retropepsin wild-type Asp25Asn variant; complex with decamer NCP1 substrate peptide 1TSU_P
AA A02.001 HIV-1 retropepsin peptidase domain only; multi-drug resistant isolate 1TW7
AA A02.001 HIV-1 retropepsin complex with peptidomimetic inhibitor KI2-Phe-Glu-Glu-NH2 1U8G_A
AA A02.001 HIV-1 retropepsin complex with [3-[1-(4-bromophenyl)isobutyl]-4-hydroxycoumarin (U095438) 1UPJ
AA A02.001 HIV-1 retropepsin complex with HOE/BAY 793 inhibitor 1VIJ
AA A02.001 HIV-1 retropepsin compex with HOE/BAY 793 inhibitor, orthorhombic form 1VIK
AA A02.001 HIV-1 retropepsin complex with fluoro substituted diol- based c2-symmetric inhibitor N,N-[2,5-O-di-3-fluoro-benzyl-glucaryl]-di-[1-amino-indan-2-ol] 1W5V_A
AA A02.001 HIV-1 retropepsin complex with fluoro substituted diol- based c2-symmetric inhibitor (2R,3R,4R,5R)-2,5-bis[(2,4-difluorobenzyl)oxy]-3,4-dihydroxy-N,N'-bis[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide 1W5W_A
AA A02.001 HIV-1 retropepsin complex with fluoro substituted diol- based c2-symmetric inhibitor (2R,3R,4R,5R)-2,5-bis[(2,3-difluorobenzyl)oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide 1W5X_A
AA A02.001 HIV-1 retropepsin complex with fluoro substituted diol- based c2-symmetric inhibitor (2R,3R,4R,5R)-2,5-bis[(2,5-difluorobenzyl)oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide 1W5Y_A
AA A02.001 HIV-1 retropepsin complex with asymmetric inhibitor BEA568 1WBK_A
AA A02.001 HIV-1 retropepsin complex with symmetric inhibitor BEA450 1WBM_A
AA A02.001 HIV-1 retropepsin complex with pyrrolidinmethanamine 1XL2_A
AA A02.001 HIV-1 retropepsin complex with amidhyroxysulfone 1XL5_A
AA A02.001 HIV-1 retropepsin complex with Pro-Ile-Val-NH2 peptide product 1YTG
AA A02.001 HIV-1 retropepsin complex with ac-Ser-Leu-Asn-Phe peptide product 1YTH
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 3 1Z1H_A
AA A02.001 HIV-1 retropepsin complex with macrocyclic peptidomimetic inhibitor 2 1Z1R_A
AA A02.001 HIV-1 retropepsin lle63Pro, Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2 1Z8C_A
AA A02.001 HIV-1 retropepsin Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2 1ZBG_A
AA A02.001 HIV-1 retropepsin Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2 1ZJ7_A
AA A02.001 HIV-1 retropepsin Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor 1ZLF_A
AA A02.001 HIV-1 retropepsin Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2 1ZPK_A
AA A02.001 HIV-1 retropepsin complex with a hydroxyethylamine inhibitor N-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl-L-phenylalanyl-L-alpha-glutamyl-L-phenylalaninamide 1ZSF_A
AA A02.001 HIV-1 retropepsin complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2 1ZSR_A
AA A02.001 HIV-1 retropepsin complex with cobalt bis(1,2-dicarbollide) 1ZTZ_A
AA A02.001 HIV-1 retropepsin complex with ts-126 2A1E_A
AA A02.001 HIV-1 retropepsin synthesis and activity of n-axyl azacyclic urea hiv-1 protease inhibitors with high potency against multiple drug resistant viral strains. 2A4F_A
AA A02.001 HIV-1 retropepsin complex with UCSF8 inhibitor 2AID
AA A02.001 HIV-1 retropepsin Ile84Val mutant; complex with a substrate analog p2-nc 2AOC_A
AA A02.001 HIV-1 retropepsin complex with a substrate analog p2-nc 2AOD_A
AA A02.001 HIV-1 retropepsin Val82Ala mutant; complex with a substrate analog ca-p2 2AOE_A
AA A02.001 HIV-1 retropepsin Val82Ala mutant; complex with a substrate analog p1-p6 2AOF_A
AA A02.001 HIV-1 retropepsin Val82Ala mutant; complex with a substrate analog p2-nc 2AOG_A
AA A02.001 HIV-1 retropepsin Val82Ala mutant; complex with a substrate analog p6-pr 2AOH_A
AA A02.001 HIV-1 retropepsin complex with a substrate analog p1-p6 2AOI_A
AA A02.001 HIV-1 retropepsin complex with a substrate analog p6-pr 2AOJ_A
AA A02.001 HIV-1 retropepsin complex with atazanavir 2AQU_A
AA A02.001 HIV-1 retropepsin kinetics, stability, and structural changes in high resolution crystalstructures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s 2AVM_A
AA A02.001 HIV-1 retropepsin kinetics, stability, and structural changes in high resolution crystalstructures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s 2AVO_A
AA A02.001 HIV-1 retropepsin kinetics, stability, and structural changes in high resolution crystalstructures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s 2AVQ_A
AA A02.001 HIV-1 retropepsin kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s 2AVS_A
AA A02.001 HIV-1 retropepsin kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s 2AVV_A
AA A02.001 HIV-1 retropepsin ML4-3 mutant; complex with inhibitorTL3 2AZ8_A
AA A02.001 HIV-1 retropepsin hiv-1 protease nl4-3 1x mutant 2AZ9_A
AA A02.001 HIV-1 retropepsin NL4-3 3X mutant; complex with inhibitorTL-3 2AZB_A
AA A02.001 HIV-1 retropepsin hiv-1 protease nl4-3 6x mutant ***caveat 2azc incorrect chirality at ca of ala j 201 2AZC_A
AA A02.001 HIV-1 retropepsin complex with ritonavir 2B60_A
AA A02.001 HIV-1 retropepsin mutant; complex with indinavir 2B7Z_B
AA A02.001 HIV-1 retropepsin complex with akc4p_133a 2BB9_A
AA A02.001 HIV-1 retropepsin complex with hh1_173_3a 2BBB_A
AA A02.001 HIV-1 retropepsin complex with L-738,317 inhibitor 2BPV
AA A02.001 HIV-1 retropepsin complex with L-738,317 inhibitor 2BPW
AA A02.001 HIV-1 retropepsin complex with L-735,524 inhibitor 2BPX
AA A02.001 HIV-1 retropepsin complex with L-739,622 inhibitor 2BPY
AA A02.001 HIV-1 retropepsin complex with L-739,622 inhibitor 2BPZ
AA A02.001 HIV-1 retropepsin complex with inhibitor AHA455 2BQV_A
AA A02.001 HIV-1 retropepsin wild-type; complex with r01 2F3K_A
AA A02.001 HIV-1 retropepsin Asp30Asn mutant; complex with inhibitor TMC114 2F80_A
AA A02.001 HIV-1 retropepsin Leu90Met mutant; complex with inhibitor TMC114 2F81_A
AA A02.001 HIV-1 retropepsin Ile50Val mutant; complex with inhibitor TMC114 2F8G_A
AA A02.001 HIV-1 retropepsin Thr80Ser variant; complex with the inhibitor saquinavir 2FGU_A
AA A02.001 HIV-1 retropepsin Thrt80Asn variant; complex with the inhibitor saquinavir 2FGV_A
AA A02.001 HIV-1 retropepsin Asp25Asn mutant; complex with wild-type HIV-1 NC-P1 substrate. 2FNS_A
AA A02.001 HIV-1 retropepsin drug-resistant (Val82Ala) inactive (Asp25Asn) mutant; complex with AP2V variant of hiv-1 NC-P1 substrate. 2FNT_A
AA A02.001 HIV-1 retropepsin structure of hiv protease 6x mutant in apo form 2HB2_A
AA A02.001 HIV-1 retropepsin complex with potent inhibitor GRL06579 2HB3_A
AA A02.001 HIV-1 retropepsin structure of hiv protease nl4-3 in an unliganded state 2HB4_A
AA A02.001 HIV-1 retropepsin 6x mutant; complex with AB-2. 2HC0_A
AA A02.001 HIV-1 retropepsin recombinant 2HVP
AA A02.001 HIV-1 retropepsin complex with KB-19 2I0A_A
AA A02.001 HIV-1 retropepsin complex with AD-81 2I0D_A
AA A02.001 HIV-1 retropepsin complex with inhibitor jg-365 2J9J_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MVT-101 2J9K_A
AA A02.001 HIV-1 retropepsin complex with jg-365 2JE4_A
AA A02.001 HIV-1 retropepsin Val82Ala mutant; complex with a inhibitor saquinavir 2NMY_A
AA A02.001 HIV-1 retropepsin Val82Ala mutant; complex with a inhibitor saquinavir 2NMZ_A
AA A02.001 HIV-1 retropepsin Ile84Val mutant; complex with a inhibitor saquinavir 2NNK_A
AA A02.001 HIV-1 retropepsin Ile84Val mutant; complex with a inhibitor saquinavir 2NNP_A
AA A02.001 HIV-1 retropepsin complex with product in situ 2NPH_A
AA A02.001 HIV-1 retropepsin Asp25Asn mutant; complex with rt-rh analogue peptide gly-ala-asp-ile-phe*tyr-leu-asp-gly-ala 2NXD_A
AA A02.001 HIV-1 retropepsin Asp25Asn mutant; complex with peptide Gly-Ala-Glu-Val-Phe*Tyr-Val-Asp-Gly-Ala 2NXL_A
AA A02.001 HIV-1 retropepsin Asp25Asn mutant; complex with the rt-rh analogue peptide gly-ala-gln-thr-phe*tyr-val-asp-gly-ala 2NXM_A
AA A02.001 HIV-1 retropepsin Gln7Lys mutant; complex with Atazanavir 2O4K_A
AA A02.001 HIV-1 retropepsin Gln7Lys, Ile50Val mutant; complex with Tipranavir 2O4L_A
AA A02.001 HIV-1 retropepsin TRM mutant; complex with Tipranavir 2O4N_A
AA A02.001 HIV-1 retropepsin Gln7Lys mutant; complex with Tipranavir 2O4P_A
AA A02.001 HIV-1 retropepsin Gln7Lys mutant; complex with Lopinavir 2O4S_A
AA A02.001 HIV-1 retropepsin complex with TL-3 inhibitor 2P3B_A
AA A02.001 HIV-1 retropepsin subtype F; complex with TL-3 inhibitor 2P3C_A
AA A02.001 HIV-1 retropepsin multi-drug resistant mutant subtype F; complex with TL-3 inhibitor 2P3D_A
AA A02.001 HIV-1 retropepsin apo wild-type hiv protease in the open conformation 2PC0_A
AA A02.001 HIV-1 retropepsin Gln7Lys, Leu33Ile, Leu63Ile mutant; complex with KNI-10075 2PK5_A
AA A02.001 HIV-1 retropepsin Gln7Lys, Leu33Ile, Leu63Ile mutant; complex with KNI-10033 2PK6_A
AA A02.001 HIV-1 retropepsin complex with N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzylbenzenesulfonamide) 2PQZ_A
AA A02.001 HIV-1 retropepsin complex with CARB-AD37 2PSU_A
AA A02.001 HIV-1 retropepsin complex with CARB-KB45 2PSV_A
AA A02.001 HIV-1 retropepsin complex with N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide) 2PWC_A
AA A02.001 HIV-1 retropepsin complex with 4,4'-(3S,4S)-pyrrolidine-3,4-diylbis[(benzylimino)sulfonyl]dibenzamide 2PWR_A
AA A02.001 HIV-1 retropepsin mutant; complex with nelfinavir 2PYM_A
AA A02.001 HIV-1 retropepsin mutant; complex with Nelfinavir 2PYN_A
AA A02.001 HIV-1 retropepsin complex with a lysine sulfonamide inhibitor 2Q3K_A
AA A02.001 HIV-1 retropepsin complex with KB73 2Q54_A
AA A02.001 HIV-1 retropepsin complex with KK44 2Q55_A
AA A02.001 HIV-1 retropepsin complex with lopinavir 2Q5K_A
AA A02.001 HIV-1 retropepsin mutant; complex with nelfinavir 2Q63_A
AA A02.001 HIV-1 retropepsin mutant; complex with nelfinavir 2Q64_A
AA A02.001 HIV-1 retropepsin mutant; complex with nelfinavir 2QAK_A
AA A02.001 HIV-1 retropepsin hiv-1 protease mutant d30n with potent antiviral inhibitor grl-98065 2QCI_A
AA A02.001 HIV-1 retropepsin hiv-1 protease mutant i50v with potent antiviral inhibitor grl-98065 2QD6_A
AA A02.001 HIV-1 retropepsin hiv-1 protease mutant v82a with potent antiviral inhibitor grl-98065 2QD7_A
AA A02.001 HIV-1 retropepsin hiv-1 protease mutant i84v with potent antiviral inhibitor grl-98065 2QD8_A
AA A02.001 HIV-1 retropepsin the influence of i47a mutation on reduced susceptibility to the protease inhibitor lopinavir 2QHC_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-1-AC6 2QHY_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-1-AC87 2QHZ_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-1-KK80 2QI0_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-1-KK81 2QI1_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-2-AD94 2QI3_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-2-AD93 2QI4_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-2-KC08 2QI5_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-2-KB98 2QI6_A
AA A02.001 HIV-1 retropepsin complex with inhibitor MIT-2-AD86 2QI7_A
AA A02.001 HIV-1 retropepsin complex with PL-100 2QMP_A
AA A02.001 HIV-1 retropepsin complex with 4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis([4- (trifluoromethyl)benzyl]iminosulfonyl)]dibenzamide 2QNN_A
AA A02.001 HIV-1 retropepsin complex with 2QNP_A
AA A02.001 HIV-1 retropepsin complex with a chloro decorated pyrrolidine-based inhibitor 2QNQ_A
AA A02.001 HIV-1 retropepsin i84v hiv-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor 2R38_A
AA A02.001 HIV-1 retropepsin Ile50Val mutant; complex with a carbamoyl decorated pyrrolidine-based inhibitor 2R3T_A
AA A02.001 HIV-1 retropepsin Ile84Val mutant; complex with a amino decorated pyrrolidine-based inhibitor 2R3W_A
AA A02.001 HIV-1 retropepsin i50v hiv-1 protease in complex with an amino decorated pyrrolidine-based inhibitor 2R43_A
AA A02.001 HIV-1 retropepsin subtype c protease; complex with indinavir 2R5P_A
AA A02.001 HIV-1 retropepsin subtype c; complex with nelfinavir 2R5Q_A
AA A02.001 HIV-1 retropepsin subtype C 2R8N
AA A02.001 HIV-1 retropepsin complex with U100313 2UPJ
AA A02.001 HIV-1 retropepsin two-carbon-elongated hiv-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic 2UXZ_A
AA A02.001 HIV-1 retropepsin two-carbon-elongated hiv-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic 2UY0_A
AA A02.001 HIV-1 retropepsin hiv-1 protease inhibitors containing a tertiary alcohol in the transition-state mimic with improved cell-based antiviral activity 2WKZ_A
AA A02.001 HIV-1 retropepsin wild type hiv-1 protease with potent antiviral inhibitor grl-98065 2Z4O_A
AA A02.001 HIV-1 retropepsin Ile47Ala mutant on reduced susceptibility to the protease inhibitor lopinavir 2Z54_A
AA A02.001 HIV-1 retropepsin complex with (3S,4S),-3,4-Bis-[(4-carbamoyl-benzensulfonyl)- (3-methyl-but-2-enyl)-amino]-pyrrolidine 2ZGA_A
AA A02.001 HIV-1 retropepsin complex with potent inhibitor KNI-272 2ZYE_A
AA A02.001 HIV-1 retropepsin complex with kni-1689 3A2O_A
AA A02.001 HIV-1 retropepsin complex with benzoylamino-benzyl-methyl-[2-hydroxy-3-[1-methyl-ethyl-oxy-N-formamidyl]-4-phenyl-butyl]-ammonium 3AID
AA A02.001 HIV-1 retropepsin complex with gem-diol-amine tetrahedral intermediate nlltqi 3B7V_A
AA A02.001 HIV-1 retropepsin Ile54Val mutant; complex with gem-diol-amine intermediate nlltqi 3B80_A
AA A02.001 HIV-1 retropepsin Ile84Val mutant; complex with a pyrrolidine diester 3BC4_A
AA A02.001 HIV-1 retropepsin complex with N,N'-(iminodiethane-2,1-diyl)bis[4-amino- N-(2-methylpropyl)benzenesulfonamide] 3BGB_A
AA A02.001 HIV-1 retropepsin complex with N,N'-(iminodiethane-2,1-diyl)bis(4-amino- N-benzylbenzenesulfonamide) 3BGC_A
AA A02.001 HIV-1 retropepsin complex with a three armed pyrrolidine derivative 3BHE_A
AA A02.001 HIV-1 retropepsin Asp25Asn mutant; complex with p2-nc analog inhibitor 3BVA_A
AA A02.001 HIV-1 retropepsin cystal structure of hiv-1 active site mutant d25n and inhibitor darunavir 3BVB_A
AA A02.001 HIV-1 retropepsin crystal structures of highly constrained substrate and hydrolysis products bound to hiv-1 protease. implications for catalytic mechanism 3BXR_A
AA A02.001 HIV-1 retropepsin crystal structures of highly constrained substrate and hydrolysis products bound to hiv-1 protease. implications for catalytic mechanism 3BXS_A
AA A02.001 HIV-1 retropepsin complex with (3S,4S),-3,4-Bis-[(4-carbamoyl-benzensulfonyl)- (3-methyl-but-2-enyl)-amino]-pyrrolidine (orthorhombic space group) 3CKT_A
AA A02.001 HIV-1 retropepsin effect of flap mutations inhibition by saquinavir and darunavir 3CYW_A
AA A02.001 HIV-1 retropepsin Ile50Val mutant; complex with inhibitor saquinavir 3CYX_A
AA A02.001 HIV-1 retropepsin Ile54Met mutant; complex with inhibitor saquinavir 3D1X_A
AA A02.001 HIV-1 retropepsin Ile54Val mutant; complex with inhibitor saquinavir 3D1Y_A
AA A02.001 HIV-1 retropepsin Ile54Met mutant; complex with inhibitor darunavir 3D1Z_A
AA A02.001 HIV-1 retropepsin Ile54Val mutant; complex with inhibitor darunavia 3D20_A
AA A02.001 HIV-1 retropepsin complex with substrate p1-p6 3D3T_A
AA A02.001 HIV-1 retropepsin wild type hiv-1 protease with potent antiviral inhibitor grl-0255a 3DJK_A
AA A02.001 HIV-1 retropepsin wild type hiv-1 protease with potent antiviral inhibitor grl-0105a 3DK1_A
AA A02.001 HIV-1 retropepsin multidrug resistant variant (Leu10Ile/Gly48Val/Ile54Val/Val64Ile/Val82Ala); complex with inhibitor amprenavir (apv) 3EKP_A
AA A02.001 HIV-1 retropepsin multi-drug resistant form (Leu63Pro/Val82Thr/Ile84Val); complex with inhibitor saquinavir (sqv) 3EKQ_A
AA A02.001 HIV-1 retropepsin multi-drug resistant variant (Leu10Phe/Gly48Val/Ile54Val/Val64Ile/Val82Ala); complex with darunavir (drv) 3EKT_A
AA A02.001 HIV-1 retropepsin wild type; complex with the inhibitor, amprenavir 3EKV_A
AA A02.001 HIV-1 retropepsin multi-drug resistance variant (Leu10Ile/Gly48Val/Ile54Val/Val64Ile/Val82Ala); complex with the inhibitor atazanavir (atv) in complex with a refer: flap+ in citation. 3EKW_A
AA A02.001 HIV-1 retropepsin wild-type; complex with the inhibitor nelfinavir 3EKX_A
AA A02.001 HIV-1 retropepsin wild-type; complex with the inhibitor, atazanavir 3EKY_A
AA A02.001 HIV-1 retropepsin multi-drug resistant variant (Leu10Ile/Gly48Val/Ile54Val/Val64Ile/Val82Ala); in complex with inhibitor nelfinavir (nfv) 3EL0_A
AA A02.001 HIV-1 retropepsin wild-type; complex with the inhibitor, atazanavir 3EL1_A
AA A02.001 HIV-1 retropepsin drug resistant Ile50Leu/Ala71Val variant; complex with amprenavir (apv) 3EM3_A
AA A02.001 HIV-1 retropepsin drug- resistant Ile50Val/Ala71Val variant; complex with the protease inhibitor atazanavir 3EM4_A
AA A02.001 HIV-1 retropepsin Ile50Leu/Ala71val mutant; complex with inhibitor darunavir 3EM6_A
AA A02.001 HIV-1 retropepsin complex with potent inhibitor KNI-272 3FX5_A
AA A02.001 HIV-1 retropepsin hiv protease inhibitors with pseudo-symmetric cores 3GGA_G
AA A02.001 HIV-1 retropepsin hiv protease, pseudo-symmetric inhibitors 3GGV_B
AA A02.001 HIV-1 retropepsin hiv protease, pseudo-symmetric inhibitors 3GGX_A
AA A02.001 HIV-1 retropepsin wild type; complex with inhibitor kb60 3GI4_A
AA A02.001 HIV-1 retropepsin wild type; complex with inhibitor kb62 3GI5_A
AA A02.001 HIV-1 retropepsin wild type; complex with inhibitor ad78 3GI6_A
AA A02.001 HIV-1 retropepsin Cys replaced with alpha-amino-N-butyric acid 3HVP
AA A02.001 HIV-1 retropepsin complex with mutant resistant inhibitor uic-98038 3I7E_A
AA A02.001 HIV-1 retropepsin complex with saquinavir 3K4V_A
AA A02.001 HIV-1 retropepsin complex with darunavir 3LZS_A
AA A02.001 HIV-1 retropepsin nelfinavir resistant variant (Asn88Ser); complex with the protease inhibitor darunavir. 3LZU_B
AA A02.001 HIV-1 retropepsin nelfinavir-resistant variant (Asp30Asn/Asn88Asp); complex with darunavir. 3LZV_A
AA A02.001 HIV-1 retropepsin wild-type; complex with inhibitor kc53 3MXD_A
AA A02.001 HIV-1 retropepsin wild-type; complex with inhibitor kc32 3MXE_A
AA A02.001 HIV-1 retropepsin complex with saquinavir:ritonavir 1:1 3NDT_A
AA A02.001 HIV-1 retropepsin complex with saquinavir:ritonavir 1:5 3NDU_A
AA A02.001 HIV-1 retropepsin complex with saquinavir:ritonavir 1:15 3NDW_A
AA A02.001 HIV-1 retropepsin complex with saquinavir:ritonavir 1:50 3NDX_A
AA A02.001 HIV-1 retropepsin wild-type; complex with antiviral drug amprenavir 3NU3_A
AA A02.001 HIV-1 retropepsin Val32Ile mutant; complex with antiviral drug amprenavir 3NU4_A
AA A02.001 HIV-1 retropepsin Ile50Val mutant; complex with antiviral drug amprenavir 3NU5_A
AA A02.001 HIV-1 retropepsin Ile54Met mutant; complex with antiviral drug amprenavir 3NU6_A
AA A02.001 HIV-1 retropepsin Ile54Val mutant; complex with antiviral drug amprenavir 3NU9_A
AA A02.001 HIV-1 retropepsin Ile54Val mutant; complex with antiviral drug amprenavir 3NUJ_A
AA A02.001 HIV-1 retropepsin Ile90Met mutant; complex with antiviral drug amprenavir 3NUO_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kd13 3O99_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kd14 3O9A_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kd25 3O9B_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kd20 3O9C_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kd19 3O9D_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af60 3O9E_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kd27 3O9F_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af53 3O9G_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kd26 3O9H_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af61 3O9I_A
AA A02.001 HIV-1 retropepsin wild-type; complex with oxatricyclic designed inhibitor GRL-0519a 3OK9_A
AA A02.001 HIV-1 retropepsin complex with saquinavir 3OXC_A
AA A02.001 HIV-1 retropepsin Ile50Val, Ala71 variant; complex with the protease inhibitor amprenavir. 3OXV_B
AA A02.001 HIV-1 retropepsin Ile50Val/Ala71Val variant; complex with the protease inhibitor darunavir 3OXW_B
AA A02.001 HIV-1 retropepsin drug- resistant Ile50Val/Ala71Val variant; complex with the protease inhibitor atazanavir 3OXX_B
AA A02.001 HIV-1 retropepsin Leu76Val variant; complex with the protease inhibitor darunavir. 3OY4_A
AA A02.001 HIV-1 retropepsin recombinant 3PHV
AA A02.001 HIV-1 retropepsin wild type; complex with a substituted bis-tetrahydrofuran inhibitor, GRL-044-10a 3QAA_A
AA A02.001 HIV-1 retropepsin wild-type; complex with tmc310911 3R4B_A
AA A02.001 HIV-1 retropepsin Val32Ile/Ile47Val/Val82Ile mutant; complex with antiviral drug amprenavir 3S43_A
AA A02.001 HIV-1 retropepsin triple mutant Val32Ile/Ile47Val/Val82Ile; complex with antiviral drug darunavir in space group p212121 3S53_A
AA A02.001 HIV-1 retropepsin triple mutant Val32Ile/Ile47Val/Val82Ile; complex with antiviral drug darunavir in space group p21212 3S54_A
AA A02.001 HIV-1 retropepsin triple mutants Val32Ile, Ile47Val, Val82Ile with antiviral drug saquinavir 3S56_A
AA A02.001 HIV-1 retropepsin discovery of new hiv protease inhibitors with potential for convenientdosing and reduced side effects: a-790742 and a-792611. 3S85_A
AA A02.001 HIV-1 retropepsin wild-type; complex with ag23 3SA3_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af72 3SA4_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af69 3SA5_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af71 3SA6_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af55 3SA7_A
AA A02.001 HIV-1 retropepsin wild-type; complex with kb83 3SA8_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af68 3SA9_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af77 3SAA_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af78 3SAB_A
AA A02.001 HIV-1 retropepsin wild-type; complex with af80 3SAC_A
AA A02.001 HIV-1 retropepsin complex with TL-3-093 inhibitor 3TLH
AA A02.001 HIV-1 retropepsin South African wild type subtype c 3U71_A
AA A02.001 HIV-1 retropepsin wild-type; complex with mkp56 4DJO_A
AA A02.001 HIV-1 retropepsin wild-type; complex with mkp73 4DJP_A
AA A02.001 HIV-1 retropepsin wild-type; complex with mkp86 4DJQ_A
AA A02.001 HIV-1 retropepsin wild-type; complex with mkp97 4DJR_A
AA A02.001 HIV-1 retropepsin hiv protease (pr) dimer with acetate in exo site and peptide in activesite 4E43_A
AA A02.001 HIV-1 retropepsin apo hiv protease (pr) dimer in closed form with fragment 1f1 in the outside/top of flap 4EJ8_A
AA A02.001 HIV-1 retropepsin dimer in closed form with pepstatin in active site and fragment 1f1 in the outside/top of flap 4EJD_A
AA A02.001 HIV-1 retropepsin dimer in closed form with pepstatin in active site and fragment 1f1-n in the outside/top of flap 4EJK_A
AA A02.001 HIV-1 retropepsin apo hiv protease (pr) dimer in closed form with fragment 1f1-n in the outside/top of flap 4EJL_A
AA A02.001 HIV-1 retropepsin inactive single chain wild-type; complex with the substrate rt-rh 4EP2_A
AA A02.001 HIV-1 retropepsin inactive single chain wild-type; complex with the substrate rt-rh 4EP2_B
AA A02.001 HIV-1 retropepsin inactive single chain variant; complex with the substrate ca-p2 4EP3_A
AA A02.001 HIV-1 retropepsin inactive single chain variant; complex with the substrate p2-nc 4EPJ_A
AA A02.001 HIV-1 retropepsin inactive single chain variant; complex with the substrate p2-nc 4EQ0_A
AA A02.001 HIV-1 retropepsin inactive single chain variant; complex with the substrate rt-rh 4EQJ_A
AA A02.001 HIV-1 retropepsin inactive single chain variant; complex with the substrate rt-rh 4EQJ_G
AA A02.001 HIV-1 retropepsin complex with the n terminal product of ca-p2 cleavage site 4F73_A
AA A02.001 HIV-1 retropepsin complex with the n terminal product of the substrate ma-ca. 4F74_A
AA A02.001 HIV-1 retropepsin complex with the n terminal product of the substrate rh-in 4F75_A
AA A02.001 HIV-1 retropepsin complex with the products of p1-p6 substrate 4F76_A
AA A02.001 HIV-1 retropepsin complex with N-Ac-Thr-Ile-Nle-PSI(CH2-NH)-Nle-Gln-Arg amide 4HVP
AA A02.001 HIV-1 retropepsin tl-3 inhibited trp6ala hiv protease 4K4P_A
AA A02.001 HIV-1 retropepsin tl-3 inhibited trp6ala hiv protease with 3-bromo-2,6-dimethoxybenzoic acid bound in flap site ***caveat 4k4q chirality error on c10 center of 3tl 108 a 4K4Q_A
AA A02.001 HIV-1 retropepsin tl-3 inhibited trp6ala hiv protease with 1-bromo-2-napthoic acid boundin exosite 4K4R_A
AA A02.001 HIV-1 retropepsin wild-type; complex with novel tricyclic p2-ligands GRL-0739a 4KB9_A
AA A02.001 HIV-1 retropepsin wild-type; complex with darunavir 4LL3_A
AA A02.001 HIV-1 retropepsin gs-8374, a novel phosphonate-containing inhibitor of hiv-1 protease, effectively inhibits hiv pr mutants with amino acid insertions 4M8X_A
AA A02.001 HIV-1 retropepsin multidrug-resistant clinical isolate; complex with non-peptidic inhibitor, GRL008 4NJS_A
AA A02.001 HIV-1 retropepsin multidrug-resistant clinical isolate; complex with darunavir 4NJT_A
AA A02.001 HIV-1 retropepsin multidrug-resistant clinical isolate; complex with tipranavir 4NJU_A
AA A02.001 HIV-1 retropepsin multidrug-resistant clinical isolate; complex with ritonavir 4NJV_A
AA A02.001 HIV-1 retropepsin nelfinavir-resistant, inactive Asp30Asn/Asn88Asp; complex with the p1-p6 substrate variant (Leu449Phe/Ser451Asn) 4OBD_A
AA A02.001 HIV-1 retropepsin nelfinavir-resistant, inactive Asp30Asn/Asn88Asp; complex with the p1-p6 substrate variant (Ser451Asn) 4OBF_A
AA A02.001 HIV-1 retropepsin nelfinavir-resistant, inactive Asp30Asn/Asn88Asp; complex with the p1-p6 substrate. 4OBG_A
AA A02.001 HIV-1 retropepsin complex with N,N-bis(2(R)-hydroxy-1(S)-indanyl)-2,6-(R,R)-diphenylmethyl-4-hydroxy-1,7,-heptandiamide 4PHV
AA A02.001 HIV-1 retropepsin multidrug-resistant clinical isolate; complex with non-peptidic inhibitor, GRL0519 4RVI_A
AA A02.001 HIV-1 retropepsin multidrug-resistant clinical isolate; complex with amprenavir 4RVJ_A
AA A02.001 HIV-1 retropepsin multidrug-resistant clinical isolate; complex with non-peptidic inhibitor, GRL079 4RVX_A
AA A02.001 HIV-1 retropepsin dimer in closed form with pepstatin in active site and fragment ak-2097 in the outside/top of flap 4TVG_A
AA A02.001 HIV-1 retropepsin hiv protease (pr) dimer in closed form with tl-3 in active site and fragment ak-2097 in the outside/top of flap ***caveat 4tvh chiral center atom c10 of 3tl a 200 has sp2 hybridization ***caveat 2 4tvh instead of sp3 4TVH_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-050-10a (a gem-difluoro-bis- tetrahydrofuran as p2-ligand) 4U8W_A
AA A02.001 HIV-1 retropepsin multidrug resistant clinical isolate pr20; complex with inhibitor GRL-4410a 4YE3_A
AA A02.001 HIV-1 retropepsin multidrug resistant clinical isolate pr20; complex with inhibitor GRL-5010a 4YHQ_A
AA A02.001 HIV-1 retropepsin multidrug resistant clinical isolate pr20d25n with open flap 4Z4X_A
AA A02.001 HIV-1 retropepsin crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20d25n with tucked flap 4Z50_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-0648a (a isophthalamide-derived p2- ligand) 4ZIP_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-096-13a (a boc-derivative p2-ligand,3,-5-dimethylbiphenyl p1-ligand) 4ZLS_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-011-11a (a methylamine bis- tetrahydrofuran p2-ligand, sulfonamide isostere derivate) 5BRY_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-047-11a (a methylamine bis- tetrahydrofuran p2-ligand, 4-amino sulfonamide derivative) 5BS4_A
AA A02.001 HIV-1 retropepsin complex with inhibitor GRL-004-11a containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligand 5DGU_A
AA A02.001 HIV-1 retropepsin complex with inhibitor GRL-105-11a containing substituted fused-tetrahydropyranyl tetrahydrofuran as p2-ligand 5DGW_A
AA A02.001 HIV-1 retropepsin triple mutant (Val32Ile/Ile47Val/Val82Ile); complex with darunavir at ph 6.0 5E5J_A
AA A02.001 HIV-1 retropepsin complex with acetyl-pepstatin 5HVP
AA A02.001 HIV-1 retropepsin complex with methyl n-[(1s)-1- benzhydryl-2-(3-morpholin-4-ium-2-ylpropylamino)-2-oxo- ethyl]carbamate 5IVQ_A
AA A02.001 HIV-1 retropepsin complex with methyl n-[(1s)-1-[[2-[(3s)-3-[(4-aminophenyl)methylamino]-4-hydroxy- butyl]phenyl]carbamoyl]-2,2-diphenyl-ethyl]carbamate 5IVR_A
AA A02.001 HIV-1 retropepsin complex with methyl n-[(1s)-1- benzhydryl-2-[2-[2-[(2r,5s)-5-(benzylcarbamoyloxymethyl)morpholin-2- yl]ethyl]anilino]-2-oxo-ethyl]carbamate 5IVS_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL- 10413 5KAO_A
AA A02.001 HIV-1 retropepsin Val32Ile/Ile47Val/Val82Ile mutant; complex with amprenavir at ph 6.0 5T8H_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-09510 5V4Y_A
AA A02.001 HIV-1 retropepsin hiv protease (pr) with tl-3 in active site and 4-methylbenzene-1,2- diamine in exosite 5VEA_A
AA A02.001 HIV-1 retropepsin hiv protease (pr) in open form with mg2+ in active site and hive-9 in eye site 5VJ3_A
AA A02.001 HIV-1 retropepsin hiv protease (pr) in open form with mg2+ in active site and hive-9 in eye site 5W5W_A
AA A02.001 HIV-1 retropepsin complex with (s)-n-(3-fluoro-2-(2-(1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4- fluorophenyl)propanamide 6B36_A
AA A02.001 HIV-1 retropepsin complex with n-(3-fluoro-2-(2- ((2s,6r)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide 6B38_A
AA A02.001 HIV-1 retropepsin complex with n-(3-fluoro-2-(2- ((2s,6r)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide 6B3C_A
AA A02.001 HIV-1 retropepsin complex with n-(3-fluoro-2-(2- ((2s,5s)-5-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide 6B3F_A
AA A02.001 HIV-1 retropepsin complex with n-(3-fluoro-2-(2- ((2s,6s)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide 6B3G_A
AA A02.001 HIV-1 retropepsin complex with n-(2-(2-((6r,9s)-2,2-dioxido-2-thia-1,7-diazabicyclo[4.3.1]decan-9-yl)ethyl)-3- fluorophenyl)-3,3-bis(4-fluorophenyl)propanamide 6B3H_A
AA A02.001 HIV-1 retropepsin nl4-3 wt; complex with darunavir 6DGX_B
AA A02.001 HIV-1 retropepsin nl4-3 wt; complex with umass1 6DGY_B
AA A02.001 HIV-1 retropepsin nl4-3 wt; complex with umass6 6DGZ_B
AA A02.001 HIV-1 retropepsin nl4-3 v82i mutant; complex with darunavir 6DH3_B
AA A02.001 HIV-1 retropepsin nl4-3 Val82Ile mutant; complex with umass1 6DH4_B
AA A02.001 HIV-1 retropepsin nl4-3 Val82Ile mutant; complex with umass6 6DH5_B
AA A02.001 HIV-1 retropepsin nl4-3 i50v mutant; complex with darunavir 6DH6_B
AA A02.001 HIV-1 retropepsin nl4-3 Ile50Val mutant; complex with umass1 6DH7_B
AA A02.001 HIV-1 retropepsin nl4-3 Ile50Val mutant; complex with umass6 6DH8_B
AA A02.001 HIV-1 retropepsin wild-type hiv-1 protease in complex with tipranavir 6DIF_A
AA A02.001 HIV-1 retropepsin Leu76Val mutant; complex with tipranavir 6DIL_A
AA A02.001 HIV-1 retropepsin wild-type; complex with lopinavir 6DJ1_A
AA A02.001 HIV-1 retropepsin Leu76Val mutant; complex with lopinavir 6DJ2_A
AA A02.001 HIV-1 retropepsin Leu76Val mutant; complex with GRL-0519 (tris- tetrahydrofuran as p2 ligand) 6DJ5_A
AA A02.001 HIV-1 retropepsin Leu76Val mutant; complex with GRL-5010 (gem- difluoro-bis-tetrahydrofuran as p2 ligand) 6DJ7_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-02815a, a thiochroman heterocycle with (s)-boc-amine functionality as the p2 ligand 6DV0_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-04315a, a tetrahydronaphthalene carboxamide with (r)-boc-amine and (s)-hydroxyl functionalities as the p2 ligand 6DV4_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-042-17a, 3-phenylhexahydro-2h- cyclopenta[d]oxazol-2-one with a bicyclic oxazolidinone scaffold as the p2 ligand 6E7J_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-034-17a, (3as, 5r, 6ar)-2-oxohexahydcyclopenta[d]-5-oxazolyl urethane with a bicyclic oxazolidinone scaffas the p2 ligand 6E9A_A
AA A02.001 HIV-1 retropepsin complex with bpi-11 6IXD_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-001 6MCR_A
AA A02.001 HIV-1 retropepsin wild type; complex with GRL-003 6MCS_A
AA A02.001 HIV-1 retropepsin wild-type hiv-1 protease in complex with a substrate analog ca-p2 6O48_A
AA A02.001 HIV-1 retropepsin Val32Ile/Ile47Val/Val82Ile mutant; complex with GRL-011-11a (a methylamine bis-tetrahydrofuran p2-ligand, sulfonamide isostere derivate) 6OTG_A
AA A02.001 HIV-1 retropepsin complex with ACE-Ser-Leu-Asn-Phe-PSI(CH(OH)-CH2)-Pro-Ile-Val-OME 7HVP
AA A02.001 HIV-1 retropepsin complex with U101935 7UPJ
AA A02.001 HIV-1 retropepsin complex with Val-Ser-Gln-Asn-Leu-PSI(CH(OH)-CH2)-Val-Ile-Val 8HVP
AA A02.001 HIV-1 retropepsin complex with A-74704l 9HVP
AA A02.002 HIV-2 retropepsin complex with inhibitor CGP 53820 1HII
AA A02.002 HIV-2 retropepsin 1HSH
AA A02.002 HIV-2 retropepsin 1HSI
AA A02.002 HIV-2 retropepsin complex with BILA 1906 1IDA
AA A02.002 HIV-2 retropepsin complex with BILA 2450 1IDB
AA A02.002 HIV-2 retropepsin Lys57Leu mutant; complex with NOA-His-CHA-PSI[CH(OH)CH(OH)]Val-Ile-APY 1IVP
AA A02.002 HIV-2 retropepsin Lys57Leu mutant; complex with QNC-Asn-CHA-PSI[CH(OH)CH(OH)]Val-NPT 1IVQ
AA A02.002 HIV-2 retropepsin complex with inhibitor containing an (hydroxyethyl) amide isostere 1JLD
AA A02.002 HIV-2 retropepsin theoretical model; complex with N-ac-Val-Val-Sta-Ala-Sta 1PHV
AA A02.002 HIV-2 retropepsin Lys57Leu mutant 2HPE
AA A02.002 HIV-2 retropepsin Lys57Leu mutant 2HPF
AA A02.002 HIV-2 retropepsin complex with Phe-Val-Phe-PSI(CH2NH)-Leu-Glu-Ile amide inhibitor 2MIP
AA A02.002 HIV-2 retropepsin theoretical model; complex with renin inhibitor H261 2PHV
AA A02.002 HIV-2 retropepsin complex with clinical drug darunavir 3EBZ_A
AA A02.002 HIV-2 retropepsin complex with antiviral inhibitor GRL-06579a 3EC0_A
AA A02.002 HIV-2 retropepsin complex with antiviral inhibitor GRL-98065 3ECG_A
AA A02.002 HIV-2 retropepsin wild-type; complex with antiviral drug amprenavir 3S45_A
AA A02.002 HIV-2 retropepsin complex with U096333 3UPJ
AA A02.002 HIV-2 retropepsin complex with U097410 4UPJ
AA A02.002 HIV-2 retropepsin complex with U99283 5UPJ
AA A02.002 HIV-2 retropepsin complex with U99294 6UPJ
AA A02.004 equine infectious anaemia virus retropepsin theoretical model 1EQI
AA A02.004 equine infectious anaemia virus retropepsin complex with inhibitor HBY-793 1FMB
AA A02.004 equine infectious anaemia virus retropepsin complex with inhibitor LP-130 2FMB
AA A02.005 bovine immunodeficiency virus retropepsin 3KKR
AA A02.005 bovine immunodeficiency virus retropepsin 3KKS
AA A02.006 Visna lentivirus-type retropepsin 3HPG
AA A02.006 Visna lentivirus-type retropepsin 3HPH
AA A02.007 feline immunodeficiency virus retropepsin complex with TL-3-093 inhibitor 1B11
AA A02.007 feline immunodeficiency virus retropepsin complex with acAla-Val-Sta-Glu-Ala-NH2 1FIV
AA A02.007 feline immunodeficiency virus retropepsin complex with Ac-naphylAla-Val-Sta-Glu-naphthylaminoAla substrate 2FIV
AA A02.007 feline immunodeficiency virus retropepsin complex with tl-3 2HAH_A
AA A02.007 feline immunodeficiency virus retropepsin complex with Ac-naphthylAla-Val-Leu-Ala-Glu-naphthylaminoAla substrate 3FIV
AA A02.007 feline immunodeficiency virus retropepsin complex with darunavir 3OGP_A
AA A02.007 feline immunodeficiency virus retropepsin complex with lopinavir 3OGQ_A
AA A02.007 feline immunodeficiency virus retropepsin complex with LP-130 inhibitor 4FIV
AA A02.007 feline immunodeficiency virus retropepsin complex with TL-3-093 inhibitor 5FIV
AA A02.007 feline immunodeficiency virus retropepsin complex with TL-3-093 inhibitor 6FIV
AA A02.008 murine leukemia virus-type retropepsin 1D0E
AA A02.008 murine leukemia virus-type retropepsin 1D1U
AA A02.008 murine leukemia virus-type retropepsin 1I6J
AA A02.008 murine leukemia virus-type retropepsin 1MML
AA A02.008 murine leukemia virus-type retropepsin 1N4L
AA A02.008 murine leukemia virus-type retropepsin 1NND
AA A02.008 murine leukemia virus-type retropepsin 1QAI
AA A02.008 murine leukemia virus-type retropepsin 1QAJ
AA A02.008 murine leukemia virus-type retropepsin 1ZTT
AA A02.008 murine leukemia virus-type retropepsin 1ZTW
AA A02.008 murine leukemia virus-type retropepsin 2FJV
AA A02.008 murine leukemia virus-type retropepsin 2FJW
AA A02.008 murine leukemia virus-type retropepsin 2FJX
AA A02.008 murine leukemia virus-type retropepsin 2FVP
AA A02.008 murine leukemia virus-type retropepsin 2FVQ
AA A02.008 murine leukemia virus-type retropepsin 2FVR
AA A02.008 murine leukemia virus-type retropepsin 2FVS
AA A02.008 murine leukemia virus-type retropepsin 2HB5
AA A02.008 murine leukemia virus-type retropepsin 2M9U
AA A02.008 murine leukemia virus-type retropepsin 2MQV
AA A02.008 murine leukemia virus-type retropepsin 2MS0
AA A02.008 murine leukemia virus-type retropepsin 2MS1
AA A02.008 murine leukemia virus-type retropepsin 2R2R
AA A02.008 murine leukemia virus-type retropepsin 2R2S
AA A02.008 murine leukemia virus-type retropepsin 2R2T
AA A02.008 murine leukemia virus-type retropepsin 2R2U
AA A02.008 murine leukemia virus-type retropepsin 3FSI
AA A02.008 murine leukemia virus-type retropepsin 3NNQ
AA A02.008 murine leukemia virus-type retropepsin peptidase domain only; complex with TL-3 3SLZ
AA A02.008 murine leukemia virus-type retropepsin peptidase domain only; complex with pepstatin 3SM1
AA A02.008 murine leukemia virus-type retropepsin peptidase domain only; complex with amprenavir 3SM2
AA A02.008 murine leukemia virus-type retropepsin complex with acetyl-pepstatin 4EXH_A
AA A02.008 murine leukemia virus-type retropepsin 4M94
AA A02.008 murine leukemia virus-type retropepsin 4M95
AA A02.008 murine leukemia virus-type retropepsin 4MH8
AA A02.008 murine leukemia virus-type retropepsin 4NZG
AA A02.008 murine leukemia virus-type retropepsin 4XO0
AA A02.008 murine leukemia virus-type retropepsin 4XPC
AA A02.008 murine leukemia virus-type retropepsin 4XPE
AA A02.008 murine leukemia virus-type retropepsin 3NR6_A
AA A02.008 murine leukemia virus-type retropepsin 3P1G
AA A02.008 murine leukemia virus-type retropepsin 4E89
AA A02.008 murine leukemia virus-type retropepsin 4HKQ
AA A02.009 Mason-Pfizer leukemia virus retropepsin 1NSO
AA A02.009 Mason-Pfizer leukemia virus retropepsin 2D4L
AA A02.009 Mason-Pfizer leukemia virus retropepsin 2D4M
AA A02.009 Mason-Pfizer leukemia virus retropepsin 2D4N
AA A02.009 Mason-Pfizer leukemia virus retropepsin 3SQF
AA A02.009 Mason-Pfizer leukemia virus retropepsin 3TP1
AA A02.009 Mason-Pfizer leukemia virus retropepsin 3TPW
AA A02.012 retropepsin (human T-cell leukemia virus) 2B7F
AA A02.012 retropepsin (human T-cell leukemia virus) complex with the inhibitor, kni- 10562 3LIN_A
AA A02.012 retropepsin (human T-cell leukemia virus) complex with the inhibitor, kni- 10673 3LIQ_A
AA A02.012 retropepsin (human T-cell leukemia virus) complex with the inhibitor kni-10681 3LIT_A
AA A02.012 retropepsin (human T-cell leukemia virus) complex with the inhibitor kni- 10683 3LIV_A
AA A02.012 retropepsin (human T-cell leukemia virus) complex with the inhibitor kni- 10729 3LIX_A
AA A02.012 retropepsin (human T-cell leukemia virus) complex with statine-containing peptide inhibitor 3LIY_A
AA A02.012 retropepsin (human T-cell leukemia virus) complex with the hiv-1 protease inhibitor indinavir 3WSJ_A
AA A02.012 retropepsin (human T-cell leukemia virus) complex with compound 9 4YDF_A
AA A02.013 bovine leukemia virus retropepsin 2IM6
AA A02.013 bovine leukemia virus retropepsin 2IM7
AA A02.015 Rous sarcoma virus retropepsin NMR structure 1A6S
AA A02.015 Rous sarcoma virus retropepsin complex with Arg-Val-Leu-Phe-Glu-Ala-norLeu-NH2 inhibitor 1BAI
AA A02.015 Rous sarcoma virus retropepsin 1EM9
AA A02.015 Rous sarcoma virus retropepsin 1EOQ
AA A02.015 Rous sarcoma virus retropepsin 1P7N
AA A02.015 Rous sarcoma virus retropepsin 2IHX
AA A02.015 Rous sarcoma virus retropepsin 2RSP_B
AA A02.015 Rous sarcoma virus retropepsin 2X8Q
AA A02.015 Rous sarcoma virus retropepsin 3G0V
AA A02.015 Rous sarcoma virus retropepsin 3G1G
AA A02.015 Rous sarcoma virus retropepsin 3G1I
AA A02.015 Rous sarcoma virus retropepsin 3G21
AA A02.015 Rous sarcoma virus retropepsin 3G26
AA A02.015 Rous sarcoma virus retropepsin 3G28
AA A02.015 Rous sarcoma virus retropepsin 3G29
AA A02.015 Rous sarcoma virus retropepsin 5A9E
AA A02.018 simian T-cell lymphotropic virus retropepsin 1JVR
AA A02.022 Ty3 transposon peptidase 4OL8
AA A02.UPA subfamily A2A unassigned peptidases open conformation 1AZ5
AA A02.UPA subfamily A2A unassigned peptidases 1C6V
AA A02.UPA subfamily A2A unassigned peptidases 1ECW
AA A02.UPA subfamily A2A unassigned peptidases 1ED1
AA A02.UPA subfamily A2A unassigned peptidases 1SIP
AA A02.UPA subfamily A2A unassigned peptidases complex with SKF107457 1SIV
AA A02.UPA subfamily A2A unassigned peptidases complex with SB203386 1TCW
AA A02.UPA subfamily A2A unassigned peptidases complex with Phe-Leu-Glu-Lys peptide product 1YTI
AA A02.UPA subfamily A2A unassigned peptidases complex with p-nitroPhe-Glu-Ala-norLeu-Ser peptide product 1YTJ
AA A02.UPA subfamily A2A unassigned peptidases mutant Ser4His 2SAM
AA A02.UPA subfamily A2A unassigned peptidases 3JTS
AA A02.UPW family A2 unassigned peptidases 1MVP
AA A02.UPW family A2 unassigned peptidases theoretical model 2MVP
AA A02.UPW family A2 unassigned peptidases 1BV7_A
AA A02.UPW family A2 unassigned peptidases 1BV9_A
AA A02.UPW family A2 unassigned peptidases 1BVE_A
AA A02.UPW family A2 unassigned peptidases 1BVG_A
AA A02.UPW family A2 unassigned peptidases 1BWA_A
AA A02.UPW family A2 unassigned peptidases 1BWB_A
AA A02.UPW family A2 unassigned peptidases 1C0T
AA A02.UPW family A2 unassigned peptidases 1C0U
AA A02.UPW family A2 unassigned peptidases 1C1B
AA A02.UPW family A2 unassigned peptidases 1C1C
AA A02.UPW family A2 unassigned peptidases 1DMP_A
AA A02.UPW family A2 unassigned peptidases 1DTQ
AA A02.UPW family A2 unassigned peptidases 1DTT
AA A02.UPW family A2 unassigned peptidases 1E6J
AA A02.UPW family A2 unassigned peptidases 1EP4
AA A02.UPW family A2 unassigned peptidases 1ESK
AA A02.UPW family A2 unassigned peptidases 1EX4
AA A02.UPW family A2 unassigned peptidases 1EXQ
AA A02.UPW family A2 unassigned peptidases Val48Gly, Met90Leu mutant; complex with saquinavir 1FB7
AA A02.UPW family A2 unassigned peptidases 1FK9
AA A02.UPW family A2 unassigned peptidases 1FKO
AA A02.UPW family A2 unassigned peptidases 1FKP
AA A02.UPW family A2 unassigned peptidases 1G6L_A
AA A02.UPW family A2 unassigned peptidases 1HIV_A
AA A02.UPW family A2 unassigned peptidases 1HVH_A
AA A02.UPW family A2 unassigned peptidases 1HVR_A
AA A02.UPW family A2 unassigned peptidases 1HWR_A
AA A02.UPW family A2 unassigned peptidases 1HXB_A
AA A02.UPW family A2 unassigned peptidases 1JKH
AA A02.UPW family A2 unassigned peptidases 1JLA
AA A02.UPW family A2 unassigned peptidases 1JLB
AA A02.UPW family A2 unassigned peptidases 1JLC
AA A02.UPW family A2 unassigned peptidases 1JLE
AA A02.UPW family A2 unassigned peptidases 1JLF
AA A02.UPW family A2 unassigned peptidases 1JLG
AA A02.UPW family A2 unassigned peptidases 1JLQ
AA A02.UPW family A2 unassigned peptidases 1KLM
AA A02.UPW family A2 unassigned peptidases 1LV1_A
AA A02.UPW family A2 unassigned peptidases 1LW0
AA A02.UPW family A2 unassigned peptidases 1LW2
AA A02.UPW family A2 unassigned peptidases 1LWC
AA A02.UPW family A2 unassigned peptidases 1LWE
AA A02.UPW family A2 unassigned peptidases 1LWF
AA A02.UPW family A2 unassigned peptidases 1NCP_N
AA A02.UPW family A2 unassigned peptidases 1O1W
AA A02.UPW family A2 unassigned peptidases 1ODW_A
AA A02.UPW family A2 unassigned peptidases complex with inhibitor LP-130 1ODY
AA A02.UPW family A2 unassigned peptidases 1QBR_A
AA A02.UPW family A2 unassigned peptidases 1QBS_A
AA A02.UPW family A2 unassigned peptidases 1QBT_A
AA A02.UPW family A2 unassigned peptidases 1QBU_A
AA A02.UPW family A2 unassigned peptidases 1REV
AA A02.UPW family A2 unassigned peptidases 1RT1
AA A02.UPW family A2 unassigned peptidases 1RT2
AA A02.UPW family A2 unassigned peptidases 1RT3
AA A02.UPW family A2 unassigned peptidases 1RT4
AA A02.UPW family A2 unassigned peptidases 1RT5
AA A02.UPW family A2 unassigned peptidases 1RT6
AA A02.UPW family A2 unassigned peptidases 1RT7
AA A02.UPW family A2 unassigned peptidases 1RTD
AA A02.UPW family A2 unassigned peptidases 1RTH
AA A02.UPW family A2 unassigned peptidases 1RTI
AA A02.UPW family A2 unassigned peptidases 1RTJ
AA A02.UPW family A2 unassigned peptidases 1S1T
AA A02.UPW family A2 unassigned peptidases 1S1U
AA A02.UPW family A2 unassigned peptidases 1S1V
AA A02.UPW family A2 unassigned peptidases 1S1W
AA A02.UPW family A2 unassigned peptidases 1S1X
AA A02.UPW family A2 unassigned peptidases 1T05
AA A02.UPW family A2 unassigned peptidases 1TAM
AA A02.UPW family A2 unassigned peptidases 1TKT
AA A02.UPW family A2 unassigned peptidases 1TKX
AA A02.UPW family A2 unassigned peptidases 1TKZ
AA A02.UPW family A2 unassigned peptidases 1TL1
AA A02.UPW family A2 unassigned peptidases 1TL3
AA A02.UPW family A2 unassigned peptidases 1VRT
AA A02.UPW family A2 unassigned peptidases 1VRU
AA A02.UPW family A2 unassigned peptidases 2HND
AA A02.UPW family A2 unassigned peptidases 2HNY
AA A02.UPW family A2 unassigned peptidases 2HNZ
AA A02.UPW family A2 unassigned peptidases 2KOD
AA A02.UPW family A2 unassigned peptidases 2NPH
AA A02.UPW family A2 unassigned peptidases 2OPP
AA A02.UPW family A2 unassigned peptidases 2OPQ
AA A02.UPW family A2 unassigned peptidases 2OPR
AA A02.UPW family A2 unassigned peptidases 2OPS
AA A02.UPW family A2 unassigned peptidases 2RF2
AA A02.UPW family A2 unassigned peptidases 2RKI
AA A02.UPW family A2 unassigned peptidases 2WHH
AA A02.UPW family A2 unassigned peptidases 2WOM
AA A02.UPW family A2 unassigned peptidases 2WON
AA A02.UPW family A2 unassigned peptidases 2YNF
AA A02.UPW family A2 unassigned peptidases 2YNG
AA A02.UPW family A2 unassigned peptidases 2YNH
AA A02.UPW family A2 unassigned peptidases 2YNI
AA A02.UPW family A2 unassigned peptidases 3AO2
AA A02.UPW family A2 unassigned peptidases 3C6T
AA A02.UPW family A2 unassigned peptidases 3C6U
AA A02.UPW family A2 unassigned peptidases 3DI6
AA A02.UPW family A2 unassigned peptidases 3DLE
AA A02.UPW family A2 unassigned peptidases 3DLG
AA A02.UPW family A2 unassigned peptidases 3DM2
AA A02.UPW family A2 unassigned peptidases 3DMJ
AA A02.UPW family A2 unassigned peptidases 3DOK
AA A02.UPW family A2 unassigned peptidases 3DOL
AA A02.UPW family A2 unassigned peptidases 3DOX
AA A02.UPW family A2 unassigned peptidases 3DRP
AA A02.UPW family A2 unassigned peptidases 3DRR
AA A02.UPW family A2 unassigned peptidases 3DRS
AA A02.UPW family A2 unassigned peptidases 3DYA
AA A02.UPW family A2 unassigned peptidases 3E01
AA A02.UPW family A2 unassigned peptidases 3FFI
AA A02.UPW family A2 unassigned peptidases 3I0R
AA A02.UPW family A2 unassigned peptidases 3I0S
AA A02.UPW family A2 unassigned peptidases 3KJV
AA A02.UPW family A2 unassigned peptidases 3KK1
AA A02.UPW family A2 unassigned peptidases 3KK2
AA A02.UPW family A2 unassigned peptidases 3KK3
AA A02.UPW family A2 unassigned peptidases 3KT2
AA A02.UPW family A2 unassigned peptidases 3KT5
AA A02.UPW family A2 unassigned peptidases 3LAK
AA A02.UPW family A2 unassigned peptidases 3LAL
AA A02.UPW family A2 unassigned peptidases 3LAM
AA A02.UPW family A2 unassigned peptidases 3LAN
AA A02.UPW family A2 unassigned peptidases 3LP0
AA A02.UPW family A2 unassigned peptidases 3LP1
AA A02.UPW family A2 unassigned peptidases 3LP2
AA A02.UPW family A2 unassigned peptidases 3M8P
AA A02.UPW family A2 unassigned peptidases 3M8Q
AA A02.UPW family A2 unassigned peptidases 3MEC
AA A02.UPW family A2 unassigned peptidases 3MED
AA A02.UPW family A2 unassigned peptidases 3MEE
AA A02.UPW family A2 unassigned peptidases 3MEG
AA A02.UPW family A2 unassigned peptidases 3MIM
AA A02.UPW family A2 unassigned peptidases 3N3I
AA A02.UPW family A2 unassigned peptidases 3NBP
AA A02.UPW family A2 unassigned peptidases 3PHV_A
AA A02.UPW family A2 unassigned peptidases 3QIN
AA A02.UPW family A2 unassigned peptidases 3QIO
AA A02.UPW family A2 unassigned peptidases 3QIP
AA A02.UPW family A2 unassigned peptidases 3T19
AA A02.UPW family A2 unassigned peptidases 3T1A
AA A02.UPW family A2 unassigned peptidases 3TAM
AA A02.UPW family A2 unassigned peptidases 4B3O
AA A02.UPW family A2 unassigned peptidases 4B3P
AA A02.UPW family A2 unassigned peptidases 4B3Q
AA A02.UPW family A2 unassigned peptidases 4I7F
AA A02.UPW family A2 unassigned peptidases 4KSE
AA A02.UPW family A2 unassigned peptidases 4KV8
AA A02.UPW family A2 unassigned peptidases 4NCG
AA A02.UPW family A2 unassigned peptidases 4Q1W
AA A02.UPW family A2 unassigned peptidases 4Q1X
AA A02.UPW family A2 unassigned peptidases 4Q1Y
AA A02.UPW family A2 unassigned peptidases 4Q5M
AA A02.UPW family A2 unassigned peptidases 4QLH
AA A02.UPW family A2 unassigned peptidases 4U1H
AA A02.UPW family A2 unassigned peptidases 4U1I
AA A02.UPW family A2 unassigned peptidases 4U1J
AA A02.UPW family A2 unassigned peptidases 4U7Q
AA A02.UPW family A2 unassigned peptidases 4U7V
AA A02.UPW family A2 unassigned peptidases x-ray snapshot of hiv-1 protease in action: observation of tetrahedralintermediate and its sihb with catalytic aspartate 5YRS_A
AC A08.UPW family A8 unassigned peptidases 5DIR
AC A08.UPW family A8 unassigned peptidases imisx-ep of se-lspa 6FMS_A
AA A09.001 spumapepsin 2LSN
AA A09.001 spumapepsin 2X6N
AA A09.001 spumapepsin 2X6S
AA A09.001 spumapepsin 2X74
AA A09.001 spumapepsin 2X78
AA A09.001 spumapepsin 3DLR
AA A09.001 spumapepsin 3L2Q
AA A09.001 spumapepsin 3L2R
AA A09.001 spumapepsin 3L2U
AA A09.001 spumapepsin 3L2V
AA A09.001 spumapepsin 3L2W
AA A09.001 spumapepsin 3OS0
AA A09.001 spumapepsin 3OS1
AA A09.001 spumapepsin 3OS2
AA A09.001 spumapepsin 3OY9
AA A09.001 spumapepsin 3OYA
AA A09.001 spumapepsin 3OYB
AA A09.001 spumapepsin 3OYC
AA A09.001 spumapepsin 3OYD
AA A09.001 spumapepsin 3OYE
AA A09.001 spumapepsin 3OYF
AA A09.001 spumapepsin 3OYG
AA A09.001 spumapepsin 3OYH
AA A09.001 spumapepsin 3OYI
AA A09.001 spumapepsin 3OYJ
AA A09.001 spumapepsin 3OYK
AA A09.001 spumapepsin 3OYL
AA A09.001 spumapepsin 3OYM
AA A09.001 spumapepsin 3OYN
AA A09.001 spumapepsin 3S3M
AA A09.001 spumapepsin 3S3N
AA A09.001 spumapepsin 3S3O
AA A09.001 spumapepsin 4BAC
AA A09.001 spumapepsin 4BDY
AA A09.001 spumapepsin 4BDZ
AA A09.001 spumapepsin 4BE0
AA A09.001 spumapepsin 4BE1
AA A09.001 spumapepsin 4BE2
AA A09.001 spumapepsin 4E7H
AA A09.001 spumapepsin 4E7I
AA A09.001 spumapepsin 4E7J
AA A09.001 spumapepsin 4E7K
AA A09.001 spumapepsin 4E7L
AA A09.001 spumapepsin 4IKF
AA A09.001 spumapepsin 4ZTF
AA A09.001 spumapepsin 4ZTJ
AA A09.001 spumapepsin NMR structure 2JYS
AD A22.001 presenilin 1 NMR structure; CTF subunit 2KR6
AD A22.001 presenilin 1 4UIS
AD A22.001 presenilin 1 5A63
AD A22.001 presenilin 1 5FN2
AD A22.001 presenilin 1 5FN3
AD A22.001 presenilin 1 5FN4
AD A22.001 presenilin 1 5FN5
AD A22.001 presenilin 1 complex with a notch fragment 6IDF_B
AD A22.001 presenilin 1 recognition of the amyloid precursor protein by human gamma-secretase 6IYC_B
AD A22.007 signal peptide peptidase-like protein 2A 2FC7
AD A22.007 signal peptide peptidase-like protein 2A 2YUM
AD A22.015 intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1) 4HYC
AD A22.015 intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1) 4HYD
AD A22.015 intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1) 4HYG
AD A22.015 intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1) complex with an inhibitor 4Y6K_A
AD A24.016 FlaK peptidase 3S0X
AE A25.001 gpr peptidase precursor 1C8B_A
AF A26.001 omptin 1I78
AF A26.003 plasminogen activator Pla Ala106Asp mutant 2X4M
AF A26.003 plasminogen activator Pla 2X55
AF A26.003 plasminogen activator Pla 2X56
AF A26.003 plasminogen activator Pla 4DCB_A
AA A28.001 DNA-damage inducible protein 1 2I1A
AA A28.001 DNA-damage inducible protein 1 2MR9
AA A28.001 DNA-damage inducible protein 1 2MRO
AA A28.001 DNA-damage inducible protein 1 2MRP
AA A28.001 DNA-damage inducible protein 1 2MWS
AA A28.001 DNA-damage inducible protein 1 4Z2Z
AA A28.001 DNA-damage inducible protein 1 3S8I_A
AA A28.003 DNA-damage inducible protein 2 human dna damage-inducible protein: from protein chemistry and 3d structure to deciphering its cellular role 4RGH_A
AA A28.A01 gene name 1700011N24Rik (Mus musculus) NMR structure 1V5O
AA A28.UPA subfamily A28A unassigned peptidases protease-like domain 5YQ8_A
AA A28.UPA subfamily A28A unassigned peptidases protease-like domain 5YS4_A
AE A31.001 HybD peptidase 1CFZ_A
AE A31.001 HybD peptidase NMR structure 2KML
AE A31.003 HycI peptidase 3PU6_A
AE A31.007 TK2004 peptidase 5ZBY
AE A31.008 TK2066 peptidase 5IJA
AE A31.UPW family A31 unassigned peptidases 5TTX_A
AE A31.UPW family A31 unassigned peptidases 2E85_A
AA A32.002 RC1339 g.p. (Rickettsia conorii) 5C9B
AA A32.002 RC1339 g.p. (Rickettsia conorii) 5C9D
AA A32.002 RC1339 g.p. (Rickettsia conorii) 5C9F
CA C01.001 papain complex with carbobenzyloxy-Leu-leucinal inhibitor 1BP4
CA C01.001 papain complex with carboxybenzyloxy-Leu-Leu-methoxymethylketone 1BQI
CA C01.001 papain complex with inhibitor CLIK148 1CVZ
CA C01.001 papain theoretical model; complex with N-acetyl-p-benzoquinone imine 1EFF
CA C01.001 papain complex with Z-Leu-Phe-Gly-diazomethylketone inhibitor 1KHP
CA C01.001 papain complex with Z-Leu-Phe-Gly-diazomethylketone inhibitor (orthorhombic form) 1KHQ
CA C01.001 papain Cys25Ac-Ala-Ala-Phe-methylenylAla derivative 1PAD
CA C01.001 papain complex with E64C 1PE6
CA C01.001 papain complex with Suc-Gln-Vla-Val-Ala-Ala-pNA 1PIP
CA C01.001 papain complex with leupeptin 1POP
CA C01.001 papain hydroxyethylthiopapain 1PPD
CA C01.001 papain Cys25 with bound atom 1PPN
CA C01.001 papain complex with E64C 1PPP
CA C01.001 papain complex with cystatin B Cys18Ser 1STF_E
CA C01.001 papain complex with ICP 2CIO_A
CA C01.001 papain cysteinyl derivative of Cys25 2PAD
CA C01.001 papain complex with chagasin 3E1Z_B
CA C01.001 papain complex with tarocystatin 3IMA_A
CA C01.001 papain complex with CTD of tarocystatin 3LFY_A
CA C01.001 papain precursor; thermostable variant 3TNX_A
CA C01.001 papain precursor; thermostable variant from a crystal soaked at ph 4 3USV_A
CA C01.001 papain TOS-methylenylLys derivative of Cys25 4PAD
CA C01.001 papain Ile86Leu mutant 4QRG_A
CA C01.001 papain Ile86Phe mutant 4QRV_A
CA C01.001 papain precursor mutant at ph 4.0 4QRX_A
CA C01.001 papain benzyloxycarbonyl-Gly-Phe-methylenylGly derivative 5PAD
CA C01.001 papain modified by achiral ru(ii)complex 6H8T_A
CA C01.001 papain benzyloxycarbonyl-Gly-Phe-methylenylGly derivative 6PAD
CA C01.001 papain Cys25 oxidized 9PAP
CA C01.002 chymopapain 1YAL
CA C01.003 caricain theoretical model; Asp158Glu mutant; complex with carbobenzoxy-Phe-3-amino-butan-2-one 1C7X
CA C01.003 caricain theoretical model; Asp158Glu mutant in complex with E64c 1EUX
CA C01.003 caricain theoretical model; Asp158Glu mutant in complex with leupeptin 1F1I
CA C01.003 caricain Asp185Glu mutant; complex with E64 1MEG
CA C01.003 caricain precursor 1PCI
CA C01.003 caricain Cys25 with bound mercury 1PPO
CA C01.004 glycyl endopeptidase complex with benzyloxycarbonyl-Leu-Val-Gly-methylene bound to Cys25 1GEC
CA C01.005 stem bromelain 1W0Q
CA C01.007 actinidin complex with E64 1AEC
CA C01.007 actinidin theoretical model; complex with ZPACK (Z-Phe-Ala-Ala-chloromethyl ketone) 1F3Q
CA C01.007 actinidin theoretical model; complex with leupeptin 1FOG
CA C01.007 actinidin theoretical model; complex with E64c 1FTV
CA C01.007 actinidin 2ACT
CA C01.009 cathepsin V complex with 4-methylpiperazin-1-ylcarbonyl-Phe-3-amino-5-phenylpentane inhibitor 1FH0
CA C01.009 cathepsin V complex with clitocypin 3H6S_A
CA C01.010 vignain complex with D-Val-Leu-dexoxy-methyl-Lys. 1S4V_A
CA C01.011 calotropain 0CDI
CA C01.013 cathepsin X precursor 1DEU
CA C01.013 cathepsin X 1EF7
CA C01.017 zingipain tetramer 1CQD
CA C01.018 cathepsin F theoretical model 1D5U
CA C01.018 cathepsin F 1M6D_A
CA C01.024 endopeptidase-B (Hordeum-type) isoform 2 (EP-B2); complex with leupeptin 2FO5_A
CA C01.026 ananain complex with E-64 6MIS_A
CA C01.026 ananain native ananain from ananas comosus 6OKJ_A
CA C01.032 cathepsin L precursor 1CJL
CA C01.032 cathepsin L procathepsin L 1CJL_P
CA C01.032 cathepsin L precursor 1CS8_A
CA C01.032 cathepsin L procathepsin L 1CS8_P
CA C01.032 cathepsin L complex with MHC class II associated P41 II fragment 1ICF_A
CA C01.032 cathepsin L complex with propeptide-based inhibitor biphenyl-4-yl-acetaldehyde-Cys-D-Arg-Tyr-2-phenylethylamine 1MHW
CA C01.032 cathepsin L complex with chagasin 2NQD_B
CA C01.032 cathepsin L cathsilicatein, a chimera 2VHS_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2XU1_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2XU3_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2XU4_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2XU5_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2YJ2_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2YJ8_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2YJ9_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2YJB_A
CA C01.032 cathepsin L complex with a nitrile inhibitor 2YJC_A
CA C01.032 cathepsin L exploring inhibitor binding at the s subsites of cathepsin l 3BC3_A
CA C01.032 cathepsin L complex with retro-binding inhibitor compound 4 3H89_A
CA C01.032 cathepsin L complex with retro-binding inhibitor compound 9 3H8B_A
CA C01.032 cathepsin L complex with retro-binding inhibitor compound 14 3H8C_A
CA C01.032 cathepsin L complex with az12878478 3HHA_A
CA C01.032 cathepsin L cathepsin l with az13010160 3HWN_A
CA C01.032 cathepsin L Cys25Ala mutant 3IV2_A
CA C01.032 cathepsin L Cys25Ala mutant; complex with Gln-Leu-Ala peptide 3K24_A
CA C01.032 cathepsin L complex with dipeptidyl glyoxal and diazomethylketone inhibitors 3OF8_A
CA C01.032 cathepsin L complex with adiazomethylketone inhibitor 3OF9_A
CA C01.032 cathepsin L human cathepsin l apo form with zn 4AXL_A
CA C01.032 cathepsin L triazine cathepsin inhibitor complex 4AXM_A
CA C01.032 cathepsin L complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide 5F02_A
CA C01.032 cathepsin L cleaved cathepsin L bound to the active site of cathepsin L 5I4H_A
CA C01.032 cathepsin L complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-car boxylic acid (1-cyano-cyclopropyl)-amide 5MAE_A
CA C01.032 cathepsin L complex with 4-[cyclopentyl(imidazo[1,2-a]pyridin-2- ylmethyl)amino]-6-morpholino-1,3,5-triazine-2-carbonitrile 5MAJ_A
CA C01.032 cathepsin L complex with 4-[1,3-benzodioxol-5-ylmethyl(2- phenoxyethyl)amino]-5-fluoropyrimidine-2-carbonitrile 5MQY_A
CA C01.032 cathepsin L complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6(11),7,9, 14,18(22),19-heptaene-3-carboxamide 6EZP_A
CA C01.032 cathepsin L complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-17-oxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6,8,10,14, 18(22),19-heptaene-3-carboxamide 6EZX_A
CA C01.032 cathepsin L complex with (3s,14e)-8-(azetidin-3-yl)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06, 11]docosa-1(21),6,8,10,14,18(22),19-heptaene-3-carboxamide 6F06_A
CA C01.032 cathepsin L theoretical model 1MVV
CA C01.033 cathepsin L1 (Fasciola sp.) precursor 2O6X
CA C01.034 cathepsin S theoretical model 1BXF
CA C01.034 cathepsin S Cys25Ser mutant 1GLO
CA C01.034 cathepsin S complex with dipeptide nitrile inhibitor BLN 1MS6
CA C01.034 cathepsin S complex with inhibitor C1P 1NPZ
CA C01.034 cathepsin S complex with inhibitor C4P 1NQC
CA C01.034 cathepsin S precursor Cys25Ala mutant 2C0Y_A
CA C01.034 cathepsin S complex with non-covalent 2-(benzoxazol-2- ylamino)-acetamide 2F1G_A
CA C01.034 cathepsin S complex with CRA-27934, a nitrile inhibitor 2FRA_A
CA C01.034 cathepsin S complex with inhibitor CRA-26871 2FRQ_A
CA C01.034 cathepsin S complex with inhibitor CRA-29728 2FT2_A
CA C01.034 cathepsin S complex with inhibitor CRA-27566 2FUD_A
CA C01.034 cathepsin S complex with irreversible inhibitor CRA-14013 2FYE_A
CA C01.034 cathepsin S complex with vinyl sulfone inhibitor CRA-14009 2G6D_A
CA C01.034 cathepsin S complex with inhibitor CRA-16981 2G7Y_A
CA C01.034 cathepsin S complex with N-[(1S)-1-1-[(1R,3E)-1-acetylpent-3-en-1-yl]-1H-1,2,3-triazol-4-yl-1,2-dimethylpropyl]benzamide 2H7J_A
CA C01.034 cathepsin S complex with N-[(1R)-1-[(benzylsulfonyl)methyl]-2-[(1S)-1-methyl-2-[4-(trifluoromethoxy)phenyl]aminoethyl]amino-2-oxoethyl]morpholine-4-carboxamide 2HH5_A
CA C01.034 cathepsin S complex with non covalent arylaminoethyl amide. 2HHN_A
CA C01.034 cathepsin S complex with N-[(1S)-1-1-[(1R,3E)-1-acetylpent-3-en-1-yl]-1H-1,2,3-triazol-4-yl-1,2-dimethylpropyl]benzamide 2HXZ_A
CA C01.034 cathepsin S complex with a novel 2- arylphenoxyacetaldehyde inhibitor derived by the substrate activity screening (sas) method 2OP3_A
CA C01.034 cathepsin S complex with compound 15 2R9M_A
CA C01.034 cathepsin S complex with compound 26 2R9N_A
CA C01.034 cathepsin S complex with compound 8 2R9O_A
CA C01.034 cathepsin S complex with a pyrazole-based inhibitor with an arylalkynes as P1 binding element 3IEJ_A
CA C01.034 cathepsin S complex with 4-(3-trifluoromethylphenyl)-pyrimidine-2-carbonitrile 3N3G_A
CA C01.034 cathepsin S complex with 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile 3N4C_A
CA C01.034 cathepsin S complex with a covalent inhibitor with an aldehyde warhead 3OVX_A
CA C01.034 cathepsin S complex with a non-covalent inhibitor 4P6E_A
CA C01.034 cathepsin S complex with a non-covalent inhibitor. 4P6G_A
CA C01.034 cathepsin S complex with bound ligand 5QBU_A
CA C01.034 cathepsin S complex with bound ligand 5QBV_A
CA C01.034 cathepsin S complex with bound ligand 5QBW_A
CA C01.034 cathepsin S complex with bound ligand 5QBX_A
CA C01.034 cathepsin S complex with bound ligand 5QBY_A
CA C01.034 cathepsin S complex with bound ligand 5QBZ_A
CA C01.034 cathepsin S complex with bound ligand 5QC0_A
CA C01.034 cathepsin S complex with bound ligand 5QC1_A
CA C01.034 cathepsin S complex with bound ligand 5QC2_A
CA C01.034 cathepsin S complex with bound ligand 5QC3_A
CA C01.034 cathepsin S complex with bound ligand 5QC4_A
CA C01.034 cathepsin S complex with bound ligand 5QC5_A
CA C01.034 cathepsin S complex with bound ligand 5QC6_A
CA C01.034 cathepsin S complex with bound ligand 5QC7_A
CA C01.034 cathepsin S complex with bound ligand 5QC8_A
CA C01.034 cathepsin S complex with bound ligand 5QC9_A
CA C01.034 cathepsin S complex with bound ligand 5QCA_A
CA C01.034 cathepsin S complex with bound ligand 5QCB_A
CA C01.034 cathepsin S complex with bound ligand 5QCC_A
CA C01.034 cathepsin S complex with bound ligand 5QCE_A
CA C01.034 cathepsin S complex with bound ligand 5QCF_A
CA C01.034 cathepsin S complex with bound ligand 5QCG_A
CA C01.034 cathepsin S complex with bound ligand 5QCH_A
CA C01.034 cathepsin S complex with bound ligand 5QCI_A
CA C01.034 cathepsin S complex with bound ligand 5QCJ_A
CA C01.034 cathepsin S theoretical model; precursor 1M0H
CA C01.034 cathepsin S 4BPV
CA C01.034 cathepsin S 4BQV
CA C01.034 cathepsin S 4BS5
CA C01.034 cathepsin S 4BS6
CA C01.034 cathepsin S 4BSQ
CA C01.034 cathepsin S 4MZO
CA C01.034 cathepsin S 4MZS
CA C01.036 cathepsin K complex with E64 1ATK
CA C01.036 cathepsin K complex with a covalent symmetric diacylaminomethyl ketone inhibitor 1AU0
CA C01.036 cathepsin K complex with a covant propanone inhibitor 1AU2
CA C01.036 cathepsin K complex with 1-[N[(phenylmethoxy)carbonyl]-l-leucyl-4-[[N/N-[(phenylmethoxy)carbonyl]-/NL-leucyl]amino]-3-pyrrolidinone 1AU3
CA C01.036 cathepsin K complex with 4-[[N-[(phenylmethoxy)carbonyl]-L-leucyl]amino]-1[(2S)-2-[[[4-(pyridinylmethoxy)carbonyl]amino]-4-methylpentyl]-3-pyrrolidinone 1AU4
CA C01.036 cathepsin K complex with 1,5-bis(N-benzyloxycarbonyl-L-leucinyl)carbohydrazide 1AYU
CA C01.036 cathepsin K complex with N-[2-[1-(N-benzyloxycarbonylamino)-3-methylbutyl]thiazol-4-ylcarbonyl]-N'-(benzyloxycarbonyl-L-leucinyl)hydrazide 1AYV
CA C01.036 cathepsin K complex with 1-(N-benzyloxycarbonyl-L-leucinyl)-5-(3-benzyloxy benzoyl)carbohydrazide 1AYW
CA C01.036 cathepsin K complex with covalent peptidomimetic inhibitor 1-[2-(3-bipheyl)-4-methylvaleryl)]-amino-3-(2-pyridylsulfonyl)amino-2-propanone 1BGO
CA C01.036 cathepsin K precursor 1BY8
CA C01.036 cathepsin K Ser149Ala mutant; complex with vinyl sulfone inhibitor 1MEM
CA C01.036 cathepsin K complex with covalent azepanone 5-(2-morpholin-4-ylethoxy)benzofuran-2-carboxylic acid ((S)-3-methyl-1-(S)-3-oxo-1-[2-(3-pyridin-2-ylphenyl)acetyl]azepan-4-ylcarbamoylbutyl)amide 1NL6
CA C01.036 cathepsin K complex with covalent azepanone benzofuran-2-carboxylic acid (S)-3-methyl-1-[3-oxo-1-(pyridin-2-ylsulfonyl)azepan-4-ylcarbamoyl]butylamide 1NLJ
CA C01.036 cathepsin K complex with T-butyl(1S)-1-cyclohexyl-2- oxoethylcarbamate 1Q6K_A
CA C01.036 cathepsin K complex with N2-([(4-bromophenyl)methyl]oxycarbonyl)-N1-[(1S)-1-formylpentyl]-L-leucinamide 1SNK
CA C01.036 cathepsin K complex with ketoamide inhibitor [1-(4-fluorobenzyl)cyclobutyl]methyl (1S)-1-[oxo(1h-pyrazol-5-ylamino)acetyl]pentylcarbamate 1TU6
CA C01.036 cathepsin K complex with the covalent inhibitor NVP-ABE854 1U9V_A
CA C01.036 cathepsin K complex with the covalent inhibitor NVP-ABI491 1U9W_A
CA C01.036 cathepsin K complex with the covalent inhibitor NVP-ABJ688 1U9X_A
CA C01.036 cathepsin K complex with N-(2-aminoethyl)-N~2~-(1S)-1-[4'-(aminosulfonyl)biphenyl-4-yl]-2,2,2-trifluoroethyl-L-leucinamide 1VSN_A
CA C01.036 cathepsin K complex with cyanopyrrolidine inhibitor N2-[(benzyloxy)carbonyl]-N1-[(3S)-1-cyanopyrrolidin-3-yl]-L-leucinamide 1YK7
CA C01.036 cathepsin K complex with cyanamide-based inhibitor tert-butyl 2-cyano-2-methylhydrazinecarboxylate 1YK8_A
CA C01.036 cathepsin K complex with (1R)-2,2-dimethyl-1-(5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-ylmethyl)propyl (1S)-1-oxo[(2-oxo-1,3-oxazolidin-3-yl)amino]acetylpentylcarbamate 1YT7
CA C01.036 cathepsin K complex with myocrisin 2ATO_A
CA C01.036 cathepsin K complex with semicarbazone inhibitor (1R)-2-methyl-1-(phenylmethyl)propyl[(1S)-1-formylpentyl]carbamate 2AUX
CA C01.036 cathepsin K complex with semicarbazone inhibitor 1-(phenylmethyl)cyclopentyl[(1S)-1-formylpentyl]carbamate 2AUZ_A
CA C01.036 cathepsin K complex with (3S)-1-[(3,5-dimethylisoxazol-4-yl)amino]carbonyl-4,4-dimethylpyrrolidin-3-yl(1s)-1-[1-hydroxy-2-oxo-2-[(1R)-1-phenylethyl]aminoethyl]pentylcarbamate 2BDL
CA C01.036 cathepsin K complex with a pyrrolopyrimidine inhibitor 2R6N_A
CA C01.036 cathepsin K complex with chondroitin sulfate 3C9E
CA C01.036 cathepsin K variant M5; complex with chondroitin-4-sulfate 3H7D_A
CA C01.036 cathepsin K complex with a triazine ligand 3KW9_A
CA C01.036 cathepsin K complex with a dioxo-triazine inhibitor 3KWB_X
CA C01.036 cathepsin K complex with a non-selective 2-cyano-pyrimidine inhibitor 3KWZ_A
CA C01.036 cathepsin K complex with a selective 2-cyano-pyrimidine inhibitor 3KX1_A
CA C01.036 cathepsin K complex with a cyano-pyrimidine inhibitor 3O0U_A
CA C01.036 cathepsin K complex with a 2-cyano pyrimidine inhibitor with a benzyl p3 group. 3O1G_A
CA C01.036 cathepsin K complex with a covalent inhibitor with a ketoamide warhead 3OVZ_A
CA C01.036 cathepsin K cathepsin k inhibitor 4DMX_A
CA C01.036 cathepsin K cathepsin k inhibitor 4DMY_A
CA C01.036 cathepsin K complex with dermatan sulfate 4N79_A
CA C01.036 cathepsin K complex with chondroitin sulfate 4N8W_A
CA C01.036 cathepsin K development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors. 4X6H_A
CA C01.036 cathepsin K development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors. 4X6I_A
CA C01.036 cathepsin K development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors. 4X6J_A
CA C01.036 cathepsin K complex with lichostatinal 4YV8_A
CA C01.036 cathepsin K co-crystallized with actinomycetes extract 4YVA_A
CA C01.036 cathepsin K Cys25Ser mutant; complex with the allosteric effector nsc13345 5J94_A
CA C01.036 cathepsin K Cys25Ser mutant; complex with the allosteric effector nsc94914 5JA7_A
CA C01.036 cathepsin K Cys25Ser mutant 5JH3_A
CA C01.036 cathepsin K complex with a covalently-linked inhibitor 5TDI_A
CA C01.036 cathepsin K 5TUN_A
CA C01.036 cathepsin K pycnonodysostosis disease related Ile249Thr mutant 5Z5O_A
CA C01.036 cathepsin K complex with a non-active site inhibitor 6ASH_A
CA C01.036 cathepsin K complex with n-desmethyl thalassospiramide c 6HGY_A
CA C01.036 cathepsin K complex with an alkyne moiety 6QBS_A
CA C01.036 cathepsin K 7PCK
CA C01.036 cathepsin K 5T6U_A
CA C01.036 cathepsin K Thr101Ala variant 6BKI_A
CA C01.040 cathepsin H theoretical model 1BZN
CA C01.040 cathepsin H precursor 6CZK_A
CA C01.040 cathepsin H Cys26Ser mutant 6CZS_A
CA C01.040 cathepsin H complex with cystatin A 1NB3_A
CA C01.040 cathepsin H complex with cystatin A 1NB5_A
CA C01.040 cathepsin H 8PCH
CA C01.046 falcipain-2 complex with egg-white cystatin 1YVB_A
CA C01.046 falcipain-2 complex with E64 3BPF_A
CA C01.046 falcipain-2 complex with PBICP-C 3PNR_A
CA C01.060 cathepsin B 1CSB
CA C01.060 cathepsin B 1CSB_A
CA C01.060 cathepsin B complex with a dipeptidyl nitrile inhibitor 1GMY
CA C01.060 cathepsin B 1GMY_A
CA C01.060 cathepsin B 1HUC
CA C01.060 cathepsin B 1HUC_A
CA C01.060 cathepsin B recombinant precursor 1PBH
CA C01.060 cathepsin B recombinant precursor 1PBH_A
CA C01.060 cathepsin B tetragonal form 2IPP_A
CA C01.060 cathepsin B recombinant precursor 2PBH
CA C01.060 cathepsin B recombinant precursor 2PBH_A
CA C01.060 cathepsin B 3AI8
CA C01.060 cathepsin B complex with chagasin 3CBJ_A
CA C01.060 cathepsin B complex with chagasin 3CBK_A
CA C01.060 cathepsin B 3K9M_A
CA C01.060 cathepsin B recombinant precursor 3PBH
CA C01.060 cathepsin B recombinant precursor 3PBH_A
CA C01.060 cathepsin B complex with darpin 81 5MBL_A
CA C01.060 cathepsin B complex with covalently linked compound 28 6AY2_A
CA C01.060 cathepsin B complex with E64c 1ITO
CA C01.060 cathepsin B complex with CA074 inhibitor 1QDQ
CA C01.060 cathepsin B complex with NS-134, a two headed epoxysuccinyl inhibitor 1SP4_A
CA C01.060 cathepsin B 2DC6
CA C01.060 cathepsin B 2DC7
CA C01.060 cathepsin B 2DC8
CA C01.060 cathepsin B 2DC9
CA C01.060 cathepsin B 2DCA
CA C01.060 cathepsin B 2DCB
CA C01.060 cathepsin B 2DCC
CA C01.060 cathepsin B 2DCD
CA C01.060 cathepsin B Ser115Ala mutant 1CPJ
CA C01.060 cathepsin B 1CTE
CA C01.060 cathepsin B precursor 1MIR
CA C01.060 cathepsin B Ser115Ala mutant; complex with Z-Arg-Ser(OBzl) chloromethylketone 1THE_B
CA C01.062 cathepsin B-like peptidase (platyhelminth) complex with ca074 inhibitor 3QSD_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) complex with k11017 inhibitor 3S3Q_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) complex with k11777 inhibitor 3S3R_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) zymogen 4I04_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) structure of intermediate processing form of cathepsin b1 from schistosoma mansoni 4I05_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) mature form 4I07_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) complex with wrr391 inhibitor 5OGQ_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) complex with wrr286 inhibitor 5OGR_A
CA C01.062 cathepsin B-like peptidase (platyhelminth) theoretical model 1MF3
CA C01.063 falcipain-3 complex with leupeptin 3BPM_A
CA C01.063 falcipain-3 complex with the vinyl sulfone derived inhibitor K11017 3BWK_A
CA C01.068 vitellogenic cathepsin B theoretical model 1MHG
CA C01.070 dipeptidyl-peptidase I 1JQP
CA C01.070 dipeptidyl-peptidase I exclusion domain 1K3B_A
CA C01.070 dipeptidyl-peptidase I complex with the inhibitor Gly-Phe-CHN2 2DJF_A
CA C01.070 dipeptidyl-peptidase I re-refinement of the native structure of human dipeptidyl peptidase i (cathepsin c) 2DJG_A
CA C01.070 dipeptidyl-peptidase I discovery of novel cyanamide-based inhibitors of cathepsin c 3PDF_A
CA C01.070 dipeptidyl-peptidase I human dpp1 in complex with (2s)-2-amino-n-((1s)-1-cyano-2-(4- phenylphenyl)ethyl)butanamide 4CDC_A
CA C01.070 dipeptidyl-peptidase I human dpp1 in complex with (2s)-n-((1s)-1-cyano-2-(4-(4-cyanophenyl) phenyl)ethyl)piperidine-2-carboxamide 4CDD_A
CA C01.070 dipeptidyl-peptidase I human dpp1 in complex with 4-amino-n-((1s)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)tetrahydropyran-4-carboxamide 4CDE_A
CA C01.070 dipeptidyl-peptidase I human dpp1 in complex with (2s,4s)-n-((1s)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)-4-hydroxy-piperidine-2-carboxamide 4CDF_A
CA C01.070 dipeptidyl-peptidase I complex with dipeptide substrates 4OEL_A
CA C01.070 dipeptidyl-peptidase I complex with dipeptide substrates 4OEM_A
CA C01.070 dipeptidyl-peptidase I complex with dipeptidyl cyclopropyl nitrile inhibitor 2 6IC5_A
CA C01.070 dipeptidyl-peptidase I complex with cyclopropyl peptidyl nitrile inhibitor 1 6IC6_A
CA C01.070 dipeptidyl-peptidase I complex with dipeptidyl cyclopropyl nitrile inhibitor 3 6IC7_A
CA C01.070 dipeptidyl-peptidase I theoretical model 1BMU
CA C01.072 rhodesain complex with the vinyl sulfone derived inhibitor K11777 2P7U_A
CA C01.072 rhodesain complex with the vinyl sulfone derived inhibitor K11002 2P86_A
CA C01.072 rhodesain complex with a macrolactam inhibitor 6EX8_A
CA C01.072 rhodesain complex with a macrolactam inhibitor 6EXO_A
CA C01.072 rhodesain complex with a macrolactam inhibitor 6EXQ_A
CA C01.073 peptidase 1 (mite) precursor; mutant form 1XKG
CA C01.073 peptidase 1 (mite) 2AS8_A
CA C01.073 peptidase 1 (mite) c2 crystal form of mite allergen der p 1 3F5V_A
CA C01.073 peptidase 1 (mite) 3RVW
CA C01.073 peptidase 1 (mite) 3RVX
CA C01.073 peptidase 1 (mite) 4PP1
CA C01.073 peptidase 1 (mite) 4PP2
CA C01.073 peptidase 1 (mite) complex with fab fragment of mab 5h8 5VCN_A
CA C01.073 peptidase 1 (mite) complex with fab fragment of mab 10b9 5VCO_A
CA C01.073 peptidase 1 (mite) complex with fab 4c1 5VPG_A
CA C01.073 peptidase 1 (mite) complex with fab 4c1 5VPH_A
CA C01.073 peptidase 1 (mite) 3D6S_A
CA C01.073 peptidase 1 (mite) 3RVV
CA C01.073 peptidase 1 (mite) 5VPK_A
CA C01.073 peptidase 1 (mite) complex with fab 4c1 5VPL_A
CA C01.074 CPB peptidase theoretical model 1BMJ
CA C01.075 cruzipain catalytic domain, Gly213 stop. 1AIM
CA C01.075 cruzipain complex with WRR-99 1EWL_A
CA C01.075 cruzipain complex with WRR-112 1EWM
CA C01.075 cruzipain complex with WRR-204 1EWO
CA C01.075 cruzipain complex with N-carbonylmorpholine-Leu-homophenylalanylmethane inhibitor 1EWP
CA C01.075 cruzipain complex with vinyl sulfone-derived inhibitor VS1 1F29
CA C01.075 cruzipain complex with vinyl sulfone-derived inhibitor VS2 1F2A
CA C01.075 cruzipain complex with vinyl sulfone-derived inhibitor VS3 1F2B
CA C01.075 cruzipain complex with vinyl sulfone-derived inhibitor VS4 1F2C
CA C01.075 cruzipain complex with [1-(3-hydroxy-2-oxo-1-phenethyl-propylcarbamoyl)2-phenyl-ethyl]-carbamic acid pyridin-4-ylmethyl ester 1ME3
CA C01.075 cruzipain complex with [1-(1-benzyl-3-hydroxy-2-oxo-propylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester 1ME4
CA C01.075 cruzipain complex with [1-(1-methyl-4,5-dioxo-pent-2-enylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester 1U9Q_X
CA C01.075 cruzipain catalytic domain; complex with Bz-Arg-Ala-fluoromethylketone 2AIM
CA C01.075 cruzipain complex with vinyl sulfone derived inhibitor WR483 2EFM_A
CA C01.075 cruzipain complex with the vinyl sulfone derived inhibitor K11777 2OZ2_A
CA C01.075 cruzipain 3HD3
CA C01.075 cruzipain 3I06
CA C01.075 cruzipain 3IUT
CA C01.075 cruzipain 3KKU
CA C01.075 cruzipain 3LXS
CA C01.075 cruzipain 4KLB
CA C01.075 cruzipain 4PI3
CA C01.075 cruzipain 4QH6
CA C01.075 cruzipain 4W5B
CA C01.075 cruzipain 4W5C
CA C01.075 cruzipain 4XUI
CA C01.075 cruzipain apo-form 6N3S_A
CA C01.075 cruzipain complex with mmts inhibitor 6O2X_A
CA C01.084 bleomycin hydrolase (animal) 1CB5
CA C01.084 bleomycin hydrolase (animal) Cys73Ser mutant 2CB5
CA C01.085 bleomycin hydrolase (yeast) Cys73Ala mutant 1A6R
CA C01.085 bleomycin hydrolase (yeast) 1GCB
CA C01.085 bleomycin hydrolase (yeast) Asn392Ala mutant 2DZY_A
CA C01.085 bleomycin hydrolase (yeast) Asn392Val mutant 2DZZ_A
CA C01.085 bleomycin hydrolase (yeast) Asn392Leu mutant 2E00_A
CA C01.085 bleomycin hydrolase (yeast) His369la mutant 2E01_A
CA C01.085 bleomycin hydrolase (yeast) His369Leu mutant 2E02_A
CA C01.085 bleomycin hydrolase (yeast) Asnq67e mutant 2E03_A
CA C01.085 bleomycin hydrolase (yeast) Cys73Ala mutant 3GCB
CA C01.098 CPC peptidase theoretical model 1MJ6
CA C01.098 CPC peptidase theoretical model 1BF7
CA C01.098 CPC peptidase complex with ca074 3HHI_A
CA C01.098 CPC peptidase 3MOR_A
CA C01.098 CPC peptidase 4HWY_A
CA C01.098 CPC peptidase trypanosoma brucei procathepsin b structure solved by serial microcrystallography using synchrotron radiation 4N4Z_A
CA C01.098 CPC peptidase procathepsin b s9 from trypanosoma congolense 5FPW_A
CA C01.099 ervatamin B 1IWD
CA C01.101 cathepsin B-like peptidase, nematode theoretical model 1MNW
CA C01.116 ervatamin C 1O0E_A
CA C01.116 ervatamin C 2PNS_A
CA C01.125 Cwp84 peptidase 4CI7
CA C01.125 Cwp84 peptidase Cys116Ala mutant; mature protein 4D59
CA C01.125 Cwp84 peptidase Cys116Ala mutant; mature protein 4D5A
CA C01.128 xylellain 3OIS
CA C01.134 mexicain 2BDZ
CA C01.137 ervatamin A complex with E64 2PSC
CA C01.137 ervatamin A complex with E64 3BCN
CA C01.137 ervatamin A 2PNS
CA C01.137 ervatamin A ervatamin-C; complex with E64 2PRE_A
CA C01.149 TgCPL peptidase (Toxoplasma-type) complex with propeptide 3F75_A
CA C01.171 Pd_dinase (Parabacteroides distasonis) 3PW3
CA C01.171 Pd_dinase (Parabacteroides distasonis) 5WDK_A
CA C01.171 Pd_dinase (Parabacteroides distasonis) 5WDL_A
CA C01.984 serine-repeat antigen (Plasmodium sp.) 2WBF
CA C01.984 serine-repeat antigen (Plasmodium sp.) 3CH2
CA C01.984 serine-repeat antigen (Plasmodium sp.) 3CH3
CA C01.987 papain-like protein SPE31 (Pachyrhizus erosus) 2B1M
CA C01.987 papain-like protein SPE31 (Pachyrhizus erosus) 2B1N
CA C01.UPA subfamily C1A unassigned peptidases complex with N-[(1S)-1-([(3S,4S,7R)-3-hydroxy-7-methyl-1-(pyridin-2-ylsulfonyl)-2,3,4,7-tetrahydro-1H-azepin-4-yl]aminocarbonyl)-3-methylbutyl]-1-benzofuran-2-carboxamide 2FTD
CA C01.UPA subfamily C1A unassigned peptidases structural basis for the limited antibody cross reactivity between themite allergens blo t 1 and der p 1 5JT8_A
CA C01.UPA subfamily C1A unassigned peptidases structure of digestive procathepsin l2 proteinase from tenebrio molitor larval midgut 3QJ3_A
CA C01.UPA subfamily C1A unassigned peptidases precursor 5EF4_A
CA C01.UPA subfamily C1A unassigned peptidases precursor 5EGW_A
CA C02.001 calpain-1 complex with inhibitor Z-Leu-Leu-Tyr-CH2F 1ZCM
CA C02.001 calpain-1 catalytic domain only 2ARY
CA C02.001 calpain-1 catalytic domain only 1KXR_A
CA C02.001 calpain-1 1QXP_A
CA C02.001 calpain-1 protease core; complex with leupeptin 1TL9_A
CA C02.001 calpain-1 peptidase unit only; complex with E64 1TLO
CA C02.001 calpain-1 calpain 1 proteolytic core;ncomplex with snj-1715, a cyclic hemiacetal-type inhibitor 2G8E_A
CA C02.001 calpain-1 proteolytic core; complex with snj-1945, a alpha-ketoamide-type inhibitor. 2G8J_A
CA C02.001 calpain-1 calpain 1 proteolytic core inactivated by wr18(s,s), an epoxysuccinyl-type inhibitor. 2NQG_A
CA C02.001 calpain-1 calpain 1 proteolytic core inactivated by wr13(r,r), an epoxysuccinyl-type inhibitor. 2NQI_A
CA C02.001 calpain-1 calpain 1 proteolytic core inactivated by zlak-3001, an alpha-ketoamide 2R9C_A
CA C02.001 calpain-1 calpain 1 proteolytic core inactivated by zlak-3002, an alpha-ketoamide 2R9F_A
CA C02.002 calpain-2 1KFU_L
CA C02.002 calpain-2 1KFX_L
CA C02.002 calpain-2 2NQA
CA C02.002 calpain-2 Complex with light chain 1DF0_A
CA C02.002 calpain-2 protease core 1MDW_A
CA C02.002 calpain-2 1QXP_A
CA C02.002 calpain-2 Lys10Thr mutant 1U5I_A
CA C02.002 calpain-2 complex with light chain with calpastatin 3BOW_A
CA C02.002 calpain-2 complex with light chain and calpastatin 3DF0_A
CA C02.004 calpain-3 1Y9V
CA C02.004 calpain-3 4OKH
CA C02.004 calpain-3 crystal structure of human calpain-3 protease core mutant-Cys129Ser 6BDT_A
CA C02.004 calpain-3 crystal structure of human calpain-3 protease core mutant-Cys129Ala 6BGP_A
CA C02.004 calpain-3 protease core; complex with E-64 6BJD_A
CA C02.004 calpain-3 protease core; complex with leupeptin 6BKJ_A
CA C02.006 calpain-9 catalytic domain only 1ZIV
CA C02.006 calpain-9 complex with leupeptin 2P0R_A
CA C02.011 calpain-5 core peptidase domain 6P3Q
CA C02.020 calpain-13 2I7A
CA C02.029 calpain (Plasmodium-type) C2 domain 2QFE
PA C03.001 poliovirus-type picornain 3C 1L1N_A
PA C03.001 poliovirus-type picornain 3C coxsackievirus Ala24Val mutant; complex with the d1-d2 fragment of icam-1 6EIT_3
PA C03.005 hepatitis A virus-type picornain 3C 1HAV_A
PA C03.005 hepatitis A virus-type picornain 3C complex with inhibitor iodoacetyl-Val-Phe-amide 1QA7
PA C03.005 hepatitis A virus-type picornain 3C complex with peptide-based ketone inhibitor N-acetyl-L-leucyl-L-alanyl-N-[(1S)-4-(dimethylamino)-1-(fluoroacetyl)-4-oxobutyl]-L-alaninamide 2H6M
PA C03.005 hepatitis A virus-type picornain 3C complex with peptide-based ketone inhibitor N-acetyl-L-Leu-L-Ala-N-[(1S)-4-(dimethylamino)-1-(fluoroacetyl)-4-oxobutyl]-L-alaninamide 2H9H
PA C03.005 hepatitis A virus-type picornain 3C complex with peptide-based ketone inhibitor N-acetyl-L-Leu-L-Phe-N-[(1S,2R)-1-(2-carboxyethyl)-3-fluoro-2-hydroxypropyl]-L-phenylalaninamide 2HAL
PA C03.007 human rhinovirus 2-type picornain 3C complex with AG7088 inhibitor 1CQQ_A
PA C03.007 human rhinovirus 2-type picornain 3C 1AYM_4
PA C03.007 human rhinovirus 2-type picornain 3C 1AYN_4
PA C03.007 human rhinovirus 2-type picornain 3C 1R1A
PA C03.007 human rhinovirus 2-type picornain 3C 2HWD
PA C03.007 human rhinovirus 2-type picornain 3C 2HWE
PA C03.007 human rhinovirus 2-type picornain 3C 2HWF
PA C03.008 foot-and-mouth disease virus picornain 3C type A10(61); crystal packing mutant (Lys51Gln) 2J92_A
PA C03.008 foot-and-mouth disease virus picornain 3C complex with a decameric peptide corresponding to the vp1-2a cleavage junction 2WV4_A
PA C03.008 foot-and-mouth disease virus picornain 3C complex with a decameric peptide corresponding to the vp1-2a cleavage junction with a gln to glu substitution at p1 2WV5_A
PA C03.008 foot-and-mouth disease virus picornain 3C crystal structure of the 3c protease from south african territories type 2 foot-and-mouth disease virus 5HM2_A
PA C03.008 foot-and-mouth disease virus picornain 3C 1QMY
PA C03.008 foot-and-mouth disease virus picornain 3C 1QOL_A
PA C03.008 foot-and-mouth disease virus picornain 3C 1QQP
PA C03.008 foot-and-mouth disease virus picornain 3C 2JQF_R
PA C03.008 foot-and-mouth disease virus picornain 3C 2JQG
PA C03.008 foot-and-mouth disease virus picornain 3C 4QBB
PA C03.008 foot-and-mouth disease virus picornain 3C fmdv leader protease bound to substrate isg15 6FFA_A
PA C03.011 Coxsackievirus-type picornain 3C coxsackievirus b3 coat protein 1COV_1
PA C03.011 Coxsackievirus-type picornain 3C 2VB0_A
PA C03.011 Coxsackievirus-type picornain 3C complex with epdtc 2ZTX_A
PA C03.011 Coxsackievirus-type picornain 3C space group c2 2ZTY_A
PA C03.011 Coxsackievirus-type picornain 3C space group p21 2ZTZ_A
PA C03.011 Coxsackievirus-type picornain 3C Cys147Ala mutant 2ZU1_A
PA C03.011 Coxsackievirus-type picornain 3C 2ZU3_A
PA C03.011 Coxsackievirus-type picornain 3C the novel asymmetric entry intermediate of a picornavirus captured with nanodiscs 3JD7_1
PA C03.011 Coxsackievirus-type picornain 3C crystal structure of 3c protease of coxsackievirus b3 3ZYD_A
PA C03.011 Coxsackievirus-type picornain 3C Thr68Ala mutant 3ZYE_A
PA C03.011 Coxsackievirus-type picornain 3C crystal structure of 3c protease mutant (Asn126Tyr) of coxsackievirus b3 3ZZ3_A
PA C03.011 Coxsackievirus-type picornain 3C Thr68Ala and Asn126Tyr mutant 3ZZ4_A
PA C03.011 Coxsackievirus-type picornain 3C complex with alpha, beta-unsaturated ethyl ester inhibitor 74 3ZZ5_A
PA C03.011 Coxsackievirus-type picornain 3C complex with michael receptor inhibitor 75 3ZZ6_A
PA C03.011 Coxsackievirus-type picornain 3C complex with alpha, beta-unsaturated ethyl ester inhibitor 81 3ZZ7_A
PA C03.011 Coxsackievirus-type picornain 3C complex with alpha, beta-unsaturated ethyl ester inhibitor 82 3ZZ8_A
PA C03.011 Coxsackievirus-type picornain 3C complex with alpha, beta-unsaturated ethyl ester inhibitor 83 3ZZ9_A
PA C03.011 Coxsackievirus-type picornain 3C complex with alpha, beta-unsaturated ethyl ester inhibitor 84 3ZZA_A
PA C03.011 Coxsackievirus-type picornain 3C complex with alpha, beta-unsaturated ethyl ester inhibitor 85 3ZZB_A
PA C03.011 Coxsackievirus-type picornain 3C Thr68Ala and Asn126Tyr mutant; complex with alpha, beta-unsaturated ethyl ester inhibitor 83 3ZZC_A
PA C03.011 Coxsackievirus-type picornain 3C Thr68Ala and Asn126Tyr mutant; complex with alpha, beta-unsaturated ethyl ester inhibitor 85 3ZZD_A
PA C03.011 Coxsackievirus-type picornain 3C echovirus 18 native particle 6HBG_A
PA C03.011 Coxsackievirus-type picornain 3C echovirus 18 a-particle 6HBH_A
PA C03.011 Coxsackievirus-type picornain 3C echovirus 18 empty particle 6HBJ_A
PA C03.011 Coxsackievirus-type picornain 3C echovirus 18 open particle without one pentamer 6HBK_A
PA C03.011 Coxsackievirus-type picornain 3C echovirus 18 open particle without three pentamers 6HBL_A
PA C03.011 Coxsackievirus-type picornain 3C 3ZV8
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 74 3ZV9
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 75 3ZVA
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 81 3ZVB
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 82 3ZVC
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 83 3ZVD
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 84 3ZVE
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 85 3ZVF
PA C03.011 Coxsackievirus-type picornain 3C complex with Michael receptor inhibitor 98 3ZVG
PA C03.011 Coxsackievirus-type picornain 3C crystal structure of the main protease (3c) from human enterovirus b ev93 3Q3X_A
PA C03.011 Coxsackievirus-type picornain 3C complex with compound 1 (ag7404) 3Q3Y_A
PA C03.011 Coxsackievirus-type picornain 3C complex with rupintrivir (ag7088) 3RUO_A
PA C03.014 human enterovirus 71 3C peptidase human enterovirus 71 3c protease 3OSY_A
PA C03.014 human enterovirus 71 3C peptidase Glu71Asp mutant; complex with rupintrivir 3QZQ_A
PA C03.014 human enterovirus 71 3C peptidase Glu71Ala mutant; complex with rupintrivir 3QZR_A
PA C03.014 human enterovirus 71 3C peptidase His133Gly mutant; complex with rupintrivir 3R0F_A
PA C03.014 human enterovirus 71 3C peptidase human enterovirus 71 in complex with capsid binding inhibitor win51711 3ZFE_A
PA C03.014 human enterovirus 71 3C peptidase human enterovirus 71 in complex with capsid binding inhibitor win51711 3ZFF_A
PA C03.014 human enterovirus 71 3C peptidase human enterovirus 71 in complex with capsid binding inhibitor win51711 3ZFG_A
PA C03.014 human enterovirus 71 3C peptidase crystal structure of human enterovirus 71 4AED_A
PA C03.014 human enterovirus 71 3C peptidase cryo-em reconstruction of enterovirus 71 in complex with a neutralizing antibody e18 4C0U_A
PA C03.014 human enterovirus 71 3C peptidase cryo-em reconstruction of empty enterovirus 71 in complex with a neutralizing antibody e18 4C0Y_A
PA C03.014 human enterovirus 71 3C peptidase cryo-em reconstruction of empty enterovirus 71 in complex with a neutralizing antibody e19 4C10_4
PA C03.014 human enterovirus 71 3C peptidase crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp2 4CDQ_A
PA C03.014 human enterovirus 71 3C peptidase crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp3 4CDU_A
PA C03.014 human enterovirus 71 3C peptidase crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp4 4CDW_A
PA C03.014 human enterovirus 71 3C peptidase crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp12 4CDX_A
PA C03.014 human enterovirus 71 3C peptidase crystal structure of human enterovirus 71 in complex with the uncoating inhibitor ald 4CEW_A
PA C03.014 human enterovirus 71 3C peptidase crystal structure of human enterovirus 71 in complex with the uncoating inhibitor nld 4CEY_A
PA C03.014 human enterovirus 71 3C peptidase Cys110Ala mutant 4FVB_A
PA C03.014 human enterovirus 71 3C peptidase Cys110Ala mutant; complex with substrate 4FVD_A
PA C03.014 human enterovirus 71 3C peptidase 4GHQ_A
PA C03.014 human enterovirus 71 3C peptidase complex with ag7088 4GHT_A
PA C03.014 human enterovirus 71 3C peptidase human enterovirus 71 uncoating intermediate captured at atomic resolution 4N43_C
PA C03.014 human enterovirus 71 3C peptidase complex with compound xb 5C1U_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound viii 5C1X_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 1 5C1Y_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 2 5C20_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 2 5DP3_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 3 5DP4_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 4 5DP5_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 7 5DP6_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 5 5DP7_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 8 5DP8_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 9 5DP9_A
PA C03.014 human enterovirus 71 3C peptidase complex with compound 6 5DPA_A
PA C03.014 human enterovirus 71 3C peptidase complex with nk-1.8k 5GSO_A
PA C03.014 human enterovirus 71 3C peptidase complex with n69s 1.8k 5GSW_A
PA C03.014 human enterovirus 71 3C peptidase complex with rupintrivir 5WQ2_A
PA C03.014 human enterovirus 71 3C peptidase cryo-em structure of cva6 vlp 5YHQ_C
PA C03.020 enterovirus picornain 2A 2IJD_1
PA C03.020 enterovirus picornain 2A poliovirus type 3 (strain saukett) stabilized virus-like particle 5O5B_4
PA C03.020 enterovirus picornain 2A poliovirus type 3 (strain saukett) stabilized virus-like particle in complex with the pocket factor compound gpp3 5O5P_4
PA C03.020 enterovirus picornain 2A complex with antiviral agent sch48973 1EAH_1
PA C03.020 enterovirus picornain 2A NMR structure 1Z8R
PA C03.020 enterovirus picornain 2A identification of a druggable vp1-vp3 interprotomer pocket in the capsid of enteroviruses 6GZV_A
PA C03.020 enterovirus picornain 2A 4MG3
PA C03.020 enterovirus picornain 2A 5C8C
PA C03.020 enterovirus picornain 2A human enterovirus 71 uncoating intermediate captured at atomic resolution 4N43_B
PA C03.020 enterovirus picornain 2A structural model of human decay-accelerating factor bound to echovirus7 from cryo-electron microscopy 1M11_1
PA C03.020 enterovirus picornain 2A 5X45
PA C03.021 rhinovirus picornain 2A 2HRV_A
PA C03.023 parechovirus picornain 3C 4UDF
PA C03.023 parechovirus picornain 3C 4Z92
PA C03.UNA subfamily C3A non-peptidase homologues 1QGC
PA C03.UNA subfamily C3A non-peptidase homologues 4WYL
PA C03.UNA subfamily C3A non-peptidase homologues 4WYW
PA C03.UNA subfamily C3A non-peptidase homologues 4WZM
PA C03.UNA subfamily C3A non-peptidase homologues 4WZQ
PA C03.UNA subfamily C3A non-peptidase homologues 4X2B
PA C03.UPA subfamily C3A unassigned peptidases 1MEC
PA C03.UPA subfamily C3A unassigned peptidases 2M7Y
PA C03.UPA subfamily C3A unassigned peptidases 2MEV
PA C03.UPA subfamily C3A unassigned peptidases 2MMH
PA C03.UPA subfamily C3A unassigned peptidases 2MMI
PA C03.UPA subfamily C3A unassigned peptidases 2MMK
PA C03.UPA subfamily C3A unassigned peptidases 2MML
PA C03.UPA subfamily C3A unassigned peptidases 4NYZ
PA C03.UPA subfamily C3A unassigned peptidases 4NZ0
PA C03.UPA subfamily C3A unassigned peptidases 4Y2C
PA C03.UPA subfamily C3A unassigned peptidases 4Y3C
PA C03.UPA subfamily C3A unassigned peptidases crystal structure of the 3c protease from coxsackievirus a16 3SJ8_A
PA C03.UPA subfamily C3A unassigned peptidases Cys147Ala mutant; complex with faglrqavtq peptide 3SJ9_A
PA C03.UPA subfamily C3A unassigned peptidases complex with rupintrivir (ag7088) 3SJI_A
PA C03.UPC subfamily C3C unassigned peptidases 3CJI
PA C04.004 tobacco etch virus NIa peptidase inactive form; complex with substrate 1LVB_A
PA C04.004 tobacco etch virus NIa peptidase complex with product 1LVM
PA C04.004 tobacco etch virus NIa peptidase Cys151Ala mutant 1Q31
CE C05.001 adenain complex with peptide cofactor 1AVP_A
CE C05.001 adenain complex with 11 amino acid cofactor 1NLN_A
CE C05.001 adenain 4EKF
CE C05.001 adenain complex with N-benzyl-2-[(Z)-iminomethyl]pyrimidine-5- carboxamide 4PID
CE C05.001 adenain complex with N-(2S)-2-(3-chlorophenyl)-2-[(methylsulfonyl)amino]acetyl- L-phenylalanyl-N-[(2Z)-2-iminoethyl]glycinamide 4PIE
CE C05.001 adenain structure of human adenovirus 2 protease with cofactor pvic 5FGY_A
CE C05.001 adenain complex with N-[(3,5-dichlorophenyl)acetyl]-L-threonyl- N-[(2Z)-2-iminoethyl]glycinamide 4PIQ
CE C05.001 adenain complex with N~2~-[(2R)-2-(3,5-dichlorophenyl)-2-(dimethylamino)acetyl]- N-(2-[(Z)-iminomethyl]pyrimidin-4-ylmethyl)- L-isoleucinamide 4PIS
CE C05.001 adenain complex with a nitrile inhibitor 4WX4_A
CE C05.001 adenain crystal structure of human adenovirus 8 protease with an irreversible vinyl sulfone inhibitor 4WX6_A
CE C05.001 adenain crystal structure of adenovirus 8 protease with a nitrile inhibitor 4WX7_A
CA C06.001 potato virus Y-type helper component peptidase 1LVM_A
CA C06.001 potato virus Y-type helper component peptidase 1Q31_A
CA C06.001 potato virus Y-type helper component peptidase 3MMG
CA C06.001 potato virus Y-type helper component peptidase 3RNV
CN C09.001 sindbis virus-type nsP2 peptidase 4GUA
CN C09.001 sindbis virus-type nsP2 peptidase 3GPG
CN C09.001 sindbis virus-type nsP2 peptidase 3GPO
CN C09.001 sindbis virus-type nsP2 peptidase 3GPQ
CN C09.001 sindbis virus-type nsP2 peptidase 3TRK
CN C09.001 sindbis virus-type nsP2 peptidase 4TU0
CN C09.001 sindbis virus-type nsP2 peptidase 4ZTB
CN C09.002 equine encephalitis alphavirus nsP2 peptidase 2HWK
CN C09.002 equine encephalitis alphavirus nsP2 peptidase venezuelan equine encephalitis virus (veev) nonstructural protein 2 (nsp2) cysteine protease 5EZQ_A
CN C09.002 equine encephalitis alphavirus nsP2 peptidase complex with E64d 5EZS_A
CA C10.001 streptopain precursor; Cys47Ser mutant 1DKI_A
CA C10.001 streptopain complex with inhibitor 1PVJ
CA C10.001 streptopain mature peptidase 2UZJ
CA C10.004 interpain A structure of prevotella intermedia prointerpain a fragment 39-359 (mutant c154a) 3BB7_A
CA C10.004 interpain A structure of active wild-type prevotella intermedia interpain a cysteine protease 3BBA_A
CA C100.001 agglutinin peptidase (Marasmius oreades) complex with trisaccharide Gal-Gla-GlcNAc 2IHO
CA C100.001 agglutinin peptidase (Marasmius oreades) complex with trisaccharide Galalpha(1,3)[Fucalpha(1,2)]Gal 3EF2
CA C100.001 agglutinin peptidase (Marasmius oreades) complex with Z-Val-Ala-Asp-CH(2)F, direct orientation 5D61
CA C100.001 agglutinin peptidase (Marasmius oreades) complex with Z-Val-Ala-Asp-CH(2)F, inverted orientation 5D62
CA C100.001 agglutinin peptidase (Marasmius oreades) complex with Z-Val-Ala-Asp-CH(2)F, dual orientation 5D63
CA C100.UNW family C100 non-peptidase homologues complex with trisaccharide Neu5Aca2-6Galb1-4GlcNAc 3PHZ
CA C100.UPW family C100 unassigned peptidases complex with E64 5MUA
CA C101.001 OTULIN peptidase 3ZNV
CA C101.001 OTULIN peptidase 3ZNX
CA C101.001 OTULIN peptidase 3ZNZ
CA C101.001 OTULIN peptidase OTU domain 4KSJ
CA C101.001 OTULIN peptidase complex with ubiquitin 4KSK
CA C101.001 OTULIN peptidase complex with linear di-ubiquitin 4KSL
CA C101.001 OTULIN peptidase 4OYK
CA C101.001 OTULIN peptidase 4P0B
CA C101.001 OTULIN peptidase structure of otulin bound to the met1-linked diubiquitin activity probe 5OE7_A
CA C101.001 OTULIN peptidase structure of the otu domain of otulin g281r mutant 6I9C_A
CA C101.950 protein FAM105A otu domain of fam105a 6DRM_A
CA C102.001 GtgE peptidase 4MI7
CA C102.001 GtgE peptidase 5KDG
CA C104.001 PlyC phage lysin complex with PlyCB 4F88
PA C107.UPW family C107 unassigned peptidases semet labeled derivative of cavally virus 3cl protease 5LAC_A
PA C107.UPW family C107 unassigned peptidases ligand-bound structure of cavally virus 3cl protease ***caveat 5lak tyr i 2 has wrong chirality at atom ca tyr k 2 has wrong ***caveat 2 5lak chirality at atom ca 5LAK_A
CR C108.001 Prp peptidase (Staphylococcus aureus) 2P92
CR C108.001 Prp peptidase (Staphylococcus aureus) 2IDL
CR C108.001 Prp peptidase (Staphylococcus aureus) 2G0I
CR C108.UPW family C108 unassigned peptidases 1S12
CD C11.003 PmC11 peptidase (Parabacteroides merdae) 3UWS
CD C11.003 PmC11 peptidase (Parabacteroides merdae) complex with peptide inhibitor Ac-VLTK-AOMK 4YEC
CD C11.004 fragipain (Bacteroides fragilis) 5DYN_A
CD C11.005 thetapain
CD C11.006 clostripain-related protein (Bacteroides thetaiotaomicron) complex with biotin-Val-Leu-Thr-Lys-AOMK 5L20
CD C11.006 clostripain-related protein (Bacteroides thetaiotaomicron) Arg154Ala mutant 6NAG
CD C11.007 distapain (Parabacteroides distasonis) zymogen 6MZO
CA C111.001 coagulation factor XIIIa with bound calcium 1EVU
CA C111.001 coagulation factor XIIIa zymogen; Trp279Phe mutant 1EX0
CA C111.001 coagulation factor XIIIa recombinant form 1F13
CA C111.001 coagulation factor XIIIa recombinant form 1FIE
CA C111.001 coagulation factor XIIIa 1GGT
CA C111.001 coagulation factor XIIIa with bound calcium 1GGU
CA C111.001 coagulation factor XIIIa with bound ytterbium 1GGY
CA C111.001 coagulation factor XIIIa with bound strontium 1QRK
CA C111.001 coagulation factor XIIIa complex with peptide-like ligand 4KTY
C- C116.001 dermonecrotic toxin (Pasteurella multocida) 2EBF
C- C116.001 dermonecrotic toxin (Pasteurella multocida) 2EBH
C- C116.001 dermonecrotic toxin (Pasteurella multocida) 2EC5
CA C117.001 SpvD g.p. (Salmonella enterica) Arg161 variant 5LQ6
CA C117.001 SpvD g.p. (Salmonella enterica) Gly161 variant 5LQ7
CA C12.001 ubiquitinyl hydrolase-L1 2ETL
CA C12.001 ubiquitinyl hydrolase-L1 2LEN
CA C12.001 ubiquitinyl hydrolase-L1 3IFW
CA C12.001 ubiquitinyl hydrolase-L1 3IRT
CA C12.001 ubiquitinyl hydrolase-L1 3KVF
CA C12.001 ubiquitinyl hydrolase-L1 3KW5
CA C12.001 ubiquitinyl hydrolase-L1 4DM9
CA C12.001 ubiquitinyl hydrolase-L1 4JKJ
CA C12.002 ubiquitinyl hydrolase-YUH1 complex with human ubiquitin 1CMX
CA C12.003 ubiquitinyl hydrolase-L3 1UCH
CA C12.003 ubiquitinyl hydrolase-L3 complex with ubiquitin 1XD3
CA C12.003 ubiquitinyl hydrolase-L3 complex with Lys27-linked di-ubiquitin 6ISU_A
CA C12.005 ubiquitinyl hydrolase-L5 3A7S
CA C12.005 ubiquitinyl hydrolase-L5 3IHR
CA C12.005 ubiquitinyl hydrolase-L5 catalytic domain only 3RII
CA C12.005 ubiquitinyl hydrolase-L5 catalytic domain only 3RIS
CA C12.005 ubiquitinyl hydrolase-L5 3TB3
CA C12.005 ubiquitinyl hydrolase-L5 4UEL
CA C12.005 ubiquitinyl hydrolase-L5 4UEM
CA C12.005 ubiquitinyl hydrolase-L5 4UF5
CA C12.005 ubiquitinyl hydrolase-L5 4UF6
CA C12.005 ubiquitinyl hydrolase-L5 4WLP
CA C12.005 ubiquitinyl hydrolase-L5 4WLQ
CA C12.005 ubiquitinyl hydrolase-L5 4WLR
CA C12.A09 CG8445 g.p. (Drosophila melanogaster) complex with pr 6CGA_A
CA C12.A09 CG8445 g.p. (Drosophila melanogaster) complex with DEUBAD of ASX 6HGC
CE C122.001 SdeA (Legionella pneumophila) 5CRA
CE C122.001 SdeA (Legionella pneumophila) 5CRB
CE C122.001 SdeA (Legionella pneumophila) 5CRC
CE C122.001 SdeA (Legionella pneumophila) 5YSI
CE C122.001 SdeA (Legionella pneumophila) 5YSJ
CE C122.001 SdeA (Legionella pneumophila) 5YSK
CE C122.001 SdeA (Legionella pneumophila) 6B7Q
CE C122.001 SdeA (Legionella pneumophila) 6G0C
CD C13.001 legumain (plant beta form) complex with AAN peptide 6AZT
CD C13.004 legumain, animal-type complex with Ac-Tyr-Val-Ala-Asp-chloromethylketone 4AW9
CD C13.004 legumain, animal-type complex with Ac-Tyr-Val-Ala-Asp-chloromethylketone at pH 5.0 4AWA
CD C13.004 legumain, animal-type complex with Z-Ala-Ala-AzaAsn-chloromethylketone 4AWB
CD C13.004 legumain, animal-type precursor 4FGU
CD C13.004 legumain, animal-type oxidised form in complex with cystatin E/M 4N6N_A
CD C13.004 legumain, animal-type complex with cystatin E/M 4N6O_A
CD C13.004 legumain, animal-type YVAD-CMK bound form; complex with compound 11b 5LU8_C
CD C13.004 legumain, animal-type YVAD-CMK bound form; complex with compound 11 5LU9_C
CD C13.004 legumain, animal-type complex with compound 11b 5LUA_A
CD C13.004 legumain, animal-type complex with compound 11 5LUB_B
CD C13.004 legumain, animal-type activated at pH 3.5 4NOJ
CD C13.004 legumain, animal-type precxursor at pH 7.5 4NOK
CD C13.004 legumain, animal-type Asp223Ala mutant; precursor at pH 7.5 4NOL
CD C13.004 legumain, animal-type activated at pH 4.5 4NOM
CD C13.004 legumain, animal-type 4D3X
CD C13.004 legumain, animal-type precursor 4D3Y
CD C13.004 legumain, animal-type precursor; trigonal space group 4D3Z
CD C13.006 legumain (plant gamma form) two-chain activation state 5NIJ
CD C13.006 legumain (plant gamma form) isoform gamma in complex with Ac-YVAD-CMK 5OBT
CD C13.010 OaAEP1 (Oldenlandia affinis) 5H0I
CD C14.001 caspase-1 complex with (3S)-N-methanesulfonyl-3-(1-[N-(2-naphtoyl)-Val]-Proamino)-4-oxobutanamide inhibitor 1BMQ
CD C14.001 caspase-1 complex with inhibitor ac-Trp-Glu-His-Asp 1IBC
CD C14.001 caspase-1 complex with inhibitor Ac-Tyr-Val-Ala-Asp-H 1ICE
CD C14.001 caspase-1 complex with 3-(2- mercapto-acetylamino)-4-oxo-pentanoic acid 1RWK_A
CD C14.001 caspase-1 complex with 4-oxo- 3-[2-(5-[4-(quinoxalin-2-ylamino)-benzoylamino]-methyl- thiophen-2-yl)-acetylamino]-pentanoic acid 1RWM_A
CD C14.001 caspase-1 complex with 3-2- ethyl-6-[4-(quinoxalin-2-ylamino)-benzoylamino]- hexanoylamino-4-oxo-butyric acid 1RWN_A
CD C14.001 caspase-1 complex with 4-oxo- 3-6-[4-(quinoxalin-2-ylamino)-benzoylamino]-2-thiophen-2- yl-hexanoylamino-pentanoic acid 1RWO_A
CD C14.001 caspase-1 complex with 3-6- [(8-hydroxy-quinoline-2-carbonyl)-amino]-2-thiophen-2-yl- hexanoylamino-4-oxo-butyric acid 1RWP_A
CD C14.001 caspase-1 complex with 5-[5- (1-carboxymethyl-2-oxo-propylcarbamoyl)-5-phenyl- pentylsulfamoyl]-2-hydroxy-benzoic acid 1RWV_A
CD C14.001 caspase-1 complex with 4-oxo- 3-[(6-[4-(quinoxalin-2-ylamino)-benzoylamino]-methyl- pyridine-3-carbonyl)-amino]-butyric acid 1RWW_A
CD C14.001 caspase-1 complex with 4-oxo- 3-6-[4-(quinoxalin-2-yloxy)-benzoylamino]-2-thiophen-2-yl- hexanoylamino-butyric acid 1RWX_A
CD C14.001 caspase-1 Cys285Ala mutant 1SC1
CD C14.001 caspase-1 Cys285Ala mutant; complex with malonate 1SC3
CD C14.001 caspase-1 Cys285Ala mutant; after malonate complex dissociation 1SC4
CD C14.001 caspase-1 Cys285Ala, Cys362Ala, Cys364Ala, Cys397Ala mutant; complex with 1-methyl-3- trifluoromethyl-1H-thieno[2,3-C]pyrazole-5-carboxylic acid (2-mercapto-ethyl)-amide 2FQQ_A
CD C14.001 caspase-1 Cys362Ala, Cys364Ala, Cys397Ala mutant; complex with 3-[2-(2- benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK) 2H48_A
CD C14.001 caspase-1 Glu390Asp mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-vad- fmk) 2H4W_A
CD C14.001 caspase-1 Arg286Lys mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-vad- fmk) 2H4Y_A
CD C14.001 caspase-1 Glu390Asp, Arg286Lys mutant; complex with 3-[2-(2- benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-4-oxo-pentanoic acid 2H51_A
CD C14.001 caspase-1 Thr388Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-vad- fmk) 2H54_A
CD C14.001 caspase-1 complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK) 2HBQ_A
CD C14.001 caspase-1 Arg286Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD- FMK) 2HBR_A
CD C14.001 caspase-1 Glu390Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD- FMK) 2HBY_A
CD C14.001 caspase-1 Arg286Ala, Glu390Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3- methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (Z-VAD-FMK) 2HBZ_A
CD C14.001 caspase-1 3D6F
CD C14.001 caspase-1 3D6H
CD C14.001 caspase-1 3D6M
CD C14.001 caspase-1 procaspase-1 zymogen domain crystal strucutre 3E4C_A
CD C14.001 caspase-1 3NS7
CD C14.001 caspase-1 crystal structure of human caspase-1 with 2-((2-naphthoyl)-l-valyl)-4-hydroxy-n-((3s)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-2- azabicyclo[2.2.2]octane-3-carboxamide (compound 1) 5MMV_A
CD C14.001 caspase-1 crystal structure of human caspase-1 with (3s,6s,10as)-n-((2s,3s)-2- hydroxy-5-oxotetrahydrofuran-3-yl)-6-(isoquinoline-1-carboxamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide (pge-3935199) 5MTK_A
CD C14.001 caspase-1 complex with ac-fltd-cmk 6BZ9_A
CD C14.001 caspase-1 crystal structure of human caspase-1 with n-3-[1-((s)-2-hydroxy-5- oxo-tetrahydro-furan-3-ylcarbamoyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3, 4-tetrahydro-pyrimidin-5-yl-4-(quinoxalin-2-ylamino)-benzamide 6F6R_A
CD C14.002 CED-3 peptidase 4M9R
CD C14.003 caspase-3 complex with tetrapeptide inhibitor acetyl-Asp-Val-Ala-Asp-fluoromethylketone 1CP3
CD C14.003 caspase-3 complex with isatin sulfonamide inhibitor 1-methyl-5-(2-phenoxymethyl-pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione 1GFW
CD C14.003 caspase-3 complex with BIRC-4 protein 1I3O_A
CD C14.003 caspase-3 1NME
CD C14.003 caspase-3 1NMQ
CD C14.003 caspase-3 1NMS
CD C14.003 caspase-3 complex with acetyl-Asp-Glu-Val-Asp-CHO 1PAU_A
CD C14.003 caspase-3 1QX3
CD C14.003 caspase-3 complex with nicotinic acid aldehyde (3S)-3-[(5-bromopyridin-3-yl)carbonyl]amino-4-oxobutanoic acid 1RE1_A
CD C14.003 caspase-3 complex with pryazinone inhibitor 3-(2-5-tert-butyl-3-[(4-methyl-furazan-3-ylmethyl)-amino]-2-oxo-2H-pyrazin-1-yl-butyrylamino)-5-(hexyl-methyl-amino)-4-oxo-pentanoic acid anion 1RHJ_A
CD C14.003 caspase-3 complex with phenyl- propyl-ketone N-acetyl-L-alpha-aspartyl-L-alpha-glutamyl-N-[(1S)-1-(carboxymethyl)-2-oxo-5-phenylpentyl]-L-valinamide 1RHK_A
CD C14.003 caspase-3 complex with nicotinic acid aldehyde 4-[5-(2-carboxy-1-formyl-ethylcarbamoyl)-pyridin-3-yl]-benzoic acid 1RHM_A
CD C14.003 caspase-3 complex with bromomethoxyphenyl inhibitor 5-S-benzyl-3-(N-[(5-bromo-2-methoxyphenyl)acetyl]- L-valylamino)-2,3-dideoxy-5-thio-D-erythro- pentonic acid 1RHQ_A
CD C14.003 caspase-3 complex with cinnamic acid methyl ester (3S)-5-[(2-chloro-6-fluorobenzyl)sulfanyl]-3-[N-(2-ethoxy-5-[(1E)-3-methoxy-3-oxoprop-1-enyl]phenylacetyl)-D-valyl]amino-4-oxopentanoic acid 1RHR_A
CD C14.003 caspase-3 complex with 5,6,7 tricyclic peptidomimetic inhibitor (3S)-3-[((2S)-5-[(N-acetyl-L-alpha-aspartyl)amino]-4-oxo-1,2,4,5,6,7-hexahydroazepino[3,2,1-hi]indol-2-ylcarbonyl)amino]-5-(benzylsulfanyl)-4-oxopentanoic acid 1RHU_A
CD C14.003 caspase-3 complex with (5S,8R,11S)-8-(2-carboxyethyl)-5-(carboxymethyl)-14-(4-ethoxy-4-oxobutanoyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid 2C1E_A
CD C14.003 caspase-3 complex with (5S,8R,11S)-8-(2-carboxyethyl)-5-(carboxymethyl)-14-(4-ethoxy-4-oxobutanoyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid 2C2K_A
CD C14.003 caspase-3 complex with (5S,8R,11S)-14-[4-(benzyloxy)-4-oxobutanoyl]-8-(2-carboxyethyl)-5-(carboxymethyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid 2C2M_A
CD C14.003 caspase-3 complex with Cbz-Asp-Glu-Val-AAsp-CHCH-CON(CH3)CH2Ph 2C2O_A
CD C14.003 caspase-3 complex with CBZ-Asp-Glu-Val-azaAsp-EP-CO-N(CH2PH)2 2CDR_A
CD C14.003 caspase-3 extended substrate recognition in caspase-3 revealed by high resolution x-ray structure analysis 2CJX_A
CD C14.003 caspase-3 extended substrate recognition in caspase-3 revealed by high resolution x-ray structure analysis 2CJY_A
CD C14.003 caspase-3 complex with CBZ-Asp-Glu-Val-azaAsp-EP-COO-CH2Ph 2CNK_A
CD C14.003 caspase-3 complex with CBZ-Asp-Glu-Val-azaAsp-EP-CO-NH-CH2Ph 2CNL_A
CD C14.003 caspase-3 complex with CBZ-Ile-Glu-Thr-azaAsp-EP-CO-Ala-NH-CH2-Ph 2CNN_A
CD C14.003 caspase-3 complex with CBZ-Glu-Val-azaAsp-(S,S)EP-CO-NHCH2CH2Ph 2CNO_A
CD C14.003 caspase-3 extended substrate recognition in caspase-3 revealed by high resolution x-ray structure analysis 2DKO_A
CD C14.003 caspase-3 complex with inhibitor Ac-DEVD-CHO 2H5I_A
CD C14.003 caspase-3 complex with inhibitor Ac-DMQD-CHO 2H5J_A
CD C14.003 caspase-3 complex with inhibitor Ac-VDVAD-CHO 2H65_A
CD C14.003 caspase-3 2J30
CD C14.003 caspase-3 2J31
CD C14.003 caspase-3 2J32
CD C14.003 caspase-3 2J33
CD C14.003 caspase-3 2XYG
CD C14.003 caspase-3 2XYH
CD C14.003 caspase-3 2XYP
CD C14.003 caspase-3 2XZD
CD C14.003 caspase-3 2XZT
CD C14.003 caspase-3 2Y0B
CD C14.003 caspase-3 3DEH
CD C14.003 caspase-3 3DEI
CD C14.003 caspase-3 3DEJ
CD C14.003 caspase-3 3DEK
CD C14.003 caspase-3 complex with inhibitor Ac-LDESD-CHO 3EDQ_A
CD C14.003 caspase-3 caspase-3 binds diverse p4 residues in peptides 3GJQ_A
CD C14.003 caspase-3 caspase-3 binds diverse p4 residues in peptides 3GJR_A
CD C14.003 caspase-3 caspase-3 binds diverse p4 residues in peptides 3GJS_A
CD C14.003 caspase-3 caspase-3 binds diverse p4 residues in peptides 3GJT_A
CD C14.003 caspase-3 3H0E
CD C14.003 caspase-3 3ITN
CD C14.003 caspase-3 3KJF
CD C14.003 caspase-3 3PCX
CD C14.003 caspase-3 3PD0
CD C14.003 caspase-3 3PD1
CD C14.003 caspase-3 4DCJ
CD C14.003 caspase-3 4DCO
CD C14.003 caspase-3 4DCP
CD C14.003 caspase-3 4EHA
CD C14.003 caspase-3 4EHD
CD C14.003 caspase-3 4EHF
CD C14.003 caspase-3 4EHH
CD C14.003 caspase-3 4EHK
CD C14.003 caspase-3 4EHL
CD C14.003 caspase-3 4EHN
CD C14.003 caspase-3 4JJE
CD C14.003 caspase-3 4JQY
CD C14.003 caspase-3 4JQZ
CD C14.003 caspase-3 4JR0
CD C14.003 caspase-3 4PRY
CD C14.003 caspase-3 4PS0
CD C14.003 caspase-3 4QTX
CD C14.003 caspase-3 4QTY
CD C14.003 caspase-3 4QU0
CD C14.003 caspase-3 4QU5
CD C14.003 caspase-3 4QU8
CD C14.003 caspase-3 4QU9
CD C14.003 caspase-3 4QUA
CD C14.003 caspase-3 4QUB
CD C14.003 caspase-3 4QUD
CD C14.003 caspase-3 4QUE
CD C14.003 caspase-3 4QUG
CD C14.003 caspase-3 4QUH
CD C14.003 caspase-3 4QUI
CD C14.003 caspase-3 4QUJ
CD C14.003 caspase-3 4QUL
CD C14.003 caspase-3 Val266Ala mutant 5I9B_A
CD C14.003 caspase-3 Val266Cys mutant 5I9T_A
CD C14.003 caspase-3 Val266Asp mutant 5IAB_A
CD C14.003 caspase-3 Val266Phe mutant 5IAE_A
CD C14.003 caspase-3 Val266Gln mutant 5IAG_A
CD C14.003 caspase-3 Val266Leu mutant 5IAJ_A
CD C14.003 caspase-3 Val266Ser mutant 5IAK_A
CD C14.003 caspase-3 Val266Asn mutant 5IAN_A
CD C14.003 caspase-3 Val266Trp mutant 5IAR_A
CD C14.003 caspase-3 Val266Tyr mutant 5IAS_A
CD C14.003 caspase-3 Val266Ile mutant 5IBC_A
CD C14.003 caspase-3 Val266Met mutant 5IBP_A
CD C14.003 caspase-3 Val266Lys mutant 5IBR_A
CD C14.003 caspase-3 complex with DEVE peptide 5IC4_A
CD C14.003 caspase-3 caspase-3 mutant - t245d,s249d 6BFJ_A
CD C14.003 caspase-3 caspase-3 mutant- t245a 6BFK_A
CD C14.003 caspase-3 caspase-3 mutant- d9a,d28a,t245d 6BFL_A
CD C14.003 caspase-3 caspase-3 mutant- t245d 6BFO_A
CD C14.003 caspase-3 Asp9Ala/Asp28Ala/Ser150Asp mutant 6BG0_A
CD C14.003 caspase-3 Asp9Ala/Asp28Ala/Ser150Glu mutant 6BG1_A
CD C14.003 caspase-3 caspase-3 mutant- t152d 6BG4_A
CD C14.003 caspase-3 caspase-3 mutant- d9a,d28a,t152d 6BGK_A
CD C14.003 caspase-3 Ser150Asp mutant 6BGQ_A
CD C14.003 caspase-3 caspase-3 mutant - s150e 6BGR_A
CD C14.003 caspase-3 caspase-3 mutant - s150y 6BGS_A
CD C14.003 caspase-3 caspase-3 mutant - t152a 6BH9_A
CD C14.003 caspase-3 caspase-3 mutant - t152v 6BHA_A
CD C14.003 caspase-3 complex with ac-dw3-ke 6CKZ_A
CD C14.003 caspase-3 complex with ac-ats009-ke 6CL0_A
CD C14.003 caspase-3 zebra fish caspase-3 ***caveat 5jft caspase should be connected to the chloromethyl ketone ***caveat 2 5jft residual terminus of the inhibitor through hemithioacetal ***caveat 3 5jft bond, but the model does not reflect the ideal ***caveat 4 5jft hemithio 5JFT_A
CD C14.004 caspase-7 complex with acetyl-Asp-Glu-Val-Asp-CHO 1F1J
CD C14.004 caspase-7 precursor 1GQF
CD C14.004 caspase-7 complex with XIAP 1I4O_A
CD C14.004 caspase-7 complex with XIAP inhibitor 1I51_A
CD C14.004 caspase-7 1K86
CD C14.004 caspase-7 precursor 1K88
CD C14.004 caspase-7 complex with XIAP-BIR2 1KMC_A
CD C14.004 caspase-7 theoretical model; complex with AC-DEVD inhibitor 1MIA
CD C14.004 caspase-7 complex with dica allosteric inhibitor 1SHJ_A
CD C14.004 caspase-7 complex with FICA allosteric inhibitor 1SHL
CD C14.004 caspase-7 complex with inhibitor Ac-DMQD-CHO 2QL5_A
CD C14.004 caspase-7 complex with inhibitor Ac-IEPD-CHO 2QL7_A
CD C14.004 caspase-7 complex with inhibitor Ac-DQMD-CHO 2QL9_A
CD C14.004 caspase-7 complex with inhibitor Ac-ESMD-CHO 2QLB_A
CD C14.004 caspase-7 complex with inhibitor Ac-DNLD-CHO 2QLF_A
CD C14.004 caspase-7 complex with inhibitor Ac-WEHD-CHO 2QLJ_A
CD C14.004 caspase-7 complex with acetyl- LDESD-CHO 3EDR_A
CD C14.004 caspase-7 mature caspase-7 i213a with devd-cho inhibitor bound to active site 3H1P_A
CD C14.004 caspase-7 complex with acetyl-yvad- cho 3IBC_A
CD C14.004 caspase-7 crystal structure of unliganded caspase-7 3IBF_A
CD C14.004 caspase-7 redox-controlled 3R5K_A
CD C14.004 caspase-7 crystal structure of caspase-7 4FDL_A
CD C14.004 caspase-7 complex with allosteric inhibitor 4FEA_A
CD C14.004 caspase-7 crystal structure of mutant form of caspase-7 4HQ0_A
CD C14.004 caspase-7 crystal structure of mutant form of caspase-7 4HQR_A
CD C14.004 caspase-7 complex with darpin c7_16 4JB8_A
CD C14.004 caspase-7 caspase-3 specific unnatural amino acid peptides 4JJ8_A
CD C14.004 caspase-7 precursor in complex with Ac-DEVD-CMK 4JR1
CD C14.004 caspase-7 human procaspase-7/caspase-7 heterodimer bound to ac-devd-cmk 4JR2_A
CD C14.004 caspase-7 complex with darpin d7.18 4LSZ_A
CD C14.004 caspase-7 caspase-7 variant 4 (v4) with reprogrammed substrate specificity due to y230v/w232y/s234v/q276d substitutions bound to veid inhibitor. 4ZVO_A
CD C14.004 caspase-7 caspase-7 variant 2 (v2) with reprogrammed substrate specificity due to y230v/w232m/q276c substitutions bound to devd inhibitor. 4ZVP_A
CD C14.004 caspase-7 caspase-7 variant 2 (v2) with reprogrammed substrate specificity due to y230v/w232m/q276c substitutions bound to veid inhibitor. 4ZVQ_A
CD C14.004 caspase-7 caspase-7 variant 4 (v4) with reprogrammed substrate specificity due to y230v/w232y/s234v/q276d substitutions bound to devd inhibitor. 4ZVR_A
CD C14.004 caspase-7 caspase-7 variant 1 (v1) with reprogrammed substrate specificity due to y230a/w232m/s234n substitutions, bound to devd inhibitor. 4ZVS_A
CD C14.004 caspase-7 caspase-7 variant 1 (v1) with reprogrammed substrate specificity due to y230a/w232m/s234n substitutions, bound to veid inhibitor. 4ZVT_A
CD C14.004 caspase-7 caspase-7 wild-type bound to the caspase-6 cognate tetrapeptide inhibitor ac-veid-cho 4ZVU_A
CD C14.004 caspase-7 complex with DEVE peptide 5IC6_A
CD C14.004 caspase-7 caspase-7 s239e phosphomimetic 5K20_A
CD C14.004 caspase-7 crystal structure of human caspase-7 soaked with allosteric inhibitor 2-[(2-acetylphenyl)sulfanyl]benzoic acid 5V6U_A
CD C14.004 caspase-7 crystal structure of human caspase-7 soaked with allosteric inhibitor 2-[2-(4-chlorophenyl)-2-oxoethyl]sulfanylbenzoic acid 5V6Z_A
CD C14.004 caspase-7 complex with ac-dw3-ke 6CL1_A
CD C14.004 caspase-7 complex with ac-ats009-ke 6CL2_A
CD C14.005 caspase-6 theoretical model; complex with AC-IETD inhibitor 1MI9
CD C14.005 caspase-6 2WDP
CD C14.005 caspase-6 3K7E
CD C14.005 caspase-6 3NKF
CD C14.005 caspase-6 3NR2
CD C14.005 caspase-6 3OD5
CD C14.005 caspase-6 3P45
CD C14.005 caspase-6 3P4U
CD C14.005 caspase-6 3QNW
CD C14.005 caspase-6 3S70
CD C14.005 caspase-6 3S8E
CD C14.005 caspase-6 3V6L
CD C14.005 caspase-6 3V6M
CD C14.005 caspase-6 4EJF
CD C14.005 caspase-6 4FXO
CD C14.005 caspase-6 4HVA
CD C14.005 caspase-6 4IYR
CD C14.005 caspase-6 4N5D
CD C14.005 caspase-6 4N6G
CD C14.005 caspase-6 4N7J
CD C14.005 caspase-6 4N7M
CD C14.005 caspase-6 4NBK
CD C14.005 caspase-6 4NBL
CD C14.005 caspase-6 4NBN
CD C14.005 caspase-6 Ala109Thr mutant 6DEU_A
CD C14.005 caspase-6 Glu35Lys mutant 6DEV_A
CD C14.006 caspase-2 complex with acetyl-Leu-Asp-Glu-Ser-Asp-CHO 1PYO_A
CD C14.006 caspase-2 inhibition of caspase-2 by a designed ankyrin repeat protein (darpin) 2P2C_A
CD C14.006 caspase-2 crystal structure of active caspase-2 bound with ac-advad-cho 3R5J_A
CD C14.006 caspase-2 crystal structure of active caspase-2 bound with ac-vdvad-cho 3R6G_A
CD C14.006 caspase-2 caspase-2 t380a bound with ac-vdvad-cho 3R6L_A
CD C14.006 caspase-2 complex with one molecule of Ac-DVAD-CHO 3R7B_A
CD C14.006 caspase-2 complex with two molecules of Ac-DVAD-CHO 3R7N_A
CD C14.006 caspase-2 crystal structure of apo caspase2 3R7S_A
CD C14.006 caspase-2 complex with chdi ligand 33c 3RJM_A
CD C14.009 caspase-8 complex with Z-Asp-Glu-Val-Asp-CHO inhibitor 1F9E
CD C14.009 caspase-8 complex with baculovirus P35 inhibitor 1I4E_B
CD C14.009 caspase-8 complex with tripeptide ketone inhibitor Z-Glu-Val-Asp-dichloromethylketone 1QDU
CD C14.009 caspase-8 complex with acetyl-Ile-Glu-Thr-aspartic aldehyde 1QTN
CD C14.009 caspase-8 complex with 2C2Z_A
CD C14.009 caspase-8 alternative p35-caspase-8 complex 2FUN_B
CD C14.009 caspase-8 complex with darpin-8.4 2Y1L_A
CD C14.009 caspase-8 zymogen; complex with c-flipl 3H11_B
CD C14.009 caspase-8 complex with a covalent inhibitor 3KJN_A
CD C14.009 caspase-8 complex with a covalent inhibitor 3KJQ_A
CD C14.009 caspase-8 caspase-3 specific unnatural amino acid-based peptides 4JJ7_A
CD C14.009 caspase-8 caspase-8 specific unnatural amino acid peptides 4PRZ_A
CD C14.009 caspase-8 caspase-8 specific unnatural amino acid peptides 4PS1_A
CD C14.010 caspase-9 cleaved form lacking caspase recruitment domain 1JXQ
CD C14.010 caspase-9 complex with BIR-4 protein 1NW9_B
CD C14.010 caspase-9 dimeric form 2AR9_A
CD C14.010 caspase-9 ciap1-bir3 in complex with n-terminal peptide from caspase- 9 (atpfqe) 3D9T_C
CD C14.010 caspase-9 complex with NleF 3V3K_A
CD C14.010 caspase-9 propeptide only; complex with apoptotic protease activating factor 1 3YGS
CD C14.015 caspase (insect 1) 1M72
CD C14.015 caspase (insect 1) structure of pro-sf-caspase-1 2NN3_C
CD C14.015 caspase (insect 1) 3SIP_A
CD C14.015 caspase (insect 1) 3SIR
CD C14.019 caspase DRONC (Drosophila melanogaster) complex with DIAP1 1Q4Q_K
CD C14.019 caspase DRONC (Drosophila melanogaster) Cys284Arg, Cys318Ala double mutant 2FP3
CD C14.019 caspase DRONC (Drosophila melanogaster) 3J9K
CD C14.026 paracaspase 2G7R
CD C14.026 paracaspase 3BFO
CD C14.026 paracaspase 3K0W
CD C14.026 paracaspase complex with Val-Arg-Pro-Arg inhibitor 3UO8
CD C14.026 paracaspase complex with Val-Arg-Pro-Arg inhibitor 3UOA
CD C14.026 paracaspase 3V4O
CD C14.026 paracaspase 3V55
CD C14.026 paracaspase 4I1P
CD C14.026 paracaspase 4I1R
CD C14.026 paracaspase human malt1(329-728) in complex with mlt-747 6F7I_A
CD C14.026 paracaspase human malt1(329-728) in complex with mlt-748 6H4A_A
CD C14.026 paracaspase 3V4L
CD C14.033 metacaspase-4 (Arabidopsis-type) 6W8R
CD C14.035 metacaspase Yca1 (Saccharomyces cerevisiae-type) 4F6O
CD C14.035 metacaspase Yca1 (Saccharomyces cerevisiae-type) 4F6P
CD C14.044 metacaspase TbMCA2 4AF8
CD C14.044 metacaspase TbMCA2 in presence of Samarium 4AFP
CD C14.044 metacaspase TbMCA2 Cys213Ala mutant 4AFR
CD C14.044 metacaspase TbMCA2 in presence of calcium chloride 4AFV
CD C14.048 bacterial metacaspase 3BIJ_A
CD C14.971 FLIP protein zymogen; complex with caspase-8 3H11_A
CD C14.971 FLIP protein c-flipl protease-like domain 3H13_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 1AUG
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 3RNZ
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 3RO0
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 3GIU_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 1A2Z_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 1IOF
CF C15.001 pyroglutamyl-peptidase I (prokaryote) Cys142, C188 deletion mutant 1IOI
CF C15.001 pyroglutamyl-peptidase I (prokaryote) structure of mutant pyrrolidone carboxyl peptidase (e192a) from a hyperthermophile, pyrococcus furiosus 1X10_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) structure of mutant pyrrolidone carboxyl peptidase (e192d) from a hyperthermophile, pyrococcus furiosus 1X12_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) structure of mutant pyrrolidone carboxyl peptidase (e192q) from a hyperthermophile, pyrococcus furiosus 1Z8T_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) structure of mutant pyrrolidone carboxyl peptidase (e192i) from a hyperthermophile, pyrococcus furiosus 1Z8W_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) structure of mutant pyrrolidone carboxyl peptidase (e192v) from a hyperthermophile, pyrococcus furiosus 1Z8X_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) fragment 1-204 2DF5_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) Ala199Pro mutant 2EO8
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 1IU8
CF C15.001 pyroglutamyl-peptidase I (prokaryote) crystal structure of pyrrolidone carboxylate peptidase i from deionococcus radiodurans r1 5Z40_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) crystal structure of pyrrolidone carboxylate peptidase i with disordered loop a from deinococcus radiodurans r1 5Z47_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) crystal structure of pyrrolidone carboxylate peptidase i from deinococcus radiodurans r1 bound to pyroglutamate 5Z48_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 3LAC
CF C15.001 pyroglutamyl-peptidase I (prokaryote) 2EBJ
CF C15.001 pyroglutamyl-peptidase I (prokaryote) crystal structure of a pyrrolidone-carboxylate peptidase 1 (target id nysgrc-012831) from xenorhabdus bovienii ss-2004 4GXH_A
CF C15.001 pyroglutamyl-peptidase I (prokaryote) crystal structure of a pyrrolidone-carboxylate peptidase 1 (target id nysgrc-012831) from xenorhabdus bovienii ss-2004 in space group p21 4HPS_A
CA C16.005 avian infectious bronchitis coronavirus papain-like peptidase 3EJF
CA C16.005 avian infectious bronchitis coronavirus papain-like peptidase 3EKE
CA C16.005 avian infectious bronchitis coronavirus papain-like peptidase 4X2Z
CA C16.005 avian infectious bronchitis coronavirus papain-like peptidase Cys101Ser mutant; complex with ubiquitin 5BZ0_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1P76
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1P9T
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1PA5
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1PUK
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1Q1X
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1Q2W
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1QZ8
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1UJ1
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1UK2
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1UK3
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1UW7
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1WOF
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1YSY
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1Z1I
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 1Z1J
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2A5A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2A5I
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2A5K
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2ACF
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2AHM
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2AJ5
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2ALV
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2AMD
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2AMQ
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2BX3
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2BX4
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2C3S
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2D2D
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2DUC
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2FAV
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2FE8
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2FYG
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2G9T
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2GA6
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2GDT
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2GRI
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2GX4
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2GZ7
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2GZ8
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2GZ9
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2H2Z
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2HOB
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2HSX
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2IDY
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2KAF
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2KQV
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2KQW
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2KYS
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2LIZ
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2OP9
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase Gly11Ala mutant 2PWX_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase Asn214Ala mutant 2QC2_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase monomeric form of mutant 2QCY_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase structure-based design and synthesis and biological evaluation of peptidomimetic sars-3clpro inhibitors 2QIQ_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2W2G
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2WCT
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2YY4_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2Z3C
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2Z3D
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2Z3E
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase complex with tdt 2Z94_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase complex with pma 2Z9G_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase complex with epdtc 2Z9J_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase complex with jmf1600 2Z9K_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase complex with jmf1586 2Z9L_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2ZU4
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 2ZU5
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3ATW
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3AVZ
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3AW0
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3AW1
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3clpro 3D62_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3E91
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase a new class of papain-like protease/deubiquitinase inhibitors blocks sars virus replication 3E9S_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3EA7
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3EA8
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3EA9
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3EAJ
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3EE7
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3F9E
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3F9F
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3F9G
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3F9H
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3FZD
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3IWM
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3M3S
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3M3T
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3M3V
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3MJ5
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3R24
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3SN8
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3SNA
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3SNB
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3SNC
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3SND
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3SNE
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3SZN
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3TIT
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3TIU
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3TNS
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3TNT
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3V3M
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3VB3
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3VB4
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3VB5
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3VB6
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 3VB7
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 4HI3
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 4M0W
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 4MDS
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 4MM3
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 4OVZ
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase 4OW0
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase complex with glycerol 5Y3E_A
CA C16.009 severe acute respiratory syndrome coronavirus papain-like peptidase crystal structure of sars coronavirus papain-like protease conjugated with beta-mercaptoethanol 5Y3Q_A
CA C16.011 Middle East respiratory syndrome coronavirus papain-like peptidase 5KO3
CA C16.011 Middle East respiratory syndrome coronavirus papain-like peptidase 4P16
CM C18.001 hepatitis C virus peptidase 2 2A4G
CM C18.001 hepatitis C virus peptidase 2 2GVF
CM C18.001 hepatitis C virus peptidase 2 catalytic domain of the NS2 protein only 2HD0
CM C18.001 hepatitis C virus peptidase 2 3HKW
CM C18.001 hepatitis C virus peptidase 2 3KN2
CM C18.001 hepatitis C virus peptidase 2 avoiding drug resistance against hcv ns3/4a protease inhibitors 3M5M_C
CM C18.001 hepatitis C virus peptidase 2 visualizing atp-dependent rna translocation by the ns3 helicase from hcv 3O8B_A
CM C18.001 hepatitis C virus peptidase 2 visualizing atp-dependent rna translocation by the ns3 helicase from hcv 3O8C_A
CM C18.001 hepatitis C virus peptidase 2 visualizing atp-dependent rna translocation by the ns3 helicase from hcv 3O8D_A
CM C18.001 hepatitis C virus peptidase 2 visualizing atp-dependent rna translocation by the ns3 helicase from hcv 3O8R_A
CM C18.001 hepatitis C virus peptidase 2 3QGH
CM C18.001 hepatitis C virus peptidase 2 3QGI
CM C18.001 hepatitis C virus peptidase 2 3RC4
CM C18.001 hepatitis C virus peptidase 2 3RC5
CM C18.001 hepatitis C virus peptidase 2 crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with fragment 1 [(5-bromo-1h-indol-3-yl)acetic acid] 4OJQ_A
CM C18.001 hepatitis C virus peptidase 2 crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 7 [[1-(3-chlorobenzyl)-1h-indol-3-yl]acetic acid] 4OK3_A
CM C18.001 hepatitis C virus peptidase 2 crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 9 [1-(3-ethynylbenzyl)-1h-indol-3-yl]acetic acid] 4OK5_A
CM C18.001 hepatitis C virus peptidase 2 crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 13 [[1-(2-methoxy-5-nitrobenzyl)-1h-indol-3- yl]acetic acid] 4OK6_A
CM C18.001 hepatitis C virus peptidase 2 crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 19 [[6-(3,5-diaminophenyl)-1-(2-methoxy-5- nitrobenzyl)-1h-indol-3-yl]acetic acid] 4OKS_A
CA C19.001 ubiquitin-specific peptidase 5 2DAG
CA C19.001 ubiquitin-specific peptidase 5 2DAK
CA C19.001 ubiquitin-specific peptidase 5 2G43
CA C19.001 ubiquitin-specific peptidase 5 2G45
CA C19.001 ubiquitin-specific peptidase 5 3IHP
CA C19.004 Ubp3 ubiquitin peptidase 2QIY
CA C19.010 ubiquitin-specific peptidase 4 2Y6E
CA C19.010 ubiquitin-specific peptidase 4 3JYU
CA C19.011 ubiquitin-specific peptidase 8 1WHB
CA C19.011 ubiquitin-specific peptidase 8 N-terminal domain 2A9U
CA C19.011 ubiquitin-specific peptidase 8 catalytic domain only 2GFO
CA C19.011 ubiquitin-specific peptidase 8 complex with RING finger protein 41 2GWF
CA C19.011 ubiquitin-specific peptidase 8 3N3K
CA C19.011 ubiquitin-specific peptidase 8 1UJ0
CA C19.012 ubiquitin-specific peptidase 13 2L80
CA C19.012 ubiquitin-specific peptidase 13 2LBC
CA C19.013 ubiquitin-specific peptidase 2 complex with ubiquitin 2HD5
CA C19.013 ubiquitin-specific peptidase 2 complex with ubiquitin 2IBI
CA C19.013 ubiquitin-specific peptidase 2 3NHE
CA C19.013 ubiquitin-specific peptidase 2 3V6C
CA C19.013 ubiquitin-specific peptidase 2 3V6E
CA C19.013 ubiquitin-specific peptidase 2 complex with ubiquitin and 6- thioguanine 5XU8_A
CA C19.013 ubiquitin-specific peptidase 2 Cys276Ser mutant; complex with ubiquitin 5XVE_A
CA C19.013 ubiquitin-specific peptidase 2 ubiquitin variant bound to usp2 6DGF_A
CA C19.014 ubiquitin-specific peptidase 11 4MEL
CA C19.015 ubiquitin-specific peptidase 14 2AYN
CA C19.015 ubiquitin-specific peptidase 14 complex with ubiquitin aldehyde 2AYO
CA C19.015 ubiquitin-specific peptidase 14 26S proteasome; complex with USP14-UbAl 5GJQ_x
CA C19.015 ubiquitin-specific peptidase 14 usp14 catalytic domain with iu1 6IIK_A
CA C19.015 ubiquitin-specific peptidase 14 catalytic domain; complex with iu1-47 6IIL_A
CA C19.015 ubiquitin-specific peptidase 14 usp14 catalytic domain with iu1-206 6IIM_A
CA C19.015 ubiquitin-specific peptidase 14 usp14 catalytic domain with iu1-248 6IIN_A
CA C19.015 ubiquitin-specific peptidase 14 1WGG
CA C19.016 ubiquitin-specific peptidase 7 catalytic domain only 1NB8_A
CA C19.016 ubiquitin-specific peptidase 7 complex with ubiquitin aldehyde 1NBF
CA C19.016 ubiquitin-specific peptidase 7 1YY6
CA C19.016 ubiquitin-specific peptidase 7 1YZE
CA C19.016 ubiquitin-specific peptidase 7 2F1W
CA C19.016